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Let us not take it for granted that life exists more 
fully in what is commonly thought big than in 
what is commonly thought small. 
- The Common Reader (1925), Virginia Woolf





1. Scientific environment  
Throughout this PhD, I have been affiliated with the Research Group for Infection 
and Microbiology at the Department of Clinical Science, University of Bergen, and 
the Laboratory of Trypanosomatid Physiology (BatLab) at the Institute of 
Biosciences, University of São Paulo. During the Medical Student Research 
Programme, I also worked at the Laboratory for Seroepidemiology at the Institute of 
Tropical Medicine, University of São Paulo. Professor Audun Helge Nerland, 
Professor Are Næss, and Professor Haakon Sjursen gave me supervision during the 
Medical Student Research Programme. Professor Audun Helge Nerland was my main 
supervisor and Professor Lucile Maria Floeter-Winter and Dr Juliana Ide Aoki were 
co-supervisors for my doctoral work. 
 6 
2. Acknowledgements 
In the attic at Lensmannsbakken in Brunlanes, where I grew up, my father had stored 
away his microscope. With this, as a young boy, I studied whatever I could manage to 
magnify! As a haematologist, my father had slides stored around, and I stole some of 
them to look at. What a fantastic world I discovered. As the years went by, natural 
sciences intrigued me, but I lost fascination for them during high school. I found the 
teaching dull and not open for curiosity. I found a new home in the social sciences. 
However, after completing a degree in economics, I became convinced that I had to 
get back to my old dream – to study medicine, and if possible, to study the infinitely 
small things in life. 
 
I am eternally grateful to my wise guide throughout the years, Professor Audun Helge 
Nerland. Your endless curiosity, numerous ideas and in-depth knowledge of 
immunology, microbiology and molecular biology intrigues me. You lured me into 
multiple projects: producing antibodies in fish, trying to make vaccines, digging deep 
into molecular biology. Suddenly we had three masters students at our lab and  
Audun, you thought it wise that I co-supervised all of them. Although I was doubtful, 
you somehow knew that I could do it. You have always been positive and supportive; 
and your mentorship has been invaluable to me. Without your collaboration and 
supervision, this thesis would never have existed. Thank you!  
 
My main supervisor in Brazil has been Professor Lucile Maria Floeter Winter. What a 
fantastic journey we have had together! I am grateful for the fantastic collaboration 
we have established. As a supervisor, you have always been supportive, stubborn, 
patient and wise. I feel lucky to have worked so closely with one of the leading 
scholars in Leishmania-research. Thank you, Lucile, for fantastic supervision, always 
replying promptly to my questions and for always being so interested in discussing 
anything: genes, proteins, music, politics and art! 
 
 7 
My co-supervisor, Dr Juliana Ide Aoki – thank you. Although our initial project 
didn´t work out, I have not given up. Several new projects are already up and 
running. Your example of hard and dedicated work has been a true inspiration! 
 
I am grateful for Professors Are Næss and Haakon Sjursen for including me in their 
research group in the beginning of my research days. I am also grateful to fellow 
PhD-student Karen Rebbestad for welcoming me with open arms to the research 
field. 
 
Dr Ricardo Andrade Zampieri – muito obrigado amigo! I think we have the world-
record in the number of Skype meetings! Thank you for sharing your vast knowledge 
of molecular biology – especially all the hidden tips and tricks! I have been amazed 
by how you welcomed me and how perfectly we have been working together – asking 
questions and sharing our curiosity, while at the same time being very result-oriented. 
Parabéns pra nós! 
 
 I also wish to thank Dr Sandra Marcia Muxel and all the students at the BatLab for 
making my research stays there so welcoming and nice. Vamos que vamos! 
 
The Medical Student Research Programme at the University of Bergen – without it, I 
doubt I would ever have got into research. A special thanks go to Marianne Stien and 
Professor Anne Berit Guttormsen. 
 
As a medical student, I was also able to take part in the excellent laboratory of 
Professor Hiro Goto at the Institute of Tropical Medicine at the University of São 
Paulo. I was inexperienced; despite this, Hiro and her team welcomed me and taught 
me the basics of working with Leishmania. Muito obrigado Hiro, Magnus, Chris, 
Célia, Luiza, Eduardo and the rest of the team at the Instituto de Medicina Tropical 
de São Paulo (IMT). During my year at Hiro´s lab, I also had the opportunity to go to 
the Emilio Ríbas hospital twice a week to attend to patients with leishmaniasis. The 
 8 
clinical experience was made possible by the excellent and kind mentorship of Dr 
José Angelo Lauletta Lindoso. Thank you, Angelo, for giving me that opportunity. 
 
At the infectious disease lab in Bergen, I had the great fortune of working closely 
with two fantastic engineers who have taught me a lot. Marit Gjerde Tellevik and 
Steinar Sørnes – thank you! 
 
I am also grateful to the staff and students at the Gades group of infection and 
immunity, in particular, Professors Rebecca Jane Cox Brokstad and Vidar Bakken 
who continuously encouraged me and gave helpful comments to my work. 
 
During my medical and doctoral studies, I have had the great fortune to work with 
some great colleagues in various academic settings, although somewhat outside my 
research field. Dr Carl Tollef Solberg, we shared tips and tricks for the PhD, but also 
extensively discussed various philosophical issues and we had great fun writing 
together. And now, good friends! I look forward to the numerous collaborations we 
will have in the future. Ingrid Neteland, always enthusiastic, but also clear-sighted 
and rigorous – it has always been a true inspiration to work with you. Dr Jan Reinert 
Karslen, thank you for inviting me to the Centre for the Study of Sciences and the 
Humanities, your courses and seminars were magnificent, and helped me always keep 
the critical eye open for my own research projects and their limitations while being 
open to criticism of your own work. Professor Edvin Schei, thank you for inviting me 
into the Filosofisk Poliklinikk at an early phase, a place for Bildung and thank you for 
greeting my curiosity with great enthusiasm and directing it into something 
productive. It has been fascinating to work with you to develop research and new 
inspiring courses for medical students. Dr Anna Therese Bjerkreim and Ingeborg 
Eskerud, it has been a true pleasure to uncover the secrets of the success and 
challenges to the Medical Student Research Programme in Bergen.  
 
 9 
Thank you, Drs Kristine Mørch and Bjørn Blomberg at the Norwegian Centre for 
Tropical Infectious Diseases, Haukeland University Hospital, for your inclusion and 
your patience whenever I tripped up and made a mistake.  
 
The 5th floor in the lab-building at Haukeland in Bergen has been a great and 
formative place to learn lab work. There are great opportunities here, good and 
advanced equipment is readily available. But most importantly, the technicians and 
engineers are incredibly willing to share their knowledge – all you need to do is to 
ask. Thank you Brith, Richard, Marianne, Kjerstin, Tove and Sonja for sharing of all 
your knowledge, and for all your kind help and collaboration. 
 
Dr Jan Roger Olsen - we accompanied each other in our projects ups and downs. We 
inspired each other, sharing papers and also writing together. I am always grateful for 
your friendship. Dr Lara Aqrawi, you have and continue to be a great inspiration. I 
also wish to thank the rest of the PhD-students I was lucky to work alongside, 
Christine Drengenes, Christina S. Saghaug, Ida Marie Hoel, Sunniva Sakkestad and 
Dr Tor Arne Hegvik.  
 
I am also grateful to the masters and medical students I supervised; Amalie, Eva, 
Hilde, Martha, Kathrine, Nina, Tove and Torgeir. You have all taught me a lot about 
my own strengths and limitations. Thank you also for your patience when I perhaps 
pushed you too hard.  
 
I would like to thank my teachers from primary school and through high school. In a 
time when teachers in the Norwegian public educational system are much criticised, I 
feel a need to applaud some of the teachers. I would like to mention five teachers who 
have had a particular influence on me: Britt-Kari Kobro, Grete Rimstad, Anne 




Thank you, Anders Tangen, for your continuous friendship and putting a lot of things 
in my life into perspective! 
 
Without my parents-in-law, I would never have been able to complete this PhD-
thesis. They opened up their home to me and always supported me. Muito obrigado 
meus queridos e minha familia brasilieira, Babate, Bie, Ana, Gabriel, Silvia. Maria e 
Manu! E Luzia – e sopa e meu sonho! 
 
My family in Norway. My dear mother and my dear father. They have been and 
remain an inspiration. You fostered my curiosity, taught me the value of hard and 
dedicated work, but also social engagement. You taught me from the very beginning 
that no one road holds the truth, and I think you can see this reflected in my work 
today. Thank you! Thank you also to my dear siblings for teasing me when I deserved 
it, for making fun of me when my arrogance was too much and for showing and 
telling your love.  
 
Last, but not least Julia – the rock in my life. Eu te amo! Our lives crossed each other 
in London, and since then we have been inseparable. Your dedication to your own 
work has been important to me – your level of concentration, clear sightedness and 
result orientation remain an inspiration. Furthermore, without you, this thesis would 
never have existed. There were times I had to stay long in the lab. There were times I 
had to work in the evenings at home and I had to ask not to be disturbed. You were 
supportive, you were understanding – but importantly, you also put clear limits. I am 
incredibly proud of you and of what we have been able to build together. And now 
Therese is here, exploring life! I hope that some of the exploration I did in this work, 
















The protozoan parasites of Leishmania genus are the etiological agents of the 
leishmaniases, diseases whose clinical manifestations range from being 
asymptomatic, self-healing cutaneous lesions, via mutilating muco-cutaneous lesions, 
to a potentially lethal visceral form. The World Health Organization defines the 
leishmaniases as neglected tropical diseases (NTDs). The aim of this thesis was to 
explore a new potential target, the amino acid permease 3 (aap3) coding regions and 
flanking nucleotide sequences for parasite detection and species identification. In four 
papers, the findings from research on the general and specific aims are presented. In 
paper I, the aap3 coding sequence was investigated for its potential as a target for 
parasite detection. Using real-time polymerase chain reaction (real-time PCR) the 
developed assay was useful for qualitative purposes, and when run in duplex with a 
host specific gene-assay, it was also able to quantify parasites in the mammal host. In 
paper II, the aap3 coding sequence was investigated for its potential as a target for 
species discrimination. Using high resolution melting (HRM) analysis, aap3 was 
found to be a specific and sensitive target for Leishmania species-identification. The 
method was validated on samples from humans, from experimentally infected mice, 
as well as from naturally infected sand flies. In paper III, a multi-centre prospective 
clinical study on the occurrence, diagnosis, treatment of the leishmaniases in Norway 
was performed. Biopsy material was collected to validate aap3 as a target in clinical 
samples. In this material, the small subunit ribosomal RNA coding sequence (SSU 
rDNA), a molecular target routinely used in Leishmania detection tests, was found to 
be more sensitive in conventional PCR assays. Skin biopsy was the most appropriate 
material for diagnosis in cutaneous leishmaniasis. In paper IV, the aap3 gene region 
from several Leishmania species was sequenced using single molecule real-time 
(SMRT) sequencing. In all species analysed, two copies of the encoding gene 
sequences organized in tandem were found. These sequences are conserved within 
the species and between species of the same subgenera. In conclusion, this thesis 
shows that aap3 with appropriate technology can be a sensitive and specific target for 
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both genus detection and species discrimination. Furthermore, precise sequencing of 
aap3, as described here, can be a very useful tool in subsequent gene editing studies 





Os protozoários parasitas do gênero Leishmania são os agentes etiológicos das 
leishmanioses, doenças cujas manifestações clínicas variam de formas assintomáticas 
com lesões de cura espontânea, lesões muco-cutâneas mutilantes, até a forma 
visceral, potencialmente fatal. A Organização Mundial da Saúde define as 
leishmanioses como uma doença tropical negligenciada (NTD). O objetivo desta tese 
foi explorar o potencial de um novo alvo, as sequências nucleotídicas que codificam a 
amino acid permease 3 (aap3) e as regiões que as flanqueiam, para a detecção e 
identificação das espécies do parasita. As conclusões de pesquisas sobre os objetivos 
gerais e específicos estão apresentadas em quatro artigos e manuscritos. No artigo I, 
foi investigado o potencial da sequência codificadora do aap3 como alvo de detecção 
do parasita. O ensaio desenvolvido, baseado em PCR em tempo real (real-time PCR), 
foi capaz de detectar o parasita e, quando combinado em “duplex” com um gene alvo 
específico do hospedeiro, foi capaz de quantificar o parasita em amostras de 
hospedeiro mamífero. No artigo II, foi investigado o potencial da sequência 
codificadora do aap3 como alvo de discriminação das espécies do parasita. 
Utilizando como metodologia a dissociação de DNA em alta resolução (HRM - High 
Resolution Melting), foi demonstrado que o aap3 pode ser um alvo específico e 
sensível para a identificação de espécies de Leishmania. O método foi validado em 
amostras obtidas de casos humanos, de camundongos experimentalmente infectados e 
de flebotomíneos naturalmente infectados. No artigo III, foi realizado um estudo 
multicêntrico prospectivo da ocorrência, diagnóstico e tratamento de leishmaniose na 
Noruega. Biópsias foram coletadas para validar o aap3 como alvo diagnóstico em 
amostras clínicas. Nesse material, a sequência que codifica a subunidade menor do 
ribossomo (SSU rDNA), rotineiramente utilizado como alvo em ensaios de detecção 
de Leishmania, se mostrou mais sensível na detecção do parasita por PCR 
convencional. As biópsias de pele foram o material mais apropriado para o 
diagnóstico de leishmaniose cutânea. No artigo IV as regiões codificadoras de aap3 
de várias espécies de Leishmania foram sequenciadas pela metodologia SMRT 
(Single Molecule Real-Time). Em todas as espécies analisadas foram encontradas 
duas cópias das sequências codificadoras organizadas in tandem. Essas sequências 
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são conservadas nas cepas da mesma espécie e entre as espécies do mesmo 
subgênero. Concluiu-se nesta tese que o aap3 pode ser um alvo sensível e específico 
tanto para a detecção diferencial de subgêneros quanto para a discriminação de 
espécies. Além disso, o sequenciamento preciso do aap3, como descrito aqui, pode 
ser uma ferramenta extremamente útil em posteriores estudos de edição gênica para o 





Parasitter av slekten Leishmania fører til sykdomsgruppen leishmaniasis, sykdommer 
hvis kliniske manifestasjoner spenner fra å være asymptomatiske, selvhelende kutane 
lesjoner, mutilerende muko-kutane lesjoner, til potensielt dødelig visceral form. 
Verdens Helseorganisasjon (WHO) definerer leishmaniasis som en av de glemte 
tropiske sykdommer (NTDs). Målet med denne avhandlingen var å utforske 
aminosyre permease 3 (aap3) genet og omkringliggende nukleotidsekvenser for 
parasittdeteksjon og artsidentifikasjon. I fire artikler presenteres funnene fra forsking 
på de generelle og spesifikke målene i avhandlingen. I artikkel I blir den aap3 
kodende sekvens undersøkt for dens potensial for parasittdeteksjon. Ved å bruke 
sanntids polymerase kjede reaksjon (real-time PCR) var den utviklede metoden nyttig 
for kvalitative formål, og når den ble brukt sammen med vertsspesifikk gen, kunne 
den også bli brukt til kvantifisering i verten. I artikkel II ble den aap3 kodende 
sekvensen undersøkt for dets potensial som mål for artsdiskriminering. Ved å bruke 
høy-resolusjon smeltepunktsanalyse (HRM), viste det seg at aap3 var et spesifikt og 
sensitivt mål for Leishmania arts-identifikasjon.  Metoden ble validert på prøver fra 
menneske, eksperimentelt infiserte mus og fra infiserte sandfluer. Artikkel III var en 
multi-senter prospektiv klinisk studie på forekomst, diagnose, behandling av 
leishmaniasis i Norge. Biopsimateriale ble samlet inn for å validere aap3 som et mål 
på kliniske prøver. I dette materialet fant vi at det mer vanlige brukte målet small 
subunit ribosomal RNA coding sequence (SSU rDNA), var mer sensitivt ved brukt av 
konvensjonell PCR. Hudbiopsi var det mest passende materialet for diagnostikk ved 
kutan leishmaniasis. I artikkel IV ble aap3 gen-regionen fra flere Leishmania arter 
sekvensert ved å bruke «single molecule real-time» (SMRT) sekvensering. I alle 
artene analysert, ble det funne to kopier av gensekvenser organisert i tandem. Disse 
sekvensene var bevart innenfor arten og mellom arter av ulike subgenera. Denne 
avhandlingen viser at aap3 kan være et sensitivt og spesifikt mål for både 
parasittdeteksjon og artsidentifisering. Videre, presis sekvensering av aap3, som 
beskrevet her, kan være et meget nyttig verktøy i påfølgende genredigeringsstudier 
for å bedre forstå parasittens fysiologi og genetikk.  
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“On making smear preparations from the spleen pulp, I was struck by the curious appearance, 
among the spleen cells and red corpuscles, of enormous number of small round or oval bodies, 
2 to 3 µ in diameter, which corresponded to nothing I had seen figured or described.”(1) 
 
In 1903 an army physician, W.B. Leishman described what he could see in the 
microscope in patients with so-called Dum-dum fever (1). He further explained some 
of the classical signs of visceral leishmaniasis (VL):  
 
“Clinically, these cases presented no very definite features distinguishing them from other and 
commoner forms of tropical cachexia, the chief symptoms being an irregularly remittent type 
of fever, grave anemia, progressive muscular atrophy, and great enlargement of the liver.” (1) 
 
Since Homo sapiens emerged in Africa and before, parasites have been part of our 
history. The first written records of parasites are from Egyptian, Chinese, Indian and 
Arabic  physicians (2). Without doubt, the helminths would have been known to our 
early ancestors but it was not until the development of the microscope that we could 
identify the protozoans, one of which is the theme for this thesis. And it was a 
protozoa, namely Giardia lamblia, that Antonie van Leeuwenhoek – the man to 
whom we credit the development of the microscope – first saw in his microscope at 
the end of the 17th century (2). 
 
The Leishmania parasite was likely seen before W. B. Leishman described it (1). That 
is to say, the parasite was seen by David Cunningham in 1885 and P.F. Borovsky in 
1898 (3). The parasite was first described by William Leishman and Charles 
Donovan independently (4). It was, however, not until 1921 that the sand fly was 




Besides fossil findings indicating the presence of Leishmania in ancient times, there 
are a few accounts of Leishmania. Naturally, the earliest descriptions are of cutaneous 
leishmaniasis (CL). There are descriptions of lesions that could be CL on tablets from 
the library of the Assyrian King Ashurbanipal (2). A study of mummies from Egypt 
(2050-1650 BCE) found L. (L.) donovani DNA in several of the mummies (6).  A 
skin condition called “Nile Pimple”, compatible with CL is mentioned as early as 
1500 BCE in the Ebers Papyrus scriptures (2). Furthermore, early ceramics from 
Columbia show facial conditions that could be mucocutaneous leishmaniasis (MCL) 
(7).  
 
Today, leishmaniasis2 remains a neglected tropical disease – underreported, 
underestimated, underfunded and underprioritized. The World Health Organization 
(WHO) currently classifies 20 communicable diseases and conditions as neglected 
tropical diseases (NTDs) (8). Worldwide, the NTDs affect more than a billion people 
and cause high levels of morbidity and mortality (8,9). For the leishmaniases there 
are challenges on all levels; understanding the parasite itself, its interaction with the 
vector, reservoir(s) and host. More knowledge about these are essential for the 
development of new treatment options and vaccines. Furthermore, there are no 
standard techniques for diagnosis in endemic nor non-endemic regions.  
 
Arginine is a key amino acid for macrophage defence against Leishmania, but also 
essential for Leishmania replication (10). The uptake of arginine is largely mediated 
by the amino acid permease (AAP3) in Leishmania. In this thesis, aap3 is explored as 
a diagnostic target using molecular diagnostic techniques (paper I-II), one of the 
diagnostic techniques is also explored in samples from real patients (paper III), and 
the coding sequence is explored further by third generation sequencing (paper IV). 
 
This introduction aims to give the naïve reader a broad introduction to the field before 
going into the particular issues that this doctoral work has concerned itself with. This 
                                                 
2 Leishmaniasis is also referred to as the leishmaniases, to highlight the plethora of clinical symptoms the various strains of 
the parasite can cause. This thesis will use both terms. If a specific clinical condition is referred to, it will be made clear in 
the text. 
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thesis proceeds as follows: I begin with a general introduction to the Leishmania 
parasite and the leishmaniases; thereafter I will discuss amino acid permease 3 
(AAP3) followed by a deeper discussion of diagnosis, detection and identification. 
The aims of this thesis are then presented, and I subsequently discuss materials and 
methods used, give a brief summary of the papers and a more in-depth presentation 
and discussion of the results, followed by a general conclusion and proposals for 
future studies. 
7.1 The parasite, vector, reservoir and host 





Figure 1. The taxonomy of Leishmania. The genus is divided into four subgenera, where Leishmania 
(Sauroleishmania) is not considered pathogenic to humans. The subgenus Leishmania (Mundinia) 
has recently been described (11–13). The list of species in the figure is not exhaustive. The figure is 
adapted from (11,14). *L. (L) chagasi has been found to be identical to L. (L.) infantum (15,16). 
 
Leishmaniasis is caused by the protozoan parasite from the genus Leishmania of the 
order Kinetoplastida and family Trypanosomatidae. The genus is further divided into 
three sub genera, L. (Leishmania), L. (Viannia) and L. (Sauroleishmania)3. Twenty 
one different species are known to be pathogenic to humans (14). The taxonomy of 
                                                 
3 A further subgenus has been proposed, namely Leishmania Mundinia(11). 
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Leishmania is debated. See figure 1 for an overview of a suggested taxonomy for 
Leishmania.  
 
Leishmania is a protozoan that cycles between the sand fly vector and the 
macrophages of the mammalian host, where it is an obligate intracellular parasite (17) 
(see figure 2). There are two major morphological forms in the life cycle of 
Leishmania: the promastigote and amastigote. The extracellular and flagellated 
promastigote (approximately 15-20 µM long and 1.5-3.5 µM in width) is found in the 
digestive tract of the sand fly. The amastigote (approximately 2-4 µM in diameter) 
has no apparent flagellum and resides, in general, in cells of the reticuloendothelial 
cell line of the mammalian host. The amastigotes multiply within phagocytes, in 
particular macrophages, where they scavenge for essential nutrients, like purines, 
polyamines, vitamins, iron, magnesium and more (10,18).  
 
Figure 2. The life cycle of Leishmania 
 
 
Figure 2. The life cycle of Leishmania. (1) The parasite is transmitted to the animal host through the 
bite of a sandfly. (2) Promastigotes infect cells of the reticuloendothelial systems, most commonly 
macrophages. (3) Promastigotes differentiate into amastigotes in the host cell, where they multiply 
(4). (5) sandflies are infected through a blood meal from an infected host. (6) Amastigotes are 
released into the gut of the sandfly. (7) Amastigotes differentiate into promastigotes and multiply. (8) 
Metacyclic (infective form) of promastigotes move to the sandfly proboscis, ready to be transmitted 





Sandflies of the genera Phlebotomus and Lutzomyia4 are the invertebrate host of 
Leishmania, and are the vectors for human leishmaniases. They are found worldwide 
in tropical and subtropical regions, from 50°N to 40°S (21,22). As one can expect, 
there are differences in the species of sandflies, where some feed on a wide range of 
mammals, while others prefer humans. This is reflected in human leishmaniases, 
which can be both zoonotic and anthroponotic in transmission.  
 
In Europe, North Africa, the Middle East and Asia, sandflies of the Phlebotomus spp. 
transmit the parasite, while in the Americas, sandflies of Lutzomyia spp. transmit the 
parasite. Leishmania spp. can be transmitted by sandflies in two ways: (i) from 
animals (zoonotic) or from other humans (anthroponotic). Zoonotic is the most 
common form of transmission. Anthroponotic transmission has been reported for L. 
(L.) tropica and L. (L.) donovani in some endemic regions, but the exclusivity of the 
human-to-human transmission has been debated (23,24). The transmission in Africa 
and Asia is wide, from urban centres to rural villages, it is likely that animal 
reservoirs exist, and have also been reported for L. (L.) tropica (25). Infected animals 
have been found in Nepal and Bangladesh, although their role in the transmission 
cycle remain debated (26,27). 
 
Non-vector transmission, such as accidental needle injection, is rare (28), as well as 
transmission by blood transfusion (29). Although some Trypanosoma species present 
vertical transmission, from human to human (30,31), vertical transmission of 
Leshmania has not been proved. Of the approximate 800 sand fly species, around 30 
of them are proven vectors, with more than 40 involved in transmission (21,28).  
 
                                                 
4 Other sandfly species have been implicated in transmission in Brazil, but the results have yet to be confirmed (20).  
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7.1.2 Sandflies 
Sandflies are small, approximately 3 mm long, bloodsucking insects. They mostly 
rest during day-time hours in cool and humid places, although there are considerable 
differences in the preferred resting sites (21). Their habitat is usually geographically 
limited, and their dispersal is usually less than 1 km (22). Sandflies live in remarkably 
diverse ecological habitats. In Europe, Africa and Asia the habitat is more common in 
semi-arid to desert conditions. While in South America, it is most commonly related 
to forests and has a sylvatic cycle.  
 
Sand flies are primarily nocturnal, and biting during daylight is thought to be limited 
to a few species (22). Sand flies will take their blood-meal from a range of hosts. 
Thus it is not surprising that deforestation, urbanisation and changing agricultural 
practices affect the feeding pattern and thereby also the transmission cycle in several 
regions (28) . Furthermore, in most species, females bite most commonly outdoors 
(exophagic) and they usually rest outdoors while their eggs mature (exophilic). This 
observation limits the value of indoor insecticide spraying as a control measure for 
leishmaniasis. After attempts to eradicate malaria by house spraying with 
dichlorodiphenyltrichloroethane (DDT), for example, in India, leishmaniasis 
prevalence fell in several endemic regions but returned when spraying stopped 
(30,31). However, such a strategy will not work where the transmission cycle is 
sylvatic. While both males and females feed on carbohydrates, only females feed on 
blood. The number of blood meals during the day and for each batch of eggs differs 
between species and this also affects the efficiency of transmission of Leishmania. 
 
When the female sand fly bites, she injects saliva into the skin. The saliva has, in 
numerous studies, been found to affect the outcome of the infection (32–34). The 
saliva consists of proteins, enzymes and nucleic acids (35). Its main function is 
vasodilation and counteraction of haemostasis (32,36). Saliva has been reported to 
induce expression of Th2 cytokines by activated macrophages (37) (see section 
7.1.5), and, moreover, it has been shown to have chemotactic activity on the same 
 28 
cells, potentially exacerbating an infection (38). Moreover, sand fly saliva has also 
been shown to inhibit the ability of dendritic cells to present antigens and increase 
apoptosis of neutrophils, also contributing to infection (39,40). Previous exposure to 
the saliva has been reported to lead to protection, by potentially limiting the effects of 
the saliva on the immune system (32,41). The magnitude of this effect in humans is 
still not clear.  
 
7.1.3 Host and reservoir 
The terminology around host and reservoir can at times be confusing and it is used 
variably in the literature (42,43). A reservoir can be defined as “ an ecological system 
in which an infectious agent survives indefinitely”(44). Incidental hosts, on the other 
hand, are organisms that become infected but are not essential for the maintenance of 
the transmission cycle of that pathogen. Although a range of different accidental 
hosts has been reported, their precise role in the transmission cycle remains to be 
elucidated (26,27,45). What a host is, is possibly even less clear than what a reservoir 
is. A host can be defined as “the entity that houses its associated 
microbiome/microbiota, interacts with microbes, and responds to them in a way that 
results in damage, benefit, or indifference, thus producing the states of symbiosis, 
colonization, commensalism, latency, and disease”(43). A range of animals can be 
hosts and reservoirs for the Leishmaia parasite, and rodents and carnivores are among 
the most common. Animals in the same order can serve as both reservoir and host, 
and this is partly dependent on the parasite species (46). Limited knowledge of the 
true ecology of Leishmania transmission can lead public health authorities to ill-
informed measures and initiation of policies that are less likely to be successful. An 
example is for L. (L.) infantum, where dogs are seen as the main reservoir in the 
European-Mediterranean area. However, several other animals have been reported as 
both hosts and reservoirs, such as cats and rabbits (47,48). Thus, dog culling may not 
have the expected effect on Leishmania transmission in such an area (49). 
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7.1.4 Clinical presentation 
Leishmaniasis can present with a wide spectrum of clinical manifestations. The 
clinical manifestations are commonly in the skin, mucous membranes and/or visceral 
organs. Cutaneous leishmaniasis (CL) is characterized, most commonly, by localised 
skin lesions at the site of the sand fly bite (LCL), multiple non-ulcerative nodules 
(Diffuse cutaneous leishmaniasis (DCL)), mucosal affection (MCL) and visceral 
leishmaniasis (VL). 
See table 1 for an overview over the clinical forms, their aetiology and main 
geographical distribution. The range of clinical forms is dependent on several factors, 
such as; parasite species, host age, nutritional state and host immune response which 
can be affected by genetic polymorphisms (50).  
Table 1. Leishmania species, clinical forms, transmission and main 
geographical distribution. 
Species Clinical form Transmission cycle Main geographical distribution 
Leishmania (Leishmania) 
L. (L.) amazonensis LCL, DCL Zoonotic South America 
L. (L.) aethiopia LCL, DCL Zoonotic Ethiopia, Kenya 
L. (L.) donovani VL, LCL Anthroponotic, 
zoonotic
Africa, Central and South East Asia 
L. (L.) infantum VL, LCL Anthroponotic, 
zoonotic
Europe, North Africa, Central and South 
America
L. (L.) major LCL Zoonotic Central Asia, North and East Africa, Middle 
East
L. (L.) mexicana LCL, DCL Zoonotic Central America, Mexico, USA 
L. (L.) pifanoi LCL Zoonotic South America 
L. (L.) tropica LCL Anthroponotic Central Asia, North and East Africa, Middle 
East
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Table 1: Species causing human leishmaniasis, their main clinical forms, transmission cycle and 
main geographical distribution. DCL: diffuse cutaneous leishmaniasis, LCL: local cutaneous 
leishmaniasis, MCL: mucocutaneous leishmaniasis, VL; visceral leishmaniasis. The table is partly 
adapted from (28). References regarding Leishmania (Mundinia): (12,13,51,52) 
CL is caused by several strains of both L. (Leishmania) and L. (Viannia) subgenera. 
The cutaneous manifestation is the most common, where ulcers most commonly 
occur at the site of the sand fly bite (53). The ulcers usually heal spontaneously over 
months to years (17). They often leave an atrophic and disfiguring scar. The scar may 
cause great morbidity by social isolation and stigma (54). CL, like VL, probably 
remains symptomless in most cases. Symptomatic CL typically starts with erythema, 
which develops into a papule, then nodule that ulcerates over weeks to months. The 
severity and time to self-heal varies between the lesions and seems to be related to the 
species involved. Typically, healing occurs within a year, but can be as rapid as 2 
months, but also take several years. Lymphatic spread and involvement is common, 
also before clinical disease develops (28). After spontaneous healing, it is thought 
that the person has a lifelong protection, possibly also against other species, although 
this point is debated. Resolution of the disease is, however, connected to scarring.  
DCL is a rare form, especially reported from Africa and parts of South America, is 
characterized by non-ulcerative papules that cover the entire body. This is a form that 
is difficult to treat and does not usually self-heal (28). 
Species
 




 L. (M.) LCL, DCL, Unknown West Indies, Thailand
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Mucosal leishmaniasis (ML) indicates the involvement of mucous membranes, most 
commonly nasopharynx, larynx and the oral cavity. Mucocutaneous leishmaniasis 
(MCL) can manifest itself long after CL5(17). The mucosal lesions can be severely 
disfiguring, where septum perforation is not uncommon. CL precedes MCL in 5-20% 
of the cases (55). However, isolated MCL has been described in 17-18% of patients 
with L. (V.) braziliensis (56). MCL caused by viscerotropic strains has also been 
reported, especially in immunocompromised patients, but not restricted to this patient 
group (57,58). How the parasites reach the mucous membranes is still under 
discussion and is thought to be dependent on the species causing the condition. 
Commonly cutaneous species, like L. (L.) major are thought to spread to mucous 
membranes directly from the skin lesion. On the other hand, for L. (V.) braziliensis it 
is more commonly thought that the spread is lymphatic or haematological (59). Direct 
inoculation of parasites by sandflies is also probable for oral and nasal sites, but less 
likely for laryngeal affections (60).  
 
The most common early manifestations are in the upper respiratory tract, nose and 
oral cavity. In the early phases, MCL manifests with signs of inflammation, such as 
congestion, erythema, edemia, rhinorrhea, and epistaxis which may develop into 
dysphagia and dysphonia as the disease progresses.  
 
Both subgenera may cause MCL, but in the Americas, MCL is predominantly caused 
by species of the L. (Viannia) subgenus (see table 1). In South America, MCL occurs 
most commonly in Brazil, Bolivia and Peru. In South America it is common to use 
the term American tegumentary leishmaniasis (ATL) to include CL, DCL and MCL 
(59).  The strain involved in MCL in South America is commonly L. (V.) braziliensis, 
but L. (V.) panamensis, L. (V.) guyanensis and L. (L.) amazonensis may also cause 
the condition (59,60).  Although ML/MCL is most common in South America, it has 
been reported for all the endemic regions for leishmaniasis (60). Outside of South-
                                                 
5 For practical purposes, and although it might not be accurate in all cases, this thesis will treat MCL and ML as the same. 
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America, ML/MCL is caused by different strains of the L. (Leishmania) subgenus 
(57,61). 
 
VL is mainly caused by L. (L.) infantum in Europe and South America, while in 
Africa and the Indian subcontinent, it is mainly caused by L. (L.) donovani. In Europe 
and South America, it is a zoonosis, where dogs are the main reservoir. On the Indian 
subcontinent it is thought to be mainly anthroponotic, but as mentioned in section 
7.1.1, this is debated. Differential diagnosis includes mycobacterial infections, 
haematological malignancies, like lymphoma, disseminated histoplasmosis, and 
rheumatological conditions like Feltys syndrome. Biochemically, VL is characterized 
by pancytopenia (anaemia, thrombocytopenia and leukopenia), increase in 
inflammatory markers, like C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR), hypergammaglobulinemia and hypoalbuminemia. In addition, production 
of anti-nuclear antibodies, anti dsDNA, anti-smooth muscle, anti-cardiolipin, anti-
cyclic citrullinated peptide and IgM rheumatoid factor antibodies can sometimes also 
be detected (62). 
 
7.1.5 Immune response  
The clinical outcome of the infection depends on both the species of the parasite and 
the host immune response (63). See figure 2 for a graphical depiction of the 
Leishmania life cycle. This thesis does not give an in-depth analysis of general 
immunology, nor of the immunopathology of Leishmania spp. in humans. For a good 
introduction to immunology, the reader is directed to the many excellent books and 
other publications in the field (such as (64)). The outcome of infection with 
Leishmania is thought to be dependent on several factors, including the host immune 
response, host genetics, nutritional status and parasite virulence (63,65). Most studies 
focus on one species, and as is evident through the several clinical outcomes, caution 




At the time of entry into the mammal, the parasites immediately encounter the 
complement system. The immediate effect of the complement system is activation of 
the membrane attack complex, which will puncture the membrane of the parasite. In 
addition, components of the complement system will act as opsonins thereby 
stimulating phagocytosis. GP63, a known virulence factor expressed by Leishmania 
promastigote is able to inactivate complement by binding C3b and increase the 
conversion of C3b to C3bi (66,67). L. (L.) major deficient of GP63 has been shown to 
be susceptible to complement-mediated lysis (68). GP63 is also able to suppress the 
proliferation of IL-2 activated NK-cells (69). NK-cells, in turn, are central in the 
mounting of the Th1 response through production of IFNγ. It was for L. major that 
the Th1/Th2 dichotomy response (cure/not cure) was based (70). In a Th1 response, 
Th1 cells produce IFN-γ and TNF-α. On the other hand, the exacerbation of 
leishmaniasis is in general thought to be related to a Th2 response, producing IL-4, 
IL-5 and IL-10. Caution should however be taken when interpreting a disease in such 
a strict dichotomy, as this is based on animal studies which may have limited 
applicability for the leishmaniases, both cutaneous and visceral (71). 
 
The first cells to migrate to the infected site are neutrophils, and after that 
professional antigen presenting cells, such as macrophages and dendritic cells 
migrate. The migration of these cells is stimulated by molecules from the sand fly 
saliva (72). Saliva from Lutzomyia longipalpis decrease TNF-α, IL-10, and increase 
IL-6, IL-8 and IL-12 in macrophages, reducing inflammatory response of the host 
towards the parasite (73). Furthermore, pre-exposure to sand fly saliva has been 
shown to be protective against Leishmania infection (74) 
 
Neutrophils are professional killer cells. Despite this, it has been suggested that 
neutrophils could work to the benefit of Leishmania as a “Trojan horse” (75). It has 
been shown in vitro that Leishmania can survive within the neutrophil phagosome. 
Further, the parasite may induce apoptosis, which, when the neutrophil is digested by 
a macrophage, will not induce an inflammatory response (76). The role of neutrophils 
has also been shown in vivo, where they rapidly migrate to the site of inoculation in 
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mice (77). Apoptotic neutrophils are in turn internalized by macrophages and 
dendritic cells, where the parasites may multiply.  
 
After phagocytosis, promastigotes in phagosomes fuse to lysosomes forming the 
parasitophorous vacuole that can harbour individual or several parasites, in a  species-
specific way (78,79). In addition, once inside the macrophage, the parasite may 
modulate cytokine secretion. The aforementioned virulence factor, GP63 is able to 
activate several tyrosine phosphatases that are important in several cytokine pathways 
(72). GP63 is also able to cleave CD4, a central co-receptor in T-cells, and may 
inhibit cross-presentation by DC and macrophages.  Cross-presentation is central in 
the immune response, as microbial antigens are presented to CD8+ T-cells.  
 
Cytokines are small signalling molecules that play a critical role in directing the 
immune response.  In particular, INF-γ, TNF-α and IL-10 are thought to be central 
for leishmaniases. Some authors argue that asymptomatic individuals are able to 
control the infection by balancing the immunoregulatory cytokine IL-10 with the 
effector IFN-γ (71,80). It is thought that TNF-α, IL-1α, IL-10 and TGF-β are 
significantly increased in patients with chronic disease (81). Furthermore, the 
frequency of CD8+ IFN-γ+  cells after stimulation with soluble L. (V.) braziliensis 
antigen was found to be higher for asymptomatic than for CL patients – also 
highlighting the central role of T-cells in fighting the pathogen (82). 
 
As Leishmania is an intracellular pathogen, an adaptive immune response, in 
particular a strong T-cell response, is central to keep the infection at bay. CD4+ T-
cells are important to regulate and mediate antigen presentation. A central cytokine, 
INF-γ, stimulates macrophages to produce NO, which is important for Leishmania 
killing. INF-γ, secreted by CD4+ T-cells has a dual role in infection with Leishmania, 
where it is central in activating the macrophage to keep the pathogen at bay, but it is 
also central in the tissue damage seen in CL (83). The other central cytokine, TNF-α 
also activates the leishmanicidal activity of macrophages and is central in fighting 
infection with Leishmania. TNF-α is important for granuloma formation. Anti-TNF-
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α drugs, commonly used in several autoimmune diseases, do indeed increase the risk 
of developing infections, including leishmaniasis, especially intracellular organisms 
(84).  IL-10 is an important regulatory cytokine in Leishmania, but there have been 
conflicting results as to the precise role for infections with different strains of 
parasites. 
 
The pathogenesis of MCL is only partly understood (60). The immune response 
seems to play a central part in directing the Leishmania infection towards mucosal 
leishmaniasis (ML) or CL. Whereas IL-10 levels are equal in both ML and CL, IFN-γ 
and TNF-α are higher in ML. The important role of the immune system is 
strengthened by the fact that immunocompromised patients (such as HIV patients) 
have a higher rate of ML compared to immunocompetent Leishmania patients (85). 
HIV enhances the undesirable Th2 response.  
 
7.1.6 L-Arginine and the amino acid permease 
L-arginine is an essential amino acid for both Leishmania amastigotes and 
promastigotes (10). L-arginine has to be taken up by the parasite from the 
environment as the parasite does not have the ability to synthesize it de novo. Within 
promastigotes, there is a pool of several amino acids with alanine, ornithine, 
glutamate and glycine as the most abundant (10,86,87). Control of L-arginine 
depends on both uptake and intracellular concentrations. L-arginine is further used in 
synthesis of a range of important substrates. Polyamines are synthesized from L-
arginine by arginase. L-arginine can also be decarboxylated to agmatine, that through 
hydrolysis is turned to putrescine and urea (88) Arginase is found in glycosomes (88).  
Amino acids can be transported over cell membranes by a variety of permeases. The 
amino acid permease 3 (AAP3) belongs to the amino acid/auxin permease (AAAP) 




For L. (L.) amazonensis and  L. (L.) donvani it has been shown that the parasite can 
sense the external pool, or availability, of the amino acid, and thereby regulate the 
expression of transporter proteins (87,90). Furthermore, the level of arginase activity 
also affects the intracellular pool of L-arginine. And lastly, it has been shown that the 
amastigotes can scavenge the phagolysosome for essential amino acids (91,92).   
 
The amino acid permeases have been described as transporters with high affinity for 
L-arginine in several Leishmania species (86,90,93–97). Amino acid permease 3 
(AAP3) is a high affinity transporter of L-arginine, but can also mediate uptake of 
other amino acids, such as lysine, histidine, phenylalanine of citrulline (87,94). AAP3 
expression is upregulated in response to L-arginine starvation (98). Another study 
found that temperature also affected the transcription of one of the AAP3 copies, as 
well as protein expression and localisation (96). Furthermore, AAP3 has been found 
to be localised in both the cell membrane and the glycosome, indicating direct 
transport into this organelle (96). 
 
7.1.7 Regulation of gene expression 
Leishmania belongs to the Kinetoplastida, of which Leishmania spp. and 
Trypanosoma spp. are known to cause human disease. They share the common 
feature of being flagellated during parts of their lifecycle, and also share the common 
organelle, known as the kinetoplast. The kinetoplast contains several copies of 
mitochondrial DNA. The kinetoplast is organized in mini- (∼ 1 kb) and maxi-circles 
(∼25 kb). Mini-circles code for guide RNAs and maxi-circles for pre-mRNAs. The 
size of the genome in Leishmania varies from 29 Mb to 33 Mb (99). Leishmania spp. 
have 34–36 chromosomes. Leishmania (Leishmania) spp. in the Eastern hemisphere 
have 36 chromosomes (100). Species belonging to L. (Viannia) subgenus have 35 
chromosomes where chromosome 20 and 34 are fused. While species in the Americas 
belonging to L. (Leishmania) subgenus have 34 chromosomes where chromosomes 8 
and 3, and 20 and 36 are fused (101). Although they cause different clinical 
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manifestations the genomes are, in general, very conserved, and there are few species 
specific genes (102,103).  
 
In eukaryotes gene expression can be regulated at several levels, such as the 
availability of chromatin, how the RNA is processed, the stability of mRNA and the 
rate of translation of mRNA. However, the control of transcription is central, often 
through transcription factors. In bacteria, on the other hand, transcription is 
commonly regulated by binding of proteins to an operon (regulatory sequence and 
genes). However, the gene expression in the trypanosomatids is regulated in a 
curiously different way. Leishmania lacks introns, and transcription itself is initiated 
at a few regions on each chromosome. The genome contains polycistronic gene 
clusters, where the genes are organized head-to-tail (104). The genes are thought to 
be constitutively transcribed into mRNA. The genes are transcribed in clusters 
(polycistrons) of 10-100 genes (105), but unlike polycistronic transcription in 
bacteria, the genes within a given pre-mRNA do not necessarily belong to the same 
pathways. Through trans-splicing a splice leader sequence (SL) is added to the 5´-end 
of the gene (106), and the 3´-end is polyadenylated.  Leishmania have relatively short 
5´-untranslated regions (UTRs), while the 3´-UTRs are longer, which is thought to be 
important for the stability of the RNA transcript (107,108). Polycistronic transcription 
and trans-splicing is not unique to Leishmania, but that the whole genome is 
transcribed this way is thought to be unique to the kinetoplastids (105).  
 
So, how can Leishmania adapt to such different environments as the digestive tract of 
the anthropod vector and the different environments in the mammalian host? There 
seem to be relatively few differentially expressed genes in a comparison of 
amastigotes and promastigotes. However, there are studies which show that the set of 
differentially expressed genes are different when comparing promastigotes from the 
sand fly digestive tract to in vitro cultured amastigotes (109). Regulation of protein 
level is through other mechanisms, such as mRNA processing and stability (110). It 
has also been suggested that the plasticity between and within strains (mosaic 
aneuploidy) and gene copy number is key to differential gene expression (102,111). 
 38 
This might be advantageous as beneficial mutations may spread more rapidly in 
haploid populations. On the other hand, diploid populations evolve more slowly, but 
are more stable (112).  
7.2 Epidemiology 
The neglected tropical diseases (NTDs) are a group of diseases and conditions that 
are among the most common diseases affecting the world´s poor (113). The number 
of deaths related to these diseases is lower than for diarrheal diseases, HIV-AIDS or 
malaria, but the disability and poverty related to them are considerable. According to 
the 2010 Global Burden of Disease study, the NTDs accounted for approximately 
26.06 million disability adjusted life years (DALYs) (114). The NTDs can be 
important obstacles for economic development and constitute large burdens on fragile 
health systems (113). 
 
The population in endemic regions for the NTDs are often infected with multiple 
NTDs simultaneously, furthering the disability. This highlights the importance of a 
coordinated approach where both rapid diagnosis and treatment is of paramount 
importance (113). For example, drug treatment packages have been suggested as a 
rapid initial response (113), but, as Hotez et al. point out, while preventive 
chemotherapy may be effective for some NTDs, it may not be effective against 
Chagas disease, human African trypanosomiasis and visceral leishmaniasis.  
 
As highlighted by numerous reports, there is a severe shortage of reliable 
epidemiological data for the NTDs, including for the leishmaniases. The Global 
Burden of Disease study – a critical tool for monitoring global health and prioritizing 
between health programmes – systematically undervalues the NTDs (115,116). For 
the leishmaniases, there are problems related to the exact number of people affected 
because of a complex disease cycle and epidemiology, lack of simple diagnostic 
tools, and the fact that the diseases often exist in the poorest regions of the world. 
This also makes the extrapolation from official data, as international organizations 
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sometimes have to do, difficult, if not impossible (116). The accuracy of estimated 
impact measures, such as the disability adjusted life years (DALYs), which depend 
partly on the accuracy of incidence and mortality data.  
 
The leishmaniases are endemic in 98 countries and 3 territories. See figure 3 below 
for the world distribution of cutaneous and visceral distribution of leishmaniasis. One 
of the most comprehensive analyses of the available data estimated the annual 
incidence for CL to be 0.7-1.2 million and for VL to be 0.2-0.4 million (116). The 
actual number of cases is not known in most of the endemic regions (116–118). 
 
CL is endemic in 98 countries, but 75% of the cases are found in 10 countries: 
Afghanistan, Algeria, Brazil, Columbia, Costa Rica, Ethiopia, Iran, Peru, Sudan and 
Syria (116,119). 90% of VL is found in six countries: Bangladesh, Brazil, Ethiopia, 
India, Sudan and South Sudan (116). There are over 500 000 cases of VL reported 
annually, and the annual mortality estimates range from 20 000 to 60 000 (116,120). 
VL is mainly found in the poorest parts of society, and children, young adults and 
women are disproportionally affected (121). 
 
There has been a marked increase in prevalence for both CL and MCL in recent years 
in the Middle East, Central Asia and East Africa. This is probably due to war and 
conflicts leading to increase of reported cases (114). Armed conflict has proven to be 
a major risk for an upsurge in leishmaniasis. Destruction of housing, health 
infrastructure and usually already weak leishmaniasis control programmes alongside 
major population movements has had devastating effects in several areas. Cutaneous 
leishmaniasis surged in Syria after the war (122). CL has been known in Syria for 
centuries and was widely known as the Aleppo boil. After the outbreak of the war, 
over 100 000 cases have been reported, as opposed to 25 000 to 40 000 before (122). 
 




Figure 3. World distribution of cutaneous (a) and visceral leishmaniasis (b). Source (116) 
 
The war not only escalated transmission, but CL was spread to parts of the country 
previously not thought to be endemic, and to neighbouring countries (123). 
Furthermore, in Sudan and South Sudan there have been several epidemics, where an 
outbreak between 1984 to 1994 reported over 100 000 deaths attributable to VL 
among a population of approximately 280 000 (124). India has the largest number of 
VL cases at 62 000, followed by South Sudan and Sudan.  
 
In Europe, leishmaniasis is endemic around the Mediterranean basin. Some countries 
report a high prevalence of asymptomatic carries (125). There have also been recent 
outbreaks in several regions, such as the Madrid region in Spain (126), or Bologna in 
Italy (127). Imported leishmaniasis is reported regularly due to travellers’ 
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transmission and also an increase in patients on immunosuppressant drugs (84).  In a 
recent retrospective study from Sweden on imported leishmaniasis in the period 
1993-2016, including cases from both primary health care and hospitals, 182 
laboratory confirmed cases were found of which 96 were diagnosed in the last two 
years of the study (128). Leishmaniasis, on the other hand, has been reported 
sporadically in Norway (129,130). This could be due to a lack of tools to diagnose 
correctly and rapidly. This thesis aims to give more insight into the occurrence of 
leishmaniasis in Norway, to promote better treatment and clinical management (paper 
III).  
 
It is believed that asymptomatic infection is the most common outcome of inoculation 
with Leishmania spp. (71). That leishmaniasis can cause asymptomatic infection is 
not extraordinary, this is true for many infections. People who are not aware of their 
situation, or have not been diagnosed yet, may be able to work as reservoirs and 
transmit the disease to others. Thus, people who are infectious, but who have no signs 
and symptoms are called asymptomatic carriers. The problem of asymptomatic 
carriers is a great challenge for the elimination of the disease on the Indian 
subcontinent (131). However, there is no consensus on how asymptomatic infections 
should be diagnosed. Normally a person with a positive serological test, PCR or 
leishmanin skin test (LST) but otherwise healthy is considered to be an asymptomatic 
carrier (131). The true epidemiology of asymptomatic infection is difficult to 
estimate, but the ratio of asymptomatic to clinical cases (incident) ranges from 50:1 in 
a study from Spain, 4:1 in Kenya, 18:1  to 1:2.4 in Sudan, with no obvious reason to 
these differences (131). Of note is, however, that in most endemic areas, a large part 
of the population are able to establish an effective immune response keeping the 
parasite at bay. It is not entirely clear what mechanisms are involved in controlling 
the pathogen and causing no or few clinical signs and symptoms. This knowledge is 
of particular importance for several reasons – maybe the most obvious one is for 




Immunosuppression is an important risk factor for clinical disease, but may also alter 
how leishmaniasis presents and the response to treatment (53). In Southern Europe 
there was a re-emergence of VL in 2000 with a great number of cases related to HIV- 
co-infection. The parasites were transmitted by sharing of needles and syringes by 
intravenous drug users (132). During that outbreak in France, it was also shown that 
dermatotropic strains could visceralise.  This problem was resolved in Europe with 
the introduction with highly active antiretroviral therapy (HAART). However, the 
problem has persisted in other parts of the world, especially South America and 
Africa (133,134). In Ethiopia a large number of people are immunosuppressed 
through HIV and it is also a highly endemic area for VL (53). In Ethiopia, between 
20-40% of the individuals with VL are co-infected with HIV (132). 
7.3 Treatment 
“From what I observed, it is infinitely better to apply nothing, than any of the numberless 
medicines they make use of.” (135)  
 
As Alexander Russel points out in the quote above, CL may be treated with 
observation therapy. However, the more serious MCL and VL need treatment, and a 
late diagnosis could often be lethal if untreated.  
 
Current treatment options for leishmaniasis can be defined as limited, and they have 
all been developed for other indications (120). The pentavalent antimonials, used for 
centuries, remain the first option in many parts of the world, including Brazil. Their 
mode of action is not clearly understood (136). The treatment regime is lengthy (30 
days of injections), and several toxic side effects are reported, such as cardiotoxicity, 
renal failure, pancreatitis and anaemia. Resistance has been reported in several 
endemic regions against the pentavalent antimonials (120,137–139). This resistance 
is most likely due to its widespread, uncontrolled and inappropriate use, especially in 
India (137,140).   
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Amphotericin B and liposomal amphotericin work by targeting the ergosterol 
pathway in the membrane of Leishmania (121). In human cells, on the other hand, the 
main membrane sterol is cholesterol. Development of resistance against these drugs is 
more unlikely as the parasite would need to develop new pathways to replace surface 
ergosterols (120). To improve treatment, but also to eliminate or at least greatly 
reduce the incidence of transmitted VL, new dose regimens for treatments are 
necessary as today’s treatment is lengthy and prone to toxic side effects. The WHO 
have described the use of a single-dose approach as safe and highly effective in 
Bangladesh, India and Nepal (141). Amphotericin B and paromomycin must also be 
given over lengthy periods, 21 days and 30 days, respectively. Paromomycin is an 
aminoglycoside, the mode of action against Leishmania is unknown (121). 
 
Miltefosine has been used, especially in India, to treat VL. This treatment, although 
attractive as it is an oral therapy, remains unattractive as it still requires lengthy 
treatment (28 days) and strict birth control is necessary due to it being teratogenic.  
 
For VL, combination therapy has increasingly been advocated, because of emergence 
of drug resistance, to shorten administration time of the drugs, affordability, and ease 
of administration (142).  For elimination purposes, single-dose liposomal 
amphotericin B seems to be the best option, as it ensures high compliance, but also 
reduces the cost to families and decreases time off work. Another reason for 
introducing single-dose liposomal amphotericin B in some regions is its 
attractiveness, because it is relatively safe, effective and 100% compliance is 
guaranteed (143). The single dose approach has been recommended by the WHO as 
the first line treatment option in India (120,144). Treatment regimens have to differ 
from region to region, between various patient groups (145) and between the different 
Leishmania spp. For example, a combination therapy including liposomal 
amphotericin B and miltefosine might be more attractive for males, while a 
combination of liposomal amphotericin B and paromomycin might be more attractive 
for women.  
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In a study from Bangladesh, the efficacy and safety of single-dose liposomal 
amphotericin B for VL were investigated (146). Out of 300 patients included, 90% 
achieved final cure. The authors therefore concluded that a single dose liposomal 
amphotericin B (10 mg/kg bodyweight) could be adopted in an elimination 
programme in Bangladesh. However, the problem with liposomal amphotericin B is 
its requirement for a cold chain, which might be problematic in remote locations, 
which are also typically endemic for VL. Despite this, the authors found that the 
implementation of a single-dose liposomal amphotericin B treatment strategy is 
feasible in remote locations (146). Another study in rural Bangladesh confirmed the 
feasibility of such an approach, given proper training of health-care staff (147). There 
are however several problems related to single dose regimens: (i) what is the efficacy 
and safety in selected patient groups outside the studied group, (ii) extrapolation of 
the results to other regions endemic for leishmaniasis is problematic because of 
geographical heterogeneity in VL (such as Africa or other agents, like L. (L.) 
infantum) (142). Liposomal amphotericin B (AmBisome) is costly, but a price 
reduction for all low- and middle-income countries where leishmaniasis is endemic, 
has made it more feasible (148).  
7.4 Prevention 
Leishmaniasis, given the complex interplay between host, vector and reservoir, 
probably requires a multifaceted approach for control and prevention. Elimination of 
leishmaniasis is highly unlikely. In general, to eliminate an infectious disease requires 
that every infection leads to clinical disease and is only present in humans.  For CL, 
most commonly a zoonosis, often with a sylvatic reservoir, the environmental cost of 
any preventive strategy would be too high. Furthermore, in VL the role of 
asymptomatic individuals in transmission is unclear, and it is likely that they 
contribute to the transmission (24,130). In addition, domestic animals might have a 
more prominent role as reservoirs, including in areas previously thought to be only 
anthroponotic transmission areas (26). That the sand fly in the Indian subcontinent 
should only feed on humans would be an exceptional finding, as the sand fly vector is 
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an opportunistic feeder and one could expect them to feed on wild and domestic 
animals in addition to humans.  
 
Vector control can however work in certain areas. An example is from the European 
Mediterranean area, where an important reservoir for CL, Phlebotomus obesus, is 
controlled by zinc phosphide tablets in burrow entrances or clearing of vegetation in a 
500 meter barrier zone around the habitat (119).  
 
For humans, potential control strategies could include early detection, drugs and 
vaccine. A vaccine is probably the best way forward, especially since infected people 
are known to acquire long-lasting immunity against infection from parasites of 
related strains (49,148–150). Ideally, a vaccine for leishmaniasis should be broadly 
protective against all the species of the parasite causing the different variants of 
clinical disease, but this has so far proven difficult. However, in theory, it should be 
possible. When selecting antigens for a recombinant, vector or nucleic acid vaccine, 
antigens that are highly conserved among different species of the pathogen are 
typically selected. Even if two species are relatively distant in evolutionary terms, a 
vaccine based on conserved antigens could give protection against several species. 
Intuitively, it may be most pressing to develop a vaccine for the potentially fatal 
visceral form, commonly caused by only two species – L. donovani or L. infantum. 
 
It is not entirely clear what type of vaccine is most likely to be effective against 
leishmaniasis, but as it is an intracellular pathogen, a strong T-cell response has to be 
induced. Vaccines based on killed or live attenuated pathogens have the potential to 
mimic natural infection closely. In the Middle East, so-called “leishmanisation” has 
been practised, whereby pus from cutaneous lesions and parasites from culture were 
used to induce a local infection (150). Leishmanisation was discontinued because of 
problems with reproducibility and safety issues. Furthermore, a leishmanisation 
strategy involving a viscerotropic strain, such as L. donovani, is highly unlikely, and 
probably unethical. Vaccines consisting of purified or recombinant proteins expressed 
in bacteria or eukaryotic cells usually require an adjuvant to induce a good T-cell 
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response (151). The Infectious Disease Research Institute in Seattle has developed a 
vaccine where several proteins conserved across several species of Leishmania are 
expressed in a single vaccine using a toll-like-receptor agonist as an adjuvant to 
induce a strong T-cell response (18, 19). This vaccine has shown promising results 
(152). Nucleic acid vaccines work by introducing expression vectors encoding for a 
protein antigen into the recipient. Here not the antigen itself, but the information 
required to produce it, is introduced. The recipient’s cells produce and present the 
antigens to immune cells (153). This vaccine strategy has obvious attractions, such as 
the fact that the vaccine can be rapidly and cheaply produced. The DNA-vaccine 
approach has been tested with several antigens against Leishmania-infected mice, but 
its effect remains unconvincing. Vectors such as Adenovirus, expressing recombinant 
antigens, can also be used as vaccines. A novel vaccine uses this approach by 
expressing a gene encoding for two Leishmania proteins, and initial results are 
promising (154). But this is only in phase I clinical trial stage, and there are 
significant challenges ahead. 
 
Over the years, several vaccine targets and vaccination routes have been proposed 
and tested (155). Some of them have shown great potential in protecting animals 
against leishmaniasis (156). However, remarkably few have been able to proceed to a 
clinical trial. This lack of progress is partly due to lack of a small-animal model that 
reflects human disease, and to the fact that many vaccines are tested with cutaneous 





7.5 Diagnosing the leishmaniases 
In this section, I will discuss the common diagnostic approaches more in detail. 
Particular attention will be given to the molecular application with a discussion of 
potential targets and methods. 
 
For diagnosing leishmaniasis, a range of diagnostic methods can be used, starting 
with history taking and symptoms, and - when leishmaniasis is suspected - 
microscopy, serology and molecular methods. Unfortunately, lesion characteristic 
and probable geographic area where the infection happened are not sufficient for 
diagnosis or species identification for CL. The latter is of particular importance in the 
Americas, where species from the subgenus L. (Viannia) may cause mucocutaneous 
lesions years after CL.  
 
Clinical diagnosis of VL relies on non-specific symptoms like prolonged fever, 
weight-loss and splenomegaly. Biochemically, the patients often have pancytopenia 
(anaemia, leukopenia and thrombocytopenia), elevated inflammatory markers and 
hypergammaglobulinemia. However, although these symptoms and findings raise the 
suspicion of the diagnosis in the experienced physician, they are not sensitive and 
specific enough for diagnosis alone (162).  
 
There is no standard protocol for diagnosis, and the methods used vary in endemic 
and non-endemic regions. Leishmaniasis should ideally be diagnosed using several 
approaches to improve the likelihood of a correct diagnostic result. The latest 
diagnostic recommendations from the Infectious Disease Society of America (IDSA) 
and the American Society of Tropical Medicine and Hygiene (ASTMH) suggest that 
leishmaniasis should be diagnosed to the species level for all the clinical forms to 
guide treatment and clinical management (144). 
 
In brief, leishmaniasis can be detected by seeing (clinical, microscope), by the 
measurement of the immune response (e.g. ELISA), or detection of protein, RNA or 
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DNA. All diagnostic approaches and targets come with their strengths and 
limitations. In non-endemic regions, the greatest challenge is probably the first step, 
suspecting the parasitic disease in the first place. Parasitological diagnosis involves 
the demonstration of the parasite in tissue or culture. Anti-leishmanial antibodies can 
be detected using several methods, such as enzyme linked immunosorbent assay 
(ELISA), direct agglutination test (DAT), indirect immunofluorescence (IFA) and 
immunochromatographic strip tests (IST). Assays have also been developed to detect 
antigen in urine (157). Molecular approaches, like PCR, real-time PCR and 
associated methodologies are increasingly being used.  
 
Diagnosing leishmaniasis can be a challenge because of the wide spectrum of clinical 
manifestations. There are different diagnostic approaches for the main clinical forms 
of the disease. Also, a range of differential diagnoses should be considered, and 
accurate diagnosis is therefore important. In addition, in some endemic areas, co-
infection with other trypanosomatids may cause problems with the diagnosis if the 
approach or assay used is not specific enough (158). Accurate diagnosis is also 
crucial for surveillance and epidemiological studies. Several important questions need 
to be answered when choosing a diagnostic strategy. Peeling and Mabey, highlighted 
the ASSURED-criteria when choosing diagnostic tests for the developing world 
(159). The ASSURED criteria are specifically made for rapid tests listing: 
Affordable, Sensitive, Specific, User-friendly, Robust and rapid, Equipment-free or 
minimal equipment and Deliverable to those who need them. So far, few, if any 
molecular methods meet these criteria. 
 
According to Shaw et al. (160) a diagnostic tool should differentiate Leishmania 
species, be able to measure the parasite load in host and vector as well as being able 
to monitor the efficacy of treatment. This seems somewhat unrealistic and most, if 
not all tests, are unable to meet these criteria. Furthermore, the criteria seem 
somewhat biased towards molecular methods. Besides, the demand for monitoring 
the efficacy of drug treatment remains questionable as it is, so far, not included in 
recent guidelines (144). Some authors include further requirements that all seem 
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unrealistic and more research oriented, such as the need to identify sample origins, 
relationship with non-human reservoirs and several more (161). In the next sections 
the different diagnostic modalities will be discussed in more detail.  
7.5.1 Parasitology 
Parasitological diagnosis involves the demonstration of the parasite in tissue or 
culture. The amastigote forms of the Leishmania parasite are identified intracellularly 
or extracellularly by size and characteristics morphology, including the nucleus and 
kinetoplast. The kinetoplast is particularly important to identify, as the parasite 
without the kinetoplast can be mistaken for other pathogens, like Histoplasmosis 
capsulatum, which also may be found in phagocytic cells (163,164).  
 
For VL, smears from spleen have the highest sensitivity, followed by bone-marrow 
and lymph node (165). Spleen aspirate is the recommended reference method for VL, 
especially in studies comparing diagnostic methods (148). Patients with VL often 
have pancytopenia, meaning they are at higher risk of fatal bleeding when a spleen 
biopsy is taken. However, Sundar et al. (167) only report two fatal bleedings after 
9612 splenic aspirations. Regardless, other techniques that require less invasive 
diagnostic techniques are important for VL. Microscopy, although in trained and 
capable hands, may be very specific, sensitivity on the other hand is comparatively 
low and highly influenced by smear quality, reagents and experience (168).  
 
In CL, a biopsy from the ulcer is sensitive (17). This requires invasiveness often not 
usable for large-scale screening, but also for follow-up. For CL, some studies have 
proposed that the use of filter papers able to store DNA (e.g. FTA-cards), could be a 
useful solution to avoid taking a biopsy. But our study (Paper III) and others have 
shown that although they might be of value in a research setting, in the clinical setting 
their role is more dubious (169). 
 
The traditional culture of Leishmania from biopsy specimens from patients is both 
labour intensive, lacks sensitivity and requires considerable specialist infrastructure 
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(170). Developing of new culturing techniques, like microculture, could make the 
culture approach cheaper, more sensitive and specific (170). Despite this, processing 
time did not improve greatly, only reducing the culture time from 5 to 3 days 
compared to traditional culture, making the technique unattractive for diagnosis, 
especially VL. Culturing was particularly attractive before the molecular approaches 
became established because it allowed drug sensibility testing and species 
identification with multiloci enzyme electrophoresis (MLEE). However, today, all 
these parameters can be explored with different molecular approaches.   
 
Microscopy has the advantage of being fast, and some argue it is easy to perform for 
the trained microscopist. One severe limitation is that in chronic lesions, the number 
of parasites may be difficult to find. The older the lesion, the lower the number of 
parasites in the lesion. A study from Para in Brazil, found that the parasitism was 
very low in lesions older than 12 months (171). 
 
Immunofluorescence in general is sensitive but lacks specificity. In Brazil, cross-
reactivity with other common infections, such as Chagas disease (Trypanosoma 
cruzi) has been reported (172). It has furthermore been shown to lack sensitivity in 
patients with few lesions or acute lesions (171). 
7.5.2 Serology 
Anti-leishmanial antibodies can be detected using several methods, such as enzyme-
linked immunosorbent assay (ELISA), direct agglutination test (DAT), indirect 
immunofluorescence (IFA) and immunochromatographic strip tests (IST). ELISA 
requires considerable experience and is probably only suitable for well-equipped 
reference centres. The inherent problems with ELISA could probably be overcome in 
some field-settings by a collection of material in the field and transport of the 
material to a reference centre thereafter. Although suitable for research studies, this 
would be costly, time-consuming and delay the diagnosis. DAT has and is still in use. 
The applicability of DAT in the field setting has been increased with the development 
of assays where the antigen is freeze dried, thus reducing the need for a cold chain 
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(173–175). Although relatively cheap, sensitive and specific, it requires considerable 
laboratory time (partly due to long incubations), test readings to be standardised and 
some infrastructure which is not always available in the field (176). In IFA the 
antigen is adsorbed to a slide, and antibodies present in the patient sample (serum) are 
detected by a fluorescein labelled secondary antibody using an immunofluorescence 
antibody.  Comparing ELISA and IFA, a study found that for patients with CL IFA, 
along with parasitological confirmation, could be used in diagnosis. There are also 
other sporadic reports of the usefulness of IFA in CL (177). A study from Iran, 
comparing ELISA, DAT and IFA, found the sensitivity and specificity of the latter to 
be 80.3% and 90.5% respectively (148). Although IFA may have a role in diagnosis, 
the lack of a standard antigen, proper validation in different endemic settings, and the 
requirement of considerable infrastructure and expensive equipment mean that the 
technique has limited value in a diagnostic setting. IST can have a prominent role as 
point-of-care tests, especially in rural settings. 
 
In endemic settings, the necessary skill, quality of tissue smears and staining, and a 
high quality microscope is often unavailable (167). HIV is also a major public health 
issue in many endemic regions for VL, and in half of HIV-Leishmania coinfected 
patients, serology has been found to be negative (178,179). Furthermore, 
seropositivity has been reported in over 30% of an apparently healthy population, 
probably due to the high number of asymptomatic individuals in endemic regions 
(174,180,181). For the leishmaniases, serological tests only have very limited value 
in CL and MCL but may have a more prominent role in VL. Especially useful is 
serology for VL patients where other diagnostic tests, such as spleen biopsy or bone 
marrow aspirate cannot be performed. They also have a role in screening in endemic 
areas. In elimination programmes especially, active case detection is important, 
requiring a good point-of-care (POC) test: for VL an IST seems like a very good 
option. However, currently, the available tests have great limitations in terms of 
sensitivity and specificity when it comes to different geographical locations. 
Sensitivity and specificity vary depending on the antigen used, geography and host 
factors. Furthermore, as antibodies can be detected years after clinical cure, caution 
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should be taken in the interpretation of the results.  A study from Ethiopia, found that 
89% of treated and cured VL cases had DAT positive antibodies 50–90 months (7.5 
years) post-treatment (182). The same was found in Brazil, where many patients with 
VL had persisting and detectable antibody levels years after treatment, one even 
reporting 12 years post-treatment (183). In a study from Sudan, antibody levels could 
be detected up to 24 months post treatment measured by ELISA and DAT (184). On 
the other hand, a study from India found that for 55 patients in India, IgG titer 
reached a maximum after 6 months, declined rapidly and were not detectable after 2–
3 years, measured by ELISA (185). The discrepancies between these results are not 
easily explained but it seems clear that in most cases and for most endemic areas, 
anti-leishmanial antibodies remain detectable for a long time after treatment. 
 
Several antigens have been developed for serological tests for leishmaniasis. 
Antigens for serology should, due to standardization purposes and the ability to 
produce enough antigen, preferably be manufactured as recombinant proteins. rK39, 
rK28 and rKE16 are examples of this. rK39 is based on a 39 amino acid sequence 
from the kinesin gene in L.(L.) infantum and expressed in E. coli (186). rK28 is a 
polyprotein based on three proteins: L.(L.) donovani haspb1, L. (L.) donovani haspb2 
and L. (L.) donovani kinesin (187). rKE16 is a development of the rK39, but the 
sequence is based on a kinesin gene in L. (L.) donovani (188). A study from Kenya, 
involving 131 VL patients and 88 healthy controls, and comparing a rK39 tests (IT-
LEISH, Bio-Rad) with a rKE16 test, found that for rK39 the sensitivity was 89.3% 
and specificity were 89.8%, while for rKE16 sensitivity was 77.10% and specificity 
was 95.5% (189). Although the authors strongly stress the need for improved RDTs 
for East Africa for VL, they suggest that rK39 can be used. In Bihar in India rK28 
ELISA was found to be performing as well as rK39, yielding a sensitivity of 99.6% 
and specificity of 95.45% (190). 
  
In a World Health Organization (WHO) coordinated study, 250 cases and 250 
controls were included for each region (191). Patients were recruited from 4 labs 
from India, Bangladesh and Nepal, 2 labs in Brazil and 3 labs in Kenya and Sudan. 
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For India, Bangladesh and Nepal the results were uplifting with good sensitivity and 
specificity, and all the products had good heat-stability. Among the RDTs tested, 
sensitivity ranged from 92.8–100% and specificity 96–100%.  For East Africa and 
Brazil, the situation was not as promising. In East Africa, the sensitivity ranged from 
36.8–87.2% and specificity 90.8%-98%. The same situation was reported for Brazil 
with a sensitivity of 61.5–92%, and specificity of 95.6–98.8%. For these two regions, 
the rKE16 performed worse than rK39.  Not only antigen diversity might explain the 
difference in the test, but also differences in parasite and antibody concentration 
among the study participants, again linked to age, immune status and nutritional 
status (191).  
 
A Cochrane review compared rK39 ICT, rK26 ICT, rKE16 ICT, KAtex  (see section 
7.5.3) in urine and FAST agglutination test. The authors conclude that the rK39 is 
useful in well-defined cases with no previous history of VL in India, Bangladesh and 
Nepal. However, they consider the test unsuitable in East Africa due to low 
sensitivity. The other tests, they concluded, lacked both accuracy and validation 
(192).   
                                                                                                                                                                                                                                                                         
Lateral flow techniques are often optimized for serum, although in the field setting, 
whole blood is the more common material (193). A study from Sudan found that, the 
rK28 test was positive for two controls (2%) for serum, while none were positive for 
whole blood (194). Another study from India, compared the use of the rK39 on whole 
blood and serum and found 40% of the cases to be blood and serum positive, while 
4% were blood negative and serum positive (193). 
 
To conclude, serology may be useful in the field for clearly defined cases of VL in 
India, Bangladesh and Nepal, but should be used with caution for surveillance also 
here. For other regions, the use of serology remains unclear. Serological tests are also 
limited for immunosuppressed individuals who may present with lower antibody 
titers (195). In addition, several serological tests for leishmaniasis have the potential 
for cross-reactivity with other trypanosomatids and malaria (173). 
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7.5.3 Antigen detection 
Antigen detection has been reported to be more specific than antibody detection 
(196). It is believed that the levels of antigen correspond to parasite load, thus 
enabling the test to be used for clinical cure and relapse. Furthermore, as antibody 
detection is thought to be of limited value in the immunosuppressed, antigen 
detection could have a more prominent role in this group. One of the most commonly 
used assays is KAtex (Kalon Biological, UK). KAtex detects a carbohydrate antigen 
present in both promastigote and amastigote stages. KAtex is fast and easy to use 
without the need for specialized training. However, the assay procedure involves 
several steps that must be followed strictly to yield a reliable result. The read-out of 
the tests is subjective, and the reagents require refrigeration (2-8 °C).  
 
In a study from Bangladesh with 36 patients and 40 healthy controls, KAtex was 75% 
sensitive and 100% specific (159), while another study from Bangladesh, including 
50 patients and 50 healthy controls, found the sensitivity to be 94% and specificity to 
be 98% (162). A study from India found that out of 392 patients and 185 healthy 
controls in India that the KAtex was 87% sensitive and 99% specific (197). 
Furthermore, a study of 155 VL patients and 77 healthy controls in Nepal found the 
KAtex to perform poorly with 47.7% sensitivity and 98.7% specificity, and with a 
moderate reproducibility (198).  
 
Another study performed in India compared parasitological diagnosis with DAT-FD, 
rK39 strip test, rK25 strip test and KAtex in 230 confirmed patients, 52 probable 
cases, 70 non-cases and 100 healthy endemic controls, and found the sensitivity of 
KAtext to be 67% (163). This was significantly lower than the DAT-FD (98.9%) and 
rK39 (98.9%). However, the specificity was above 90% of all the tests. On the other 
hand, a study in Ethiopia comparing the same tests as the study from India found 
KAtex to perform poorly compared to both DAT-FD and rK39 (199). 
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A study from a rural setting in Nepal including 142 patients compared the formol gel 
test (FGT), KAtex and rK39 (200). The sensitivity of FGT was 52%, for rK39 89%, 
and KAtex 57%. All tests had a specificity of approximately 90%. It is unclear why 
the sensitivity is significantly lower in Nepal than Bangladesh and India as the agent 
should be the same in the region, L. (L.) donovani.  
 
To conclude, antigen-based tests still seems to have too unsatisfactory sensitivity and 
specificity to be useful in a clinical setting.  
7.5.4 Detection of DNA 
So far, molecular diagnostic tools have had limited to no role in the diagnosis of all 
the clinical forms of leishmaniasis, but are introduced as a diagnostic tool in severeal 
diagnostic laboratories. In resource-limited settings, the molecular approaches are 
limited as they, in general, require a well-equipped laboratory, highly skilled 
technicians and expensive equipment and chemicals.  
 
Molecular approaches to diagnosis of leishmaniasis have been available since the 
1990s (201). By polymerase chain reaction (PCR), sequences of DNA or RNA are 
amplified by repetitive cycles. It requires isolation of DNA or RNA beforehand. 
PCR-based methods are sensitive and are therefore prone to contamination if a strict 
uni-directional work-flow is not established. In addition to both high sensitivity and 
specificity, PCR based methods may also be able to quantify the parasite in the tissue. 
 
PCR is a specific, sensitive, versatile and fast technique (202). PCR has been used on 
a range of materials; cell-culture, lesions, blood and sand flies. A range of different 
PCR-methods have been developed, but only a few are in routine use. One example is 
the oligochromatography-PCR (OC-PCR), where the amplification of the nucleic acid 
sequence is visualized on a dipstick. It is a simple technique involving little to no 
expert knowledge and equipment (203,204) 
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PCR techniques may not only be used for detection, but also for species 
differentiation. A range of targets and techniques have been explored. Several are in 
routine use, but there is no gold standard (145,163). By conventional PCR, the 
amplified nucleic acid fragment (amplicon) is visualized by gel-electrophoresis where 
differences in length are used either for detection or for species differentiation. 
Specificity is dependent on a range of factors, but central are the enzymes used. Taq-
polymerases, first isolated from the thermophilic bacterium Thermus aquaticus in the 
1970s, is still in wide use (205). Taq polymerase, however, lacks 3´-5´exonuclease 
activity, and is therefore prone to producing mistakes during amplification. Using an 
enzyme that has exonuclease activity may increase specificity at the cost of 
sensitivity (205). 
 
PCR products may also be digested by DNA restriction enzymes, that cut a 
nucleotide sequence at a specific site, leading to different profiles of the digested 
product. Several assays using restriction enzymes have been developed for 
Leishmania discrimination. Examples of targets are ITS1 (206) and hsp70 (207). A 
PCR may be improved by running a second PCR on an already amplified product. In 
this way, both specificity and sensitivity might be improved (208). Several targets 
may also be amplified in a multiplex PCR. Multiplex PCR are, for example, in 
routine use for parasites in stool (209).   
 
PCR products may also be used for subsequent sequencing using for example Sanger 
sequencing (first generation sequencing). This is a technique more commonly used 
for species identification. It does require expertise both in preparing the product for 
analysis and in analysing results, can only sequence a limited range of base pairs, and 
requires advanced technical facilities.   
 
In most laboratories, conventional PCR has been replaced by real-time PCR. In real-
time PCR the amplification of the target sequence is detected at each cycle (paper I 
and II). A further development of real-time PCR is High Resolution Melting analysis 
- HRM (paper II), that measures the fluorescence intensity of dissociation from 
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dsDNA to ssDNA. HRM analysis in distinct PCR products can differentiate 
Leishmania-spp. based on their composition, length, GC content and strand 
complementarity. The method can also be automated (210). 
 
ELISA, a technique widely used in immunology to detect an antigen or an antibody 
may also be combined with PCR. In a PCR-ELISA, a PCR product is detected after 
being immobilized (211). The technique may be rapid and sensitive. It is, however, 
not of widespread use in diagnosis.   
 
Loop-mediated isothermal amplification (LAMP) may be a specific and sensitive 
technique for diagnosing Leishmania in several endemic regions where diagnostic 
and laboratory facilities are scarce. The amplified sequence may be visualized to the 
eye. Although LAMP is hailed as sensitive and simple without the need for 
specialized equipment and reagents (212–214), there are several limitations to the 
technique, such as very specific requirements for the design of primers that may limit 
the development of an assay. 
  
Multilocus enzyme electrophoresis (MLEE) has, despite its limitations, been used for 
species differentiation (215). Other molecular techniques, like multilocus sequence 
typing (MLST) are not discussed further in this thesis.  
7.5.5 Molecular targets 
There are a range of molecular targets available, and Akhoundi et al. give a 
comprehensive review of the most common targets (163). In general, protein coding 
sequences in Leishmania have high specificity, but lower sensitivity compared to 
non-protein coding targets like kDNA. This is due to the lower level of copy numbers 
of chromosomal versus non-chromosomal (mitochondrial, maxicircles, minicircles) 
sequences. An example of a commonly used protein-coding target is the heat-shock 
protein 70 kDa – Hsp 70 (163,207,216). It is, rather uncommonly, a multicopy gene 
both used for detection and species identification using a range of methods (163,216).  
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Akhoundi and colleagues list important factors for validation of molecular methods 
that must be take into account when choosing a target sequence (size, number of 
copies in genome, specificity within genus and species), efficacy of the methodology 
(precision, reproducibility), and clinical sensitivity and specificity (217). In general 
terms, multi-copy genes are preferred for detection, as they improve sensitivity. 
However, multi-copy genes may vary in the copy number and may therefore be 
inappropriate to use in quantitative assays. For that purpose, single-copy genes may 
be more appropriate. 
 
There is no perfect diagnostic target for leishmaniasis that is perfect in molecular 
diagnostic assays. In line with Akhoundi and colleagues (217), and others, this thesis 
argues that for diagnostic purposes, a two-step approach is probably the most 
appropriate, where multi-copy genes are used for genus detection and a single or few-
copy gene is used for species differentiation. There are potentially genes that may 
work for both purposes: Hsp70 has been shown to be useful for both genus detection 
and species differentiation with a good specificity and sensitivity, using HRM (210). 
7.5.6 Other diagnostic possibilities 
Other techniques, which are more commonly used in microbiological diagnosis may 
have a role in diagnosing leishmaniasis and species identification. One example is 
MALDI-TOF mass spectroscopy. MALDI-TOF is increasingly being used for 
bacterial identification. There is a limited amount of evidence on the applicability of 
this method for leishmaniasis. In a relatively recent paper, MALDI-TOF was shown 
to be able to discriminate Leishmania at a species level (218). However, this 
technique is far from being useful in most settings as it requires a well-established 
mass spectral library, requiring considerable expertise and infrastructure. The 
requirement of a culture means it is of little relevance in most endemic settings in 
addition to being time-consuming. Although mass spectroscopy today is an integrated 




In the Montenegro skin test, 0,1 mL of Leishmania antigen is injected in the forearm. 
The local induration is measured 48-72 h after, and if its > 5 mm it is considered 
positive. This test measures delayed-type hypersensitivity (59). However, caution has 
to be taken as not all CL patients yield positive results. Furthermore, species used and 
how it is prepared for antigen preparation varies, thus comparability is also an 
important issue with this test (59). In  a study from Tunisia, the test remained positive 
in 20/22 patients post treatment (2 years follow-up) and in 75% of the individuals 
living in the endemic area without a history of leishmaniasis (219). This test is not 







Gaps in the literature 
The leishmaniases remain, in general, diseases related to poverty and are considered 
as neglected tropical diseases. There are considerable gaps in our understanding of 
the parasite biology, as well as its relationship with hosts (insect and mammal). In 
addition, there is no gold-standard technique for diagnosis, classical or by molecular 
methods. Therefore, there is a need to explore further diagnostic methods and 
molecular targets that can be used in both endemic and non-endemic regions (217). 
To distinguish Leishmania at the species level is paramount for several reasons: (i) in 
several endemic areas several species coexist and the correct identification of them is 
important to apply the correct therapeutic and follow-up regimes, and (ii) 
epidemiological and ecological reasons. For this purpose, techniques using genetic 
material (DNA or RNA) are useful. To be able to explore targets, precise DNA 
nucleotide sequences are central, as this has been a challenge for several Leishmania 




The aim of this thesis was to explore a new potential target, the amino acid permease 
(AAP3) coding sequence and flanking nucleotide sequences for parasite detection and 
species identification using molecular methods.  
 
Secondary aims 
• To develop an assay to detect Leishmania spp., and to quantify the parasite 
load in mice (Paper I).  
• To develop a diagnostic assay for species identification where the amplified 
product is contained in the tube thereby lowering the risk of laboratory 
contamination (Paper II). 
• To validate aap3 as a target in clinical samples (Paper II and III). 
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• To improve the quality of available complete nucleotide sequences of aap3 
coding sequences and flanking regions, to determine the nucleotide sequence 
in a larger range of Leishmania spp. comparing the genomic organization in 
both subgenera of Leishmania pathogenic to humans (Paper IV). 
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9. Methods and methodological considerations
9.1 Patient recruitment (paper III) 
The basis of clinical studies, and sometimes experimental studies, is patient 
recruitment. In this thesis, patients were recruited when either Leishmania infection 
was established (paper II) or suspected (paper III). In paper II biopsy material from 
patients was included, however, this was conducted at an earlier time-point and in 
relation to another study. In paper III, patients were included prospectively, when 
Leishmania infection was suspected at one of the participating hospitals in Norway. 
Ethical approval was obtained for both studies. For the study in paper III, it was 
planned to include approximately 50 patients. This study probably fell victim to 
Lasagna´s law, which states that investigators greatly overestimated the pool of 
patients (220). One goal of the project was to stimulate the establishment of 
molecular diagnosis of Leishmania in Norway. This was achieved when molecular 
diagnosis was established in Oslo (Ullevål University hospital) in 2015. 
Leishmaniasis is not part of the Norwegian Surveillance System for Communicable 
Diseases (MSIS), and hence the occurrence is not known. The early termination of 
the study could have been avoided if we had been more cautious when estimating the 
occurrence of leishmaniasis in Norway. 
9.2 Parasites (paper I and II) 
Leishmania promastigotes can be cultured in a range of media, from semi-solid to 
liquid medium. Novy-MacNeal-Nicolle (NNN) blood agar is used for diagnostic 
purposes in several reference laboratories. Biopsy material from splenic aspirates, 
bone marrow or lymph node is commonly cultured directly in this medium (221). For 
continuous propagation of promastigotes, a range of liquid media is commonly used 
(RPMI, M199, Schneider etc.). In this thesis, we worked in general with two media, 
M199 and RPMI1640. These two media are well-established and it is unlikely that 
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any of the results have been affected by the use of these media.  In general, they 
consist of a buffer-system (for example for RPMI1640 a bicarbonate buffer) and are 
commonly supplemented with heat inactivated serum, hemin, glutamine and 
sometimes other amino-acids, in addition to antibiotics. Human urine has been shown 
to stimulate growth of several Leishmania spp. in vitro and may be added, although it 
is not clear which substance is causing the increased growth (222). In addition, 
several Leishmania spp. may be converted to amastigotes in vitro by increasing 
incubation temperature and by making the growth medium more acidic (223,224). In 
this thesis, we worked only with promastigote forms cultured in liquid media. For all 
the works, we limited the number of passages in liquid culture to a minimum, 
generally below five passages. Although, this is probably not essential when working 
with Leishmania for diagnostic purposes and the isolation of enough DNA is the 
purpose, it is indeed the case that the parasite is adaptable to long-term culture and it 
alters several biological properties (224). Therefore, care has to be taken when 
experiments are designed and results are analysed. For example, if a particular gene is 
to be studied for functional properties, the experimental model should strive to reflect 
the situation in vivo. By adapting the experiment too much to the convenience of the 
researcher, one risks removing oneself too far from the situation in vivo and 
consequently may make false conclusions.  
9.3 Mice (paper I and II) 
Animal models are central to the study of the leishmaniases. They are, for example, 
essential when studying the immune response, pathology and functional studies of 
genes (224–227). Mice, hamsters, domestic dogs and non-human primates have been 
used, especially in the study of the immunological response to the parasite. Studies 
using mice have been central in defining cells and molecules (e.g. cytokines) that are 
important in the immune response against Leishmania (228).  However, all the 
models do not necessarily represent the situation in the infection in the human host. 
For immunological studies, all aspects of the infection, from the amount of inoculum, 
the saliva of the sand fly, the cells first recruited to the site of infection, the genetic 
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background of the host, and much more, is essential for the outcome and 
interpretation of the experiment (225–227). In the papers of this thesis only the mice 
model was used and will be further discussed. The hamster model, using the Syrian 
golden hamster (Mesocricetus auratus) is considered the best experimental model for 
visceral leishmaniasis. The model is, however, constrained by the lack of molecular 
and immunological markers available to study the gene expression and 
immunological response (225).  Dogs are the main reservoir of zoonotic visceral 
leishmaniasis in Europe, the Middle-East, South-America and parts of Asia. Dogs 
have been used as experimental models. However they are expensive and also here 
the available reagents are often lacking. Primates, like the rhesus macaques (Macaca 
mulatta) could be an attractive experimental animal because of their similarity to 
humans. Of the available animal models, macaques are evolutionarily closest to 
humans (229). They have, for example, been used in vaccine testing (229). Their 
main draw-back is that they are expensive, difficult to obtain and handle. Furthermore 
ethical committees are not encouraging the use of monkeys in animal experiments 
(225). Mice are the most common animal used, especially the BALB/c and C57BL/6 
strains. Where BALB/c mice are considered susceptible and develop a classical Th2 
immune response, while C57BL/6 are considered resistant to cutaneous strains and 
develop a strong Th1-response, although this is dependent on the inoculation site. In 
general for animal studies, but absolutely central for mice studies, is consideration of 
the developmental stage of the parasite stage, route of infection (subcutaneous, 
intraperitoneal, dermal), site of infection, inoculation dose and mouse genotype, as 
these issues will influence the results (226). 
 
The use of animals in experiments are an integral part of research, especially where 
studies cannot be undertaken on humans, for ethical reasons (drug testing, vaccine 
studies and alike). No model is perfect for leishmaniasis, no model can reproduce the 
infection in humans. Thus, care has to be taken when drawing general conclusions 
from such experiments. For all the animal experiments (paper I and II), ethical 
approval was obtained from the appropriate authorities, the animals were taken care 
of by trained staff, they had food and water ad libitum, and the minimum number of 
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animals, to statistically guarantee the results, were used. To prove that a diagnostic 
method is able to detect the target in various animals (paper I and II) it is important to 
test it under controlled conditions. It is arguable, though, that it might not have been 
necessary to test it in laboratory animals, wild infected animals would have sufficed. 
However, for paper I, the use of the method for quantitative purposes was essential to 
prove and mouse experiments were difficult to avoid. For paper II, it was important to 
prove that the diagnostic method could also be used in an experimental setting.  
9.4 DNA (paper I-III) and RNA extraction (paper IV) 
Extraction of nucleic acids from cultured cells or tissue is a central technique in any 
modern research and diagnostic laboratory. The extraction techniques are often 
overlooked as simple and just a pre-step before the real experiments. However, care 
has to be taken when nucleic acids are separated from proteins, cell membranes and 
other material as contamination has to be avoided, and one should strive for as pure a 
sample as possible to avoid inhibitory molecules for later applications. Furthermore, 
the nucleic acid extraction itself may be one of the most labour-intense parts of an 
experiment. In general, any nucleic acid extraction protocol consists of some basic 
steps: (i) lysis of the cells, (ii) purification or isolation of nucleic acid from other cell 
components.  
The DNA extraction procedure is generally divided into organic purification, using 
phenol/chloroform or inorganic purification that uses, for example, silica beads to 
bind the DNA. In papers I and III commercial kits were used to isolate DNA, based 
on DNA binding to silica beads. This method is prone to contamination, as it does 
involve multiple tube changes. However, the method may be automated which allows 
processing of a large number of samples. In paper II an organic method, using a 
salting out technique, was applied to extract DNA from trypanosomatids. The method 
was based on a protocol already described by Miller et al. (230). The protocol was 
laborious, but relatively simple, cheap and a high quality and pure DNA was isolated. 
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In paper III, FTA filer paper cards was also used for DNA isolation. The cellulose-
based matrix contains several reagents to stabilise nucleic acids for long-term storage.  
Compared to DNA extraction, RNA extraction is inherently more difficult as there 
are several enzymes in cells and tissues that rapidly degrade RNA. Thus, care has to 
be taken to ensure high-quality RNA is isolated necessary for several downstream 
applications, such as reverse- transcription real time PCR and RNA sequencing. 
Several applications exist, generally divided into: (a) organic extraction methods, (b) 
filter-based extraction methods, and (c) magnetic particle methods. In paper IV, 
TRIzol was used for isolation, a liquid extraction technique using guanidinium 
thiocyanate-phenol-chloroform for extraction. TRIzol maintains RNA integrity while 
at the same time contributing to the digestion of cell membranes and components. 
The advantage of TRIzol is that it enables high purity extraction and has a high 
recovery. However, the technique is relatively time-consuming compared to filter- 
and bead-based techniques.  
9.5 Polymerase chain reaction (PCR) (paper I-III) and high-resolution melting 
analysis (HRM) (paper II) 
“upon cooling, one would hope to obtain two structures, each containing the full length of the 
template strand appropriately complexed with the primer. DNA polymerase will be added to 
complete the process of repair replication. Two molecules of the original duplex should result. 
The whole cycle could be repeated, there being added every time a fresh dose of the 
enzyme”(231).  
The quote above is from a seminal paper by Professor Kjell Kleppe from Bergen 
where he describes one of the first polymerase chain reactions (PCR) ever conducted. 
PCR is a standard method used in molecular biology to amplify a specific DNA or 
RNA sequence. 
Conventional (or sometimes also referred to as standard or simple) PCR is relatively 
simple and highly sensitive. In reverse transcription PCR (RT-PCR), RNA can be 
used as template. RNA is reversely transcribed to complementary DNA (cDNA). RT-
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PCR can be the first step in real-time PCR (sometimes also referred to as qPCR) to 
quantify RNA transcripts in a sample.   
 
Conventional PCR is widely used in a research setting. It is laborious and generally 
needs the visualisation of the product by gel electrophoresis to estimate quantity and 
size. It has, therefore, in a diagnostic setting, largely been replaced by real-time PCR.  
Real–time PCR can be broadly divided into dye-based (paper II) and probe-based 
(paper I). In dye-based real-time PCR, a fluorescent label binds to dsDNA, the 
fluorescent signal increases proportionally to the amount of DNA and can therefore 
be measured in real time. Dye-based methods are relatively cheap but can only be 
used for one target at a time and the dye does not discriminate between target DNA or 
any other DNA that might be present in the reaction. Probe-based real-time PCR 
commonly consists of a hydrolysis probe, including a fluorophore and a quencher. 
When the target sequence is amplified, the fluorophore is separated from the 
quencher, and the fluorescence can be measured real-time. Probe-based technology is 
more specific and more commonly used in diagnostic assays.  
 
Real-time PCR may be used to quantify a target, such as a parasite, in tissue. 
Absolute or relative quantification may be applied. Absolute quantification relies on a 
standard curve. This method requires information about the copy number per cell of 
the target sequence. Furthermore, for Leishmania, the copy number should not vary 
between the species. Kinetoplastid DNA (kDNA), a common target in Leishmania, 
may indeed vary both between and within species (232–234). Single or less copy 
genes can have a more prominent role for quantification but may fall short in 
sensitivity, as can be argued for paper I and III.  
 
Real-time PCR is a sensitive, specific, robust and efficient technique for detecting 
Leishmania-spp. However, there has not been one sensitive method that is able to 
detect the parasite, quantify and also discriminate at the species level until high 
resolution melting analysis (HRM) was introduced. High resolution melting analysis 
(HRM) was first described in 2003  (235) and has been described as a method for 
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detection and genotyping for several infectious agents (236–239). The method relies 
on the accurate detection of denaturation of a DNA fragment with increasing 
temperatures. The melting temperature (Tm) is related to sequence length and GC-
content. The limit of measuring differences in Tm is approximately 0.2°C, depending 
on the instrument and chemical used. There are also limits to the length of DNA 
fragments that can be applied to yield a robust HRM analysis (240). Besides the Tm, 
the shape of the melting curve is central, which is related to the DNA sequence and 
especially the GC-content. HRM has led to development of new DNA binding dyes 
that do not have an inhibitory effect on the PCR at saturating conditions. One 
limitation of HRM is that it does not reveal all sequence variations and base 
differences which, however, do not change the GC-content in a DNA-fragment and 
thus will not be detected. In a diagnostic setting it would require a trained technician 
to perform the experiments and to analyse the results, it would also require standard 
strains. On the other hand, the speed, cost and the potential to process large samples 
makes this technique attractive.  
 
In microbiology, HRM has been used for identification of infectious agents (236–
239), genotyping (210,238) and detection of resistance genes (241,242). For 
leishmaniasis, there are relatively few studies using HRM. With a few exceptions, 
most of them are using the technique to detect and differentiate a few species in a 
certain geographical region. The earliest report is by Nicolas et al. who used the 
technique to differentiate L. (L.) major, L. (L.) donovani, from L. (L.) tropica and L. 
(L.) infantum (243). Talmi-Frank et al. used the technique to differentiate the same 
species, with the addition of L. (L.) aethiopica, by targeting polymorphisms in the 
Internal Transcribed Spacer (ITS1) gene (244). Both Nicolas et al. and Talmi-Frank 
et al. only target species from Eurasia and Africa, thus making their approaches of 
limited value in the Americas and in a non-endemic setting where infections from all 
endemic regions can be expected. Studies by Pita-Pereira et al. (245) and Ceccarelli 
et al. (246) were both able to differentiate some species from the subgenus L. 
(Leishmania) from the subgenus L. (Viannia), thus making their targets more 
attractive for the Americas. Zampieri et al. (210), targeting several polymorphic sites 
69 
on the hsp70 gene, was able to differentiate several species from both subgenera, 
making it a very attractive target. As we had before shown that the aap3 coding 
sequence could be an attractive target for detection of Leishmania (paper I), we also 
wanted to investigate if the target could be used for species identification (paper III). 
qPCR may have a role, as proposed in paper I, in monitoring treatment response. An 
argument against this is that parasite DNA is potentially detectable a long time after 
the parasite is killed, mainly if the DNA target used is stable. However, Pessoa-e-
Silva and colleagues (247) have demonstrated that parasite DNA was only detectable 
in urine before treatment for VL with L. (L.) infantum, not after. Although recent 
guidelines for diagnosis, treatment and follow-up do not recommend testing the 
patients for parasites after treatment (145), qPCR may be important in vaccine 
development and research settings. Host DNA can affect the reliability of qPCR 
results. The quantitative part of a real-time assay should therefore always be tested 
with host DNA (paper II). 
9.6 Nucleic acid sequencing (paper IV) 
Nucleic acid sequencing can be performed in a range of ways, all with their inherent 
benefits and drawbacks. The technology can be used for sequencing small parts of a 
genome, chromosomes, or entire genomes. By DNA sequencing, the order of the four 
bases; thymine (T), adenine (A), cytosin (C) and guanine (G), is determined. The 
technology of DNA sequencing has developed greatly from the initial steps in the 
1970s (248,249). Sequencing technologies are, by convention, divided into 
generations. In first generation sequencing technology, such as Sanger sequencing, 
dideoxynucleotides (dNTPs), corresponding to each of the DNA bases, are separated 
according to their size and visualised by an imaging system. This technology is still 
widely used but has limitations in output and cost. Second generation technologies 
improved output exponentially and reduced cost. Several second-generation 
technologies exist, where Illumina (originally Solexa) is the most common. Illumina 
uses sequencing by synthesis technology (SBS). The technology works by adding a 
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single base to a nucleotide strand by a polymerase enzyme. It uses a modified dNTP 
which contains a fluorescent terminator blocking further polymerisation. After the 
addition of the dNTPs, an image of the fluorescent label is taken, the terminators 
removed, and the process repeated. The process is conducted on a million templates 
simultaneously. The second-generation technology comes with their inherent 
drawbacks of short reads and problems of underrepresentation of GC-rich regions. On 
the other hand, the technology can be used to sequence multiple strands 
simultaneously, thereby facilitating high output. 
 
Third generation technology, such as single molecule real time sequencing (SMRT), 
is relatively cheap, fast and does, in general, not require PCR amplification. In 
SMRT, by fluorescent labelling, the nucleotide is detected in real time. This 
technology can provide very long reads. The drawback is a higher error rate however, 
the errors are randomly spread. Another third-generation technology is the Oxford 
Nanopore, where the MinION device is small and can be connected to a USB-port of 
a computer. In this technology, the DNA is passed through a protein pore, the ionic 
current is then detected and translated to a nucleotide sequence. The error rate is 
relatively high. This type of sequencing is relatively low cost, data are available in 
real time, and it can provide very long reads.  
 
In paper IV we used third generation sequencing technology through SMRT 
sequencing.  This technology produces relatively long read lengths (>20 kb) but, the 
error rate is slightly higher with SMRT compared to other techniques, but as the 
errors are randomly spread, the sequences remain highly accurate as the same 
molecule are sequenced multiple times. SMRT sequencing has also been used in 
whole-genome sequencing of Leishmania (250,251). In this work, we show that 
SMRT can be a very useful technology also for studying target sequence fragments in 
multiple strains of Leishmania spp. with a high accuracy, generating data that could 
be important for the understanding of gene expression regulation as well as for 
diagnostic purposes.   
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In paper IV RNA sequencing was used to establish where the untranslated regions 
(UTRs) were in relation to the coding sequences of the two copies of aap3. This was 
done using next-generation sequencing technology (Illumina). RNA sequencing relies 
on some initial steps to prepare cDNA before sequencing. RNA has to be isolated, a 
crucial and difficult step, then different types of RNA can be selected for further 
analysis (such as mRNA only), and then cDNA is synthesised. The resulting 
transcriptomic analysis often requires specialist knowledge. RNA sequencing can be 
used for a range of applications, such as differential expression (DE) studies, variant 
discovery, fusion gene detection and more. The challenge to RNA seq is potentially 
the technology itself, as it does require expertise to prepare the samples and 
bioinformatical expertise to analyse the result.  
9.7 Ethics 
For the study in paper II, ethical approval was obtained from the Committee of Ethics 
of Irmandade de Santa Casa de Misericórdia de São Paulo. For paper III, ethical 
approval was obtained from the Regional Committee for Medical and Health 
Research Ethics. 
The animal study in paper I was approved by the Laboratory animal facility at the 
University of Bergen and conducted according to local guidelines and procedures. 
Ethical approval for the experimental infection of mice in paper II was obtained from 
Instituto de Biociências at the University of São Paulo. The animals in paper I and II 
received food and water ad libitum.  
9.8 Statistics (paper I–II) 
In general, for this thesis, all experiments were performed at least three times and all 
samples were tested in duplicate or more. In paper II, statistical melting temperatures 
were analysed using a one-way ANOVA. Results were presented with 95% 
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confidence intervals and statistical significance set to p < 0.05. Analysis was 
performed in Excel and GraphPad Prism version 7.  
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10. Summary of papers
10.1 Paper I 
For Leishmania, several publications exist on different molecular targets and methods 
for identification and quantification with molecular methods (217). The aim of this 
study was to develop an assay to detect Leishmania and to quantify the parasite in 
mice. Therefore, a primer targeting a 74 bp region of the aap3 coding sequence in L. 
(L.) major was coupled with a hydrolysis probe (TaqMan). The assay was able to 
detect 9 different Leishmania species; six from subgenus L. (Leishmania) and three 
from subgenus L. (Viannia). The assay did not react with other trypanosomatids 
tested (T. cruzi and T. brucei), nor human or mice DNA. The assay had a limit of 
detection ranging from 10 fg DNA for L. (L.) major to 100 fg DNA for L. (L.) 
braziliensis. When coupled with an assay targeting the transferrin receptor (tfrc) in 
mice, it was also able to quantify parasites in mice. The limit of detection (LOD) of 
the assay was equal to other assays. The assay showed little intra-species variation in 
terms of Cq-values, but some inter-species variation for L. (V.) braziliensis and L. 
(V.) guyanensis. Coupled with tfrc, the assay was able to quantify Leishmania-DNA 
in mouse tissue independent of the amount of DNA harvested. Thus, this is one of the 
first reports of a real-time quantitative PCR assay with a low copy-number gene able 
to detect parasites with relatively good sensitivity, specificity, and replicability. Being 
an only two-copy gene, it is very useful for quantitative purposes as it is not prone to 
mis-quantification as multicopy genes are. 
10.2 Paper II 
This project was largely based in Brazil. The background were the promising findings 
in paper I, and the aim was to develop a diagnostic assay for species identification. In 
addition, to avoid over-complicated laboratory procedures, and the potential of 
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laboratory contamination, we wanted to develop a closed-tube molecular diagnostic 
method that could discriminate Leishmania species.  
Real-time PCR coupled with HRM is a relatively new technique that could offer the 
possibility that this project aimed for. Using three amplicons we managed to 
distinguish eleven Leishmania species, six from L. (Leishmania) subgenus and five 
from L. (Viannia) subgenus. The sensitivity ranged from 1 parasite per reaction 
(amplicon 1 and 2), to 5 parasites per reaction (amplicon 3). The protocol was 
validated with samples from humans, cats, sand flies and experimentally infected 
mice. 
The method, using advanced real-time PCR technology coupled to HRM, showed 
that aap3 could be a valuable target for Leishmania species discrimination and 
therefore also has potential as a diagnostic target. Furthermore, the methodology is 
relatively cheap, fast and robust, and offers the possibility for automation. It was able 
to detect Leishmania in clinical, field and experimental samples, indicating its 
usefulness in an ecological and epidemiological setting. The method was, however, 
validated on relatively few standard strains and few clinical, field and experimental 
samples, and would need further testing to reliably determine its usefulness.  
10.3 Paper III 
This project was initiated by the National Advisory Unit on Tropical Infectious 
Diseases at Haukeland University Hospital in Bergen. The aim of the study was two-
fold: (i) to gather information on occurrence, diagnosis, treatment and outcome of 
leishmaniasis at five university hospitals in Norway, and of particular relevance for 
this thesis (ii) to evaluate molecular diagnosis by comparing aap3 with SSU rDNA as 
a target and test the usability of various sample material. Patients were prospectively 
recruited from all health regions in Norway (Bergen, Oslo, Stavanger, Trondheim and 
Tromsø) from March 2014-September 2017.  
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Thirteen patients were included, of which 2 had VL and 11 CL. Both VL patients 
presented with classical symptoms and findings (fever, pancytopenia, splenomegaly, 
hypergammaglobulinemia and hypoalbuminemia). One patient was initially 
diagnosed with serology only, and both received treatment with liposomal 
amphotericin B. Eleven patients were diagnosed with CL, 10 with molecular methods 
and one was diagnosed clinically. Seven received treatment with liposomal 
amphotericin B, of which one did not respond, but responded well on subsequent 
treatment with sodium stibogluconate. Three patients with CL healed without medical 
treatment. SSU rDNA and aap3 was tested with PCR, samples from 11 patients were 
included. Using SSU rDNA as target, all patients were identified as positive, while 
only 7 were identified as positive with aap3. The material was not sufficient for a 
meaningful statistical analysis and comparison, but clearly indicated that diagnostic 
target is essential, and that SSU rDNA is more reliable than aap3 when conventional 
PCR was used. Furthermore, punch biopsy is the best sample for diagnosis with 
molecular techniques. This study shows that Leishmania is a rare disease in Norway, 
but important to know about, since VL may be lethal. In Norway, PCR and 
sequencing is recommended for species identification, to ensure the right treatment 
and follow-up regime.  
10.4 Paper IV 
This project was based in Brazil and Norway. The background was the promising 
findings in paper I and II into the diagnostic potential of aap3 as a target. During the 
work with optimisation of oligonucleotides we quickly realised that although there 
were relatively good sequences for some species, there were ambiguities in others. To 
explore aap3 further, we needed better quality sequences. After carefully exploring 
different technologies, it became clear that third generation sequencing technology 
was the most appropriate, considering speed, cost and accuracy.  
The aim of the study was to improve the quality of the available nucleotide sequences 
of aap3 coding and flanking regions in both subgenera pathogenic to humans. We 
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also wanted to investigate the presence of both copies of the gene in all species, 
explore the similarity in the coding and flanking regions, describe sequences that 
could be regulatory in transcription and/or translation, and explore whether there was 
any marked difference at the protein level we could predict. 
 
We managed to sequence long amplicons including both copies of aap3 in both 
subgenera including nine species in subgenus L. (Leishmania) and six species in L. 
(Viannia). We confirmed that aap3 is coded for by two coding sequences (CDS) and 
that they are organised in tandem. We found a high similarity between the copies in a 
strain, but also a high similarity between species, but a slightly lower when 
comparing the copies between species at the subgenus level. Using transcriptomic 
data from L. (L.) major Friedlin we analysed the flanking regions, being able to 
reliably predict the untranslated regions (UTRs) for subgenus L. (Leishmania). For 
this subgenus we found relatively long 3´UTRs compared to 5´UTRs. We could also 
find large similarities in the UTRs comparing at the strains and species level, but 
there was a marked reduction of similarity between L. (L.) major and L. (L.) 
mexicana on the one hand, and L. (L.) donovani and L. (L.) tropica on the other. At 
the protein level, all copies of AAP3 presented with 11 predicted transmembrane 
domains, while subgenus L. (Viannia) presented with CDSs with three nucleotides 
less, leading to a predicted shorter protein. We did not find any differences in protein 
conformation or transmembrane domains. 
 
Our findings indicate that the general organisation of the CDS is conserved in the 
Leishmania genus despite having undergone evolutionary processes leading to 
differences in the flanking regions. Altogether, we managed to sequence and thereby 
improve the quality of available nucleotide sequences for aap3. This could be 
important for further studies into gene and protein function and regulation.  
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11. Results and discussion
11.1 Paper I 
The real-time PCR assay, in this paper, was designed on the L. (L.) major gene 
encoding AAP3. To investigate if the assay could be used for quantitative purposes in 
an animal model, it was also coupled to a coding sequence from the transferrin 
receptor gene (tfrc) in mice. To ensure the assay would be useful for the identification 
of other Leishmania species, the test was applied on nine different species, and 
several strains of the species. The assay controls were: DNA from T. cruzi, T. brucei, 
human and mice. The controls were all negative in the amplification with aap3 
primers, the tfrc was positive only for mice DNA.  Furthermore, in silico analysis 
revealed no unspecific binding to bacterial genomic sequences. Three strains were 
chosen for sensitivity analysis, representing each clinical form: L. (V.) braziliensis 
(MCL), L. (L.) donovani (VL) and L. (L.) major (CL). The limit of detection ranged 
from ≥ 10 fg for L. (L.) donovani and L. (L.) major) and ≥ 100 fg for L. (V.) 
braziliensis. While the limit of quantification ranged from ≥ 10 fg for L. (L.) 
donovani) to ≥ 1 pg for L. (V.) braziliensis. The assay presented a good 
reproducibility. Furthermore, one aim of this project was to find a method for 
quantification of parasites in mice. To enable this, the aap3 assay detecting 
Leishmania DNA was run in duplex with a tfrc-assay detection mice DNA. The assay 
was able to quantify Leishmania DNA present in mouse tissue, independently of the 
DNA loaded.  
Traditionally, Leishmania parasites have, and are to a great extent still, been 
quantified using indirect techniques, such as the measurement of the swelling of the 
footpad of mice and limiting-dilution assay. Although these forms of measurements 
do have some value, they also have severe limitations (227). Footpad swelling in 
mice measures the extent of tissue edema in the foot, which in turn is related to 
inflammation. It is common to measure the footpad swelling as a correlate to the 
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amount of infection with parasites. This is problematic as (a) parasites may be killed 
long before the reduction in footpad size, (b) swelling in foot-pads has been reported 
without an increase in parasite numbers, (c) low numbers of parasites can be found in 
resolved lesions (227,252,253). Limiting-dilution assay may be used for all types of 
infected tissue. It is, however, a laborious and time-consuming technique where the 
infected tissue is incubated in culture medium over several days, where the 
amastigotes differentiate to promastigotes and then, the replication of this form can 
be followed in the limiting dilution. The incubation time increases the risk of 
contamination (254). Real-time PCR offers the advantage of great sensitivity, 
specificity, capacity to analyse many samples at once, and reproducibility. As long as 
DNA can be isolated, the technique can be applied. One immediate drawback is also 
its strength. It measures the presence of nucleic acids, not live parasites. That is one 
reason why some researchers have been hesitant in introducing the technique. Some 
have argued that when comparing limiting dilution assay with real-time PCR, that the 
lack of correlation between the techniques could be because limiting dilution assay 
measures only live parasites (255). For sure, the detection of DNA depends on the 
origin of the target molecule, since chromosomal DNA is more sensitive to DNase 
than the circular form of kDNA. 
A real-time PCR assay for quantifying Leishmania spp. has to take into account the 
copy number of the target gene. Many real-time PCR assays for quantification of 
Leishmania use multicopy genes which increases sensitivity greatly. But as the copy 
number among different Leishmania strains varies, and sometimes, the variation also 
occurs during the life cycle of the same strain, they are often unreliable targets for 
quantification (25,254–257). 
11.2 Paper II 
In this study, we wanted to investigate if aap3 could have potential as a diagnostic 
target and, more specifically, be able to identify Leishmania species. We designed 
three primer pairs for several amplicons, where three primer pairs were found to 
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generate good amplicons for an HRM assay. The in silico study indicated that the 
primer pairs used did not produce an unspecific amplification product. Theoretical 
melting temperatures were calculated in silico based on available sequences in 
GenBank and TriTryp Database. The amplicons were then tested for specificity in a 
conventional PCR. All amplicons were specific without any primer dimers formation 
that could potentially inhibit the performance of the assays. We also included, as 
biological controls, DNA from T. brucei, T. cruzi, Crithidia fasciculata, 
Endotrypanum schaudinni, rat, mice and human. Only C. fasciculata DNA was 
positive for amplicon 3, producing a fragment of approximately the same size of 
Leishmania DNA, in the conventional PCR. After the conventional PCR, the 
amplicons were tested in a real-time PCR followed by HRM. Although the essential 
parameter for the assay is the melting temperature (Tm), Cq was also considered. The 
limit of the equipment was 0.2 °C, but we considered a Tm value exceeding ±0.25 °C 
as discriminatory between the species.  
 
By using amplicon 1, the assay was able to distinguish the species into three clusters: 
(i) visceral - L. (L.) donovani and L. (L.) infantum, (ii) cutaneous from Eurasia and 
Africa - L. (Leishmania) strains, and (iii) cutaneous and mucocutaneous strains from 
South America. Within this last cluster, the assay was able to differentiate L. (L.) 
amazonensis, L. (L.) mexicana from L. (Viannia) strains, and the last cluster L. (V.) 
guyanensis, L. (V.) naiffi and L. (V.) shawi.  
 
Amplicon 2 was designed specifically to differentiate between the L. (Leishmania) 
subgenus. By using amplicon 2, the assay was able to differentiate L. (L.) donovani 
from L. (L.) infantum and L. (L.) major from L. (L.) tropica. It was, however, not able 
to differentiate L. (L.) amazonensis from L. (L.) mexicana, a common problem as the 
species are phylogenetically close. Therefore, amplicon 3 was designed. By using 
amplicon 3, the assay was able to amplify L. (Viannia) subgenus, in addition to being 
able to differentiate L. (L.) amazonensis from L. (L.) mexicana. 
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Although we did not propose the use of Cq-values for diagnostic reasons, the 
parameter is important to assess the specificity and efficiency of a real-time PCR 
assay. Using 25 ng as the standard DNA amount in our assay, amplicon 1 showed 
roughly similar Cq-values for all species. For the controls, we found unspecific 
amplification of human DNA at Cq >30, a different Cq and Tm profile than the ones 
obtained for Leishmania spp. Amplicon 2, designed for L. (Leishmania) subgenus 
proved to be the most effective for L. (L.) donovani, L. (L.) infantum and L. (L.) 
tropica, while the Cq value for L. (L.) major was around 30 for L. (L.) amazonensis 
and around 26 for L. (L.) mexicana. This finding was also clearly visualised in the 
conventional PCR, where there was no band detectable for L. (L.) major. For 
amplicon 3, the Cq values were similar for all species, indicating a similar specificity 
and efficiency of the assay for all species.  
 
The inter-species variability of Tm was also investigated for those species where 
additional strains were available. For amplicon 1, the variability was little except for 
L. (L.) major (average Tm 82.20 °C, SD 0.24) and L. (V.) naiffi (average Tm 
83.23°C, SD 0.26). For amplicon 2, the variability was significant for L. (L.) 
donovani (average Tm 85.23°C, SD 0.3), while for amplicon 3, the profiles were 
consistent for all strains.  
 
Sensitivity was estimated for all amplicons by diluting DNA from standard strains. 
For amplicon 1 and 2, the LOD was 100 fg for all species, except L. (L.) mexicana 
(LOD 250 fg for amplicon 1, and 50 pg for amplicon 2). The reason for this 
discrepancy is discussed later. For amplicon 3, the LOD was higher, 500 fg, except 
for L. (V.) braziliensis, which has a LOD of approximately 50 pg. The efficiency for 
all amplicons was investigated using 25 ng, 5 ng and 50 pg of DNA from selected 
species. The efficiency calculations for all amplicons showed Cq-values between 20 
and 30, slopes between -3.58 and -3.1 (except L. (L.) donovani (-4.255) and L. (L.) 
mexicana (-3.975) in amplicon 3) and R2-values >0.99 except for L. (L.) donovani in 
amplicon 1 (R2 = 0.985).  
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To finalise the analysis of the assays, we validated the assays on biological samples. 
Samples from humans, cats, mice and sand flies were tested. The results showed a 
good correlation with earlier diagnostic tests that had been performed on the same 
samples. As expected, using amplicon 2, the assay did not detect samples from L. 
(Viannia) subgenus. Using amplicon 2 or 3, the assay was not able to detect L. (L.) 
amazonensis in the human sample. 
 
Molecular methods are increasingly being used for the detection and identification of 
Leishmania spp. (258,259). In Europe, PCR followed by sequencing is increasingly 
being used, although it is relatively laborious, time-consuming, and requires expert 
knowledge and product manipulation, thereby increasing the risk of laboratory 
contamination (259). Therefore, we wanted to test if the PCR coupled HRM assay 
would be a technique where aap3 could be used as a target for species discrimination.  
The HRM methodology is attractive as the whole process is performed in a closed 
tube system, avoiding contamination. Apart from the work by Zampieri et al. (210) 
that targets hsp70, all HRM studies published so far target a limited number of 
species, or species from one or few endemic areas (243,244). Assays that target only 
a limited number of species may be of value in a study setting or for research 
purposes, but they are of limited value in a diagnostic setting. With increasing 
migration and travel to and from several endemic areas, the ability of an assay to 
target species outside the endemic region is important.  
 
The aap3-assay, by using 3 amplicons, was able to differentiate all L. (Leishmania) 
subgenus tested, and several of the species from L. (Viannia) subgenus. Any medical 
diagnosis does not rely solely on laboratory diagnosis alone. Diagnosing 
leishmaniasis relies on a rigorous patient and travel history, clinical symptoms and 
findings, and results from laboratory tests. Thus, the inability of amplicon 1 to 
reliably distinguish L. (L.) donovani from L. (L.) infantum, although compensated by 
both amplicon 2 and 3, is of limited importance. A patient diagnosed with VL would 
receive the same treatment and follow-up regime regardless (258). However, to 
 82 
reliably distinguish the species may be central in a public health perspective, 
epidemiology and research setting.  
 
Although Crithidia fasciculata was amplified in the conventional PCR producing a 
fragment of the same size as for Leishmania spp., Crithidia is a non-pathogenic 
parasite for humans that only parasitizes insects and is regarded as a model organism 
in trypanosomatid research (260). This way, for a diagnostic assay for human, 
unspecific amplification of Crithidia is less of a problem. It could, however, be a 
problem for an assay in an ecological setting. However, the HRM assay for amplicon 
3 showed that the Cq and Tm values for C. fasciculata DNA were distinct from the 
ones observed for Leishmania spp.. In addition, as the assay includes 3 amplicons, 
where the other two amplicons do not amplify Crithidia, the issue is not a problem at 
all. 
 
The sensitivity of a diagnostic assay is key to evaluating its usefulness. For 
Leishmania, multi-copy genes are known to be sensitive targets (217), while single-
copy genes are commonly used for species differentiation. Ideally, a diagnostic test 
for Leishmania should be able to detect the parasite in different material (skin, spleen, 
bone-marrow, blood). This is then also one of the attractions of a molecular approach 
to diagnosis. As long as Leishmania DNA can be isolated, it has also the potential to 
be detected. There are several variables affecting the sensitivity of a molecular 
method, such as the quality of the target, quality of the DNA, and the modality used. 
Conventional PCR commonly uses agarose gel electrophoresis to visualise an 
amplified product. It is thought of as a fairly easy technique, but the resolution is 
comparatively poor, it lacks precision, and has considerable limitations for 
quantitative purposes. Real-time PCR does not measure the end-point amplification, 
but the amplification of a nucleotide sequence in real-time in the exponential phase of 
an amplification. The fluorescent signal is proportional to the number of amplicons 
generated. Real-time PCR does not require any post-PCR processing and has a 
greater sensitivity than conventional PCR. For example, Talmi-Frank et al., 
Hernández et al. and Zampieri et al. all report LODs of less than one parasite for their 
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assays (210,244,261).  We determined a LOD of 100 fg (approximately 1 parasite) 
for amplicon 1 and 2, and 500 fg for amplicon 3. The assay was able to detect 
Leishmania in all samples tested. In the publication of this work, we suggest that the 
sensitivity could be improved with a pre-amplification step (262). Although this 
could be a solution, and indeed would be likely to improve the sensitivity, a pre-
amplification step would involve removing one of the main attractions of the method, 
i.e. the closed-tube system, thereby increasing the possibility of contamination. The 
likelihood of contamination could, of course, be greatly reduced by strict adherence 
to good laboratory practices (such as unidirectional workflow), but the risk would 
remain.
We found it very encouraging that the assay, although tested on a limited number of 
biological samples, did indeed detect Leishmania and correctly identified the species. 
The assay itself includes three amplicons, and thereby species might be confirmed in 
all amplicons being controls in themselves. We did not have samples giving 
ambiguous answers. If so, this would have to be reported as undetermined. 
For the potential of the assay and the target to be shown reliably, it would have to be 
tested on more samples, on samples using different DNA extraction techniques, using 
different PCR machines and, preferably, also tested by independent laboratories. We 
did not test the assay using different reagents and equipment. Thus, this is very likely 
to affect the result. However, the standardisation of the test in different labs, using 
DNA obtained from standard reference Leishmania DNAs can solve this problem. 
11.3 Paper III 
This was a clinical study of patients with leishmaniasis in Norway where aap3 was 
also tested as a diagnostic marker. For this thesis, the latter results are of particular 
relevance and the results from the clinical part of the study are only briefly presented 
and discussed.  
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Twenty-one patients were included from the participating university hospitals;  13 
patients were diagnosed with leishmaniasis. Of the 13, two had VL and 11 had CL. 
The patients had been infected in South America, Europe and the Middle East – as 
can be expected in a non-endemic country. The VL patients were diagnosed with 
serology and PCR on peripheral blood and spleen tissue. For one patient, the strain 
was also determined by sequencing. Ten of the CL patients were diagnosed by PCR, 
while one was diagnosed clinically. Both VL patients were treated with liposomal 
amphotericin B and recovered fully. Seven of the 11 CL patients were treated 
successfully with liposomal amphotericin B, one patient did not respond to liposomal 
amphotericin B, but responded well to sodium stibogluconate. Three patients healed 
spontaneously without medical treatment. Aap3 as a diagnostic target was tested and 
compared with SSU rDNA, using conventional PCR. Depending on the clinical 
manifestation, samples from diverse sites were collected from the patients. One of the 
patients with VL had blood and spleen samples collected, all the CL patients had 
punch biopsies taken, and from several patients, filter paper had been pressed into the 
wound for DNA conservation. Of the 11 known Leishmania positive patients from 
other diagnostic tests, ten were detected by either aap3 and/or SSU rDNA. All were 
detected by SSU rDNA, while only seven of ten were detected by aap3. For one CL 
patient, only the filter paper was positive, while for another the biopsy was positive. 
None of the negative patients from earlier diagnosis or negative controls came out 
positive in either SSU rDNA or the aap3 assay. 
 
Leishmaniasis, and VL in particular, is a severe parasitic disease that should be 
suspected in travellers with fever from endemic areas. Delayed diagnosis and 
treatment can be life-threatening. One of the VL patients was only diagnosed with 
serology, while the other patient was diagnosed with microscopy, serology and real-
time PCR and sequencing. The aim should be to diagnose using several different 
modalities. This is especially the case for VL where false negative results or delayed 
diagnosis may have fatal consequences. All patients with CL were diagnosed with 
real-time PCR and subsequent sequencing for species determination, except one 
patient that was diagnosed clinically. Modality and molecular target differed between 
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the samples. Determining the species is of value in CL, especially when the patient 
has a travel history from an area endemic for MCL. All punch biopsies were positive 
except for one when comparing aap3 and SSU rDNA. Punch biopsies are usually 
taken from the border of an ulcer and will involve several layers of the skin. In 
general, parasites are scarce in an ulcer so involving several layers will increase the 
likelihood of including a parasite in the specimen. However, punch biopsies are 
invasive. Membranes that can store nucleic acids, such as the FTA-technology 
(Whatman), can be extremely useful. Nucleic acids, from for example pathogens like 
Leishmania, can be isolated and stored on the membrane without requiring specific 
expertise, toxic chemicals or special equipment. For Leishmania, it seems that using 
the FTA-technology on cutaneous lesions can be useful in ecological settings, but 
lacks the required sensitivity for diagnostic purposes (169) In paper III, however, 
filter papers were negative in two out of five samples, most likely because of few 
parasites in the ulcer. This shows that not only the target, but also the sampling 
technique, is central when Leishmania is diagnosed. 
 
We wanted to investigate if aap3 could be used in a diagnostic setting for humans 
and if its sensitivity was comparable to commonly used targets, such as SSU rDNA. 
The results in this study were limited and not sufficient to make any meaningful 
statistical analysis. However, there was a clear trend that SSU rDNA was a more 
sensitive target. Several of the samples were negative when using aap3, a result that 
could have detrimental results for the patient. This indicates that aap3 may be a more 
suitable target for species differentiation than for genus detection (see paper II). 
 
This was a prospective study where medical doctors at five Norwegian university 
hospitals sent patient data, clinical, biochemical and diagnostic information, and 
samples from each patient were sent to the coordination centre in Bergen. When 
planning the study, we had very limited information about the occurrence of 
leishmaniasis in Norway. Therefore, the prospect of including 50 patients was 
somewhat arbitrarily set. In hindsight, this was too  high. Furthermore, the study 
protocol did not include any way of determining if we had included all patients 
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diagnosed with leishmaniasis at the respective hospitals. We determine it as likely 
that all patients were included, but resources could have been spent on regular follow-
up visits to the participating study centres. Furthermore, in Norway, all patients and 
their diagnosis are registered in the Norwegian Patient Registry. The reliability of the 
study could have been improved by cross-checking if all patients diagnosed with 
leishmaniasis in the study period were included. This should have been included in 
the initial study protocol. 
11.4 Paper IV 
In this study, we wanted to improve the quality of the available sequences of aap3 in 
several Leishmania species from both subgenera pathogenic to humans. Furthermore, 
we wanted to determine the similarity of the copies of the coding sequences, and their 
flanking regions, within a strain, between species and between subgenera. In addition, 
we wanted to explore whether there were any marked differences that we could 
predict at the protein level. 
DNA was extracted from nine species belonging to subgenus L. (Leishmania) and six 
belonging to subgenus L. (Viannia). We extracted DNA from all species and RNA 
from one species, L. (L.) major. Oligonucleotides were designed to amplify a long 
fragment including the CDSs and flanking regions of both subgenera. However, 
because of differences in the nucleotide sequences, it was necessary to design one set 
of oligonucleotides per subgenera.  
The average sequence length was 10 799 bp for L. (Leishmania) spp. and 11 083 for 
L. (Viannia) spp. In all species we sequenced, we identified two CDSs organised in 
tandem in the genome. Both of the copies in L. (Leishmania) spp. were 1443 
nucleotides long, coding for a predicted 480 amino acid protein, while the copies in 
L. (Viannia) spp. were 1440 long, coding for a 479 amino acid protein. Comparing to 




Comparing the similarity of the CDSs (named aap3-1 and aap3-2), we found the 
average similarity for aap3-1 for L. (Leishmania) to be 97.6% and for L. (Viannia) to 
be 99%. Comparing the subgenera to each other, there was a marked reduction in 
similarity to 83.5%. The same pattern was found for aap3-2 as similarity for L. 
(Leishmania) was 97.6% and for L. (Viannia) at 99.4%. Comparing aap3-1 to aap3-
2, there was a high similarity within the subgenus, at average 97.7% for L. 
(Leishmania) and 98.7% for L. (Viannia). Comparing the subgenera to one another, 
the similarity was reduced to 83.4%. Codon usage was, in general, identical for both 
CDSs, with some peculiar exceptions, where the most notable was the consistent use 
of TAA as stop-codon for L. (Viannia) spp., while L. (Leishmania) used TGA or 
TAG, depending on the CDS. Codons ending with A and T seemed to be avoided.  
 
By using transcriptomic data for L. (L.) major Friedlin, the untranslated regions 
(UTRs) for both aap3-1 and aap3–2 CDSs were mapped. For species in L. (Viannia) 
it was not possible to map the UTRs as the alignment of these regions were weakly 
similar. We found 5´UTR of aap3–2 to be 859 nucleotides, while the size of aap3-1 
was 296 nucleotides. The size of 3´UTR of aap3–2 was 2017 nucleotides, while for 
aap3-1 it was 4001 nucleotides, of which our sequences only covered 1486 
nucleotides. The similarity was also compared and was relatively high for all UTRs 
when comparing within species 98.4% for 5´UTR aap3-2 and 99.7% for aap3-1, and 
for 3´UTR aap3-2 it was 98.3% and for aap3–1 99.1%. However, the similarity was 
greatly reduced when comparing L. (L.) major and L. (L.) mexicana on the one hand, 
to L. (L.) tropica and L. (L.) donovani on the other, with average 74.2% similarity for 
5´UTR aap3-2, 89.3% for 5´UTR aap3-1, and 80.7% for 3´UTR aap3-2 and 83.7% 
for aap3-1. In all species, the gene products from both aap3-1 CDS and aap3-2 CDS 
presented with 11 trans-membrane domains and had similar structure, according to in 
silico analyses.  
 
Amino acid permease (AAP3) was first described in L. (L.) donovani (86,87) and 
later in L. (L.) amazonensis (90). Both works found two copies coding for the amino 
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acid permease, organised in tandem, and found that there was a relatively high 
similarity of the CDSs. We confirmed these findings and increased the analysis, being 
the first to describe aap3 in several species of subgenus L. (Viannia). We found that 
in L. (Viannia) a deletion has led to those species lacking an amino acid in both 
CDSs, but how this affects the protein needs further studies. Furthermore, why the 
gene exists in several copies can only be speculated on, but is likely to be related to 
rapid expression, ability to resist drugs and antigen variation.  
Gene expression in Leishmania is regulated at the post-transcriptional level, where 
the 3´UTR play a significant role. This can, for example, be seen in the relatively 
long 3´UTR domains we found for aap3 in subgenus L. (Leishmania)6. As for the 
CDSs, there was a relatively high similarity within species, while there was a marked 
loss of similarity between them. It is therefore likely, as has been repeatedly 
suggested, that gene expression in Leishmania spp. is regulated in the 3´UTRs. We 
also found the presence of a region in the 3´UTR, that has been described as an 
element regulating mRNA translation in response to intracellular stress (263). 
Furthermore, studies from our group have earlier found that transcripts of aap3-1 in 
L. (L.) amazonensis are more abundant than aap3-2, indicating that AAP3 regulation
can occur at two levels: RNA-stability and translational control.
The study could have been improved through ensuring that all regions, especially 
including all of 3´UTR of aap3-1, were sequenced. This could have been done by 
dividing the sequencing into two overlapping regions. Furthermore, the sequences 
described can now be used in the construction of mutants, by deletion or 
overexpression, of all sequence components, enabling us to explore their 
physiological role and the description of a possible chemotherapeutic target. 
6 Recall we did not have enough data to support an analysis of subgenus L. (Viannia). 
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12. Conclusions 
Paper I –To develop an assay to detect Leishmania spp. and to quantify the 
parasite load in mice 
• The real-time PCR assay targeting the aap3 coding sequence was able to 
detect Leishmania species from all endemic regions and from both L. 
(Leishmania) and L. (Viannia) subgenera. 
• The assay had a high sensitivity of 10 fg DNA for L. (L.) major and L. (L.) 
donovani, and 100 fg DNA for L. (V.) braziliensis.  
• The duplex running with a host-gene assay, such as tfrc for mice, can be used 
for quantitative purposes. It may therefore be a valuable tool in monitoring the 
effects of drugs, testing vaccine candidates and for diagnosis.  
 
Paper II – To develop a diagnostic assay for species identification where the 
amplified product is contained in the tube and thereby lowering the risk of 
laboratory contamination. And to validate aap3 in clinical samples. 
• The aap3 coding sequence could be used to distinguish Leishmania at the 
species level. 
• The target and method were able to detect Leishmania in clinical, field and 
experimental samples. 
• The assay may be useful for diagnostic purposes, as well as ecological and 
epidemiological studies. 
 
Paper III – Validate aap3 as a target in clinical samples. 
• Leishmaniasis is a rare imported infectious disease in Norway. The patients 
with VL included in the study were diagnosed late and were infected in 
countries where clinicians rarely suspect Leishmania. 
• VL and MCL were diagnosed through PCR and effectively treated with 
liposomal amphotericin B, according to guidelines. Although not according to 
guidelines, those CL patients given medical treatment received systemic 
treatment with liposomal amphotericin B, and one patient received 
subcutaneous injections with sodium stibogluconate. 
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• SSU rDNA detected all positive samples (11/11), while aap3 only detected 
7/11, indicating that SSU rDNA is the best target for genus detection. Punch 
biopsy was the best material for genus detection. 
 
Paper IV – To improve the quality of available complete nucleotide sequences of 
aap3 coding sequences and flanking regions, to determine the nucleotide sequence 
in a larger range of Leishmania species comparing the genomic organisation in 
both subgenera of Leishmania pathogenic to humans 
• In all species studied, nine from subgenus L. (Leishmania) and six from 
subgenus L. (Viannia), aap3 was organised in tandem and the two coding 
sequences (CDS) presented a high average similarity at species and strain 
levels, but lower similarity at the subgenus level. The size of the CDSs 
differed on the subgenus level, where copies in L. (Leishmania) presented the 
same size (1443 bp), while L. (Viannia) presented copies with a three 
nucleotide smaller size (1440 bp). Codon usage was in general conserved. 
• For L. (Leishmania) the 3´ UTRs were relatively long for both copies, and the 
similarity in the UTRs was relatively high at the strain and species levels. 
• Long amplicon sequencing using single molecule real-time sequencing can be 
a useful technology for target sequencing of multiple strains in Leishmania 
with high accuracy. 
• The general organisation of aap3 is conserved in Leishmania genus, with some 
marked differences at the subgenus level and also in the flanking regions, 
which could indicate some regulatory mechanism of gene expression. 
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13. Proposal for future studies 
Working with Leishmania and the leishmaniases is incredibly exciting but also 
exhausting– as you open one door, numerous other doors also open simultaneously. 
Leishmania is a diverse pathogen with transmission in rainforest, rural and urban 
areas, as well as dry climates. And the leishmaniases present with a variety of clinical 
syndromes. Working within the framework of a PhD, this gives you a lot of freedom 
and opportunity, but also a sense of “angst” – time and resources are limited and 
maybe the path you are taking is wrong or not as exciting as the other path you could 
have chosen? Thus, there are a range of different paths I would have liked to have 
taken. In particular, I would have liked to: 
• Investigate the aap3-HRM approach with more biological samples from 
different mammalian and non-mammalian backgrounds to evaluate its true 
diagnostic and epidemiological potential.  
• According to Peeling and Mabey, increasing access to treatment for infectious 
diseases can have a major impact on disease burden (161). Key to improving 
this access is diagnosis. In developing countries, due to limited laboratory 
facilities, increasing the availability of point-of-care tests is likely to be 
important. To develop a molecular based point-of-care test would therefore be 
of particular interest and importance in future studies. A likely approach would 
be an isothermal method using enzymes like recombinase, or similar. 
• A multicentre study to evaluate the best sampling method and DNA extraction 
method from all the leishmaniases. 
• Continue studies into aap3 and flanking regions on more strains and species, 
include the complete sequences of flanking regions by optimising 
oligonucleotides further, and to study the gene expression further, combine 
with RNA-sequencing data from more species. 
• Use gene-editing technology, like CRISPR-Cas9 to edit aap3 CDSs and target  
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a  b  s  t  r  a  c  t
Leishmaniasis  is  one  of the  world’s  most  neglected  infectious  diseases,  affecting  around  12  million  people
and  more  than  350  million  at risk of  infection.  The  clinical  picture  varies  from  self-healing  cutaneous
lesions  to  severe  visceral  infections,  but still  no  commercial  vaccines  for  humans  are  available  and  the
currently  used  drugs  have  unpleasant  side  effects.  Here  we  report  a real-time  PCR assay  targeting  the
arginine  permease  gene  AAP3  that  can  be  applied  for all the  nine  different  species  of  the  Leishmania
genus  tested;  4  Old  World  species  and  5 New  World  species,  from  both  L. (Leishmania)  and  L. (Viannia)
subgenera.  No  cross-reaction  was  seen  with  Trypanosoma  cruzi,  Trypanosoma  brucei,  human  or  mouse
genomic  DNA.  The  assay  has  a high  sensitivity,  with  a limit  of detection  of  10  fg DNA  for  L.  (L.)  major  and
L.  (L.)  donovani,  and  100  fg DNA  for  L.  (V.)  braziliensis,  and can  be  used  for  both  qualitative  and  quantitative
purposes.  This  AAP3-Assay,  run  in  duplex  with  a host  specific  gene-assay,  was  also  successfully  used  for
quantification  of  parasite  load of footpads  from  L. (L.) major-infected  mice.  It  can  therefore  be a valuable
tool  in applications  like  monitoring  effects  of  drugs,  the  selection  of vaccine  candidates  and  in  screening
patients,  including  asymptomatic  carriers.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Leishmaniasis is a vector-borne disease with different clinical
pictures caused by protozoa of the genus Leishmania. It is one of the
world’s most neglected infectious diseases and the second cause of
parasite related deaths after malaria (Mathers et al., 2007). Spread
of the Leishmania parasite is caused by the bite of infected sand
flies. Worldwide more than 350 million people in 98 countries
or territories are at risk (World Health Organization, 2010). The
estimated incidence of new cases each year is 0.2–0.4 million for
visceral leishmaniasis and 0.7–1.2 million for cutaneous leishman-
iasis, causing 20 000 to 40 000 deaths annually, and these data are
probably underestimates (Alvar et al., 2012). In some affected areas
both domestic and sylvatic animals seem to be important reservoirs
of the parasite, contributing to promote human infections (Quinnell
∗ Corresponding author. Tel.: +47 55977888.
E-mail addresses: marit.gjerde.tellevik@helse-bergen.no (M.G. Tellevik),
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and Courtenay, 2009). Available drugs for treating the disease can
be characterized as limited, expensive and often with unpleasant
side effects. Moreover, there has been an emergence of drug resis-
tance (Sundar and Chakravarty, 2013). No commercial vaccines are
currently available for preventing leishmaniasis in humans. There-
fore, in order to control the disease, there is a need for development
of new drugs, vaccines and more specific and sensitive diagnostic
methods. Assays for quantification of the parasite in the host tis-
sues are essential for development and testing of prophylactic and
therapeutic regimes.
Polymerase chain reaction (PCR) and its variations repre-
sent highly sensitive and specific methods for Leishmania DNA
detection. PCR has shown to be superior to other methods like
microscopy and various immunologic tests, reducing time from
sampling to test result, optimizing sensitivity and specificity and
reducing subjective evaluation (Aviles et al., 1999; Bensoussan
et al., 2006; Srivastava et al., 2011a; Wall et al., 2012). Real-time
PCR is advantageous over conventional PCR because it is faster,
less labor-intensive, reduces risk of contamination, and by using
probes the sensitivity and specificity can be increased (Dymond,
2013; Mohammadiha et al., 2013; Yang and Rothman, 2004)
http://dx.doi.org/10.1016/j.actatropica.2014.05.008
0001-706X/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Furthermore, by using standard curves real-time PCR can be used
for quantification. Exploring the Leishmania parasites and the clin-
ical manifestations they cause, quantitative real-time PCR (qPCR)
can be useful for detection and species identification, but it also has
a wider potential, like monitoring the effect of drug activity and
measuring the protection as part of vaccine development. Due to
the high sensitivity, qPCR can be used for screening of patients and
detection of asymptomatic carriers, and thereby addressing gaps
in the understanding of infection with Leishmania (Francino et al.,
2006; Mary et al., 2006; Pourabbas et al., 2013).
There are many publications of different variants of PCRs for
Leishmania, using different molecular targets, but most protocols
target a single species (Francino et al., 2006; Srivastava et al.,
2011b), a group of closely related species (Harris et al., 1998;
Odiwuor et al., 2011), or they are not quantitative (Berzunza-Cruz
et al., 2009; de Almeida et al., 2011; Harris et al., 1998; Odiwuor
et al., 2011; Srivastava et al., 2011b), and some also show low
sensitivity (Wortmann et al., 2005). There are only few publica-
tions of real-time PCR assays that target all or nearly all of the
approximately 20 different Leishmania species found in humans
(Castilho et al., 2008; Tupperwar et al., 2008; Wortmann et al.,
2001). Many protocols target multicopy genes (Bossolasco et al.,
2003; Francino et al., 2006; Talmi-Frank et al., 2010) and some pro-
tocols for multicopy genes also use SYBRGreen (de Monbrison et al.,
2007). Multicopy genes are often preferred to enhance sensitivity,
and thus are advantageous for detection, but due to potential varia-
tions and instability in copy number of the same gene both between
and within species (Weirather et al., 2011) they can be challenging
and confounding for quantification using standard curves. SYBR-
Green has the disadvantages of more unspecific binding, hence a
probe, which is more specific, is to be preferred. However, it can
be challenging to design a qPCR with a specific probe that target a
DNA sequence universal to all species of the Leishmania genus.
l-Arginine is an essential amino acid for Leishmania, for which
metabolism depends on arginine supply from external sources, as
no evidence for endogenous synthesis has been reported. The argi-
nine transporter Leishmania arginine permease AAP3 is encoded
on chromosome 31 in Leishmania (L.) major and other Leishmania
species, and on chromosome 30 in Leishmania (L.) mexicana (which
due to chromosome fusion events is the equivalent of chromosome
31 in L. (L.) major (Britto et al., 1998)). The AAP3 gene is identi-
fied in several different Leishmania species (Shaked-Mishan et al.,
2006). Likely more AAP3 sequences will be published along with
the increasing number of sequencing projects.
The aim of the study was  to develop a quantitative PCR method
that could be applied for infectivity studies in mice, focusing on L.
(L.) major,  as murine models are widely used in Leishmania research,
with the benefit that it could also be used for other Leishmania
species from both the Old- and New World groups. We  devel-
oped a PCR-Assay targeting the arginine transporter gene AAP3 and
included DNA from cell pellets or cultured promastigotes from nine
different Leishmania species, as well as different negative controls,
to validate the assay. This AAP3-Assay, run in duplex with a host
specific gene-assay, was  then used for quantification of parasite
load of footpads from L. (L.) major-infected mice.
2. Materials and methods
2.1. Strains used in this study
Leishmania strains used in this study are given in Table 1. Leish-
mania promastigotes were grown at 26 ◦C in RPMI 1640 medium
(Sigma–Aldrich, St Louis, MO,  USA) supplemented with 10% heat
inactivated fetal calf serum (Gibco®, Life Technologies – Invi-
trogen, Carlsbad, CA, USA), 100 IU/ml penicillin and 100 g/ml
streptomycin, or in Schneider’s Insect Medium (Sigma–Aldrich)
supplemented with 20% heat inactivated fetal calf serum and 1%
sterile-filtered human urine. Parasites in culture were washed and
counted by flow cytometry using reference beads (Flow-Count
Fluorospheres®, Beckman Coulter, Brea, CA, USA) after stain-
ing with Vybrant® DyeCycleTM Green Stain (Molecular probes®,
Eugene, OR, USA).
L. (L.) mexicana MHOM/BZ/82/BEL21 was a kind gift from Cen-
tro de Investigaciones Regionales ‘Dr. Hideyo Noguchi’, Universidad
Autónoma de Yucatán, Mérida, Yucatán, México. Cell pellets from
Leishmania strains as indicated in Table 1, as well as from Try-
panosoma brucei and T. cruzi, were kindly donated from Dr. Silvia
Table 1
Leishmania strains used in this study, and their Cq-value when 100 pg of DNA was used as template in the AAP3-Assay.
Speciesa International code or other reference Origin Sourceb Cqc
L. (L.) aethiopica MHOM/ET/91/Kassaye Ethiopia SMI  23.4
L.  (V.)  amazonensis MHOM/BR/73/M2269, LEM 0690 Brazil CNRL 23.7
L.  (V.)  braziliensis MHOM/BR/87/LTB12MAR87, LEM 2839 Brazil CNRL 25.0
L.  (V.)  braziliensis MHOM/BR/75/M2904, LEM 2249 Brazil CNRL 25.1
L.  (V.)  braziliensis SMI  2094 Unknown SMI  25.3
L.  (L.) donovani MHOM/CY/2006/CH33, LEM 5298 Cyprus CNRL 23.8
L.  (L.) donovani MHOM/IN/80/DD8, LEM 0703 India CNRL 23.7
L.  (L.) donovani MHOM/ET/67/HU3 Ethiopia SMI  23.7
L.  (V.)  guyanensis MHOM/GF/94/22319, LEM 2763 French Guiana CNRL 27.6
L.  (L.) major MHOM/AF/2006/LEM5344, LEM 5344 Afghanistan CNRL 23.9
L.  (L.) major MHOM/MA/2004/LEM4905, LEM 4905 Morocco CNRL 24.2
L.  (L.) major MHOM/TN/2006/LPN296, LEM 5373 Tunisia CNRL 23.9
L.  (L.) major MHOM/IL/80/FRIEDLIN, LEM 3150 Israel CNRL 23.4
L.  (L.) major-np MRHO/SU/59/LV39 USSR CNRL 23.6
L.  (L.) major-p MRHO/SU/59/LV39 USSR CNRL 24.0
L.  (L.) mexicana MHOM/MX/96/NAN01, LEM 3816 Mexico CNRL 23.8
L.  (L.) mexicana MHOM/MX/93/CRE47, LEM 2695 Mexico CNRL 23.5
L.  (L.) mexicana-np MHOM/BZ/82/BEL21 Belize CIR 24.3
L.  (L.) mexicana-p MHOM/BZ/82/BEL21 Belize CIR 24.4
L.  (V.)  naiffi MHOM/GF/97/CRE88, LEM 3426 French Guiana CNRL 24.0
L.  (L.) tropica MHOM/SU/74/K27, LEM 0419 USSR CNRL 24.2
L.  (L.) tropica MHOM/MA/2000/INHW10, LEM 5277 Morocco CNRL 24.1
a np: not been propagated in mouse; p: propagated in mouse.
b SMI: Public Health Agency of Sweden, Sweden; CNRL: Centre National de Réfèrence des Leishmanioses, Montpellier, France; CIR: Centro de Investigaciones Regionales,
Universidad Autónoma de Yucatán, Mérida, Yucatán.
c Cq-value from the AAP3-assay using 100 pg DNA as template.
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Botero-Kleiven and Dr. Leigh Davidsson at the Public Health Agency
of Sweden, Sweden, and were kept in ethanol during transport to
our laboratory and until DNA extraction.
2.2. Detection of the AAP3 gene in Leishmania species
2.2.1. DNA extraction
Cultured promastigotes from the stationary phase and cell pel-
lets in ethanol were washed with Dulbecco’s phosphate-buffered
saline (10 mM Phosphate, 137 mM  Sodium chloride, 2.7 mM Potas-
sium chloride, pH 7.4) (DPBS) before subjected to DNA extraction
using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions, except that Pro-
teinase K was used instead of protease. DNA was eluted in 100 l of
Buffer AE (Qiagen). In all DNA extractions a negative control of DPBS
was included to monitor for contamination. DNA concentration
and quality was determined by a NanoDrop® ND-1000 Spectropho-
tometer (Thermo Scientific, Wilmington, DE, USA). All DNA samples
were stored at −20 ◦C.
2.2.2. Real-time PCR
Primers and hydrolysis probe (TaqMan® MGB probe) targeting
a 74 bp region of the L. (L.) major gene encoding the arginine trans-
porter AAP3 were designed by the Custom TaqMan® Assay Design
Tool from Applied Biosystems (Applied Biosystems, Warrington,
UK). The sequences of the primers and probe were 5′-GGCGGC-
GGTATTATCTCGAT-3′ (Forward), 5′-ACCACGAGGTAGATGACAGA-
CA-3′ (Reverse) and FAM 5′-ATGTCGGGCATCATC-3′ NFQ (probe).
In silico analysis of specificity of the assay was  performed
using the Vector NTI software (Life Technologies). A global
BLAST search was undertaken by the 74 bp region wherein
the primers and probe bind. In addition, complete genome
sequences of some relevant bacteria (like Mycobacteria, Pseu-
domonas, Streptococcus,  Staphylococcus) were downloaded from
GenBank (http://www.ncbi.nlm.nih.gov/genbank/) and investi-
gated for the extent of binding (BLAST) of the primers and probe.
Each PCR test was performed in triplicate in a 20 l reaction
mixture. The reaction mixture included: 1× TaqMan Universal Mas-
ter Mix  II with UNG (Applied Biosystems), 1× Custom TaqMan®
Gene Expression Assay Mix  with primers and probe targeting the
Leishmania AAP3 gene, 1× TaqMan® Copy Number Reference Assay,
Mouse, Tfrc, water and 100 pg of DNA sample. The PCR was run as a
duplex assay after comparing the results of singleplex AAP3-Assay
and the duplex with the Tfrc-Assay (results not shown).
The qPCR was performed with an Applied Biosystems 7900HT
Fast Real-Time PCR System (Applied Biosystems), with cycling con-
ditions as follows: 50 ◦C for 2 min, 95 ◦C for 10 min, followed by 40
cycles at 95 ◦C for 15 s and 60 ◦C for 1 min  each. All samples were
run on MicroAmp® Optical 96-well Reaction Plates (Applied Biosys-
tems) sealed with MicroAmp® Optical Adhesive Film (Applied
Biosystems). Each run included multiple no-template controls.
Human DNA, T. brucei and T. cruzi was used as negative controls to
check for cross-reactivity. The human DNA for control was provided
by Christel G. Haanshuus, National Centre for Tropical Infectious
Diseases, Department of Medicine, Haukeland University Hospital,
Bergen, Norway.
Tenfold dilution series of L. (L.) major DNA (range
12 ng–1.2 × 10−7 ng) were prepared for creating standard curves
and estimating assay performance for the AAP3-Assay. Besides
quantification, dilution series and standard curves were used for
estimation of PCR efficiency, limit of quantification (LOQ) and
limit of detection (LOD). LOQ and LOD were also estimated for L.
(L.) donovani and L. (V.) braziliensis.  The dilution corresponding
to the LOQ was the highest dilution used for the standard curve.
For estimating repeatability and reproducibility, replicates of a
DNA sample from the footpads of BALB/c mice infected with L. (L.)
major parasites were used. DNA was quantified using the Absolute
Quantification Assay. Thresholds were set automatically. Ampli-
cons were run on a 2% agarose gel (SeaKemTM, Lonza, Rockland,
ME,  USA) with 1X GelRedTM (Biotium, Hayward, CA, USA) to check
for the correct size. Replicates with quantification cycle (Cq)-value
differing by more than 0.3 were omitted.
A unidirectional workflow pre- to post-qPCR was  enforced, and
preparation of qPCR reaction mixture, DNA  preparations and qPCR
were carried out in facilities physically separate from each other.
2.3. Detection of the AAP3 gene in L. (L.) major-infected mice
2.3.1. Mouse tissue samples
The left footpads of female BALB/c mice were inoculated
with 10 l of 106 ml–1 L. (L.) major parasites in stationary phase.
After swelling and lesions had developed, 56 days post inocu-
lation, mice were euthanized after first using Isoba vet. 100%
(Intervet/Schering- Plough Animal Health, Intervet Denmark A/S,
Denmark) for anesthesia. Footpads of control mice (2 animals) and
infected mice (8 animals), and liver for providing control DNA, were
harvested and stored at −80 ◦C.
2.3.2. Ethical clearance
The animal experiments were approved by the National Animal
Research Authority in Norway and carried out at the Laboratory
Animal Facility (AAALAC-accredited) at the University of Bergen,
Bergen, Norway.
2.3.3. DNA extraction from mice tissue
Mouse footpads were subjected for DNA extraction by
a phenol-chloroform based protocol from Instituto Oswaldo
Cruz, Rio de Janeiro, Brazil, available at http://clioc.fiocruz.br/
documents/mmp.pdf (Leishmaniasis Epidemiology Network South
America, 2009). DNA pellet was dissolved in 200 l TE-buffer
(10 mM  Tris–HCl, 1 mM  EDTA, pH 8.0) and incubated at room tem-
perature overnight. Mouse livers were incubated over night at 56 ◦C
in Buffer ATL (Qiagen) with 2 mg/ml  Proteinase K (Qiagen), before
subjected to DNA extraction using QIAamp DNA Mini Kit (Qiagen)
according to the manufacturer’s instructions. DNA was  eluted in
100 l of Buffer AE (Qiagen).
In all DNA extractions a negative control of DPBS was  included
to monitor for contamination. DNA concentration and quality
was determined by a NanoDrop® ND-1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). All DNA samples were
stored at −20 ◦C.
2.3.4. Quantitative real-time PCR
In order to normalize the parasite load for amount of mouse tis-
sue DNA, and hence overcome the possible quantification errors
due to different cutting points when harvesting the footpads, the
qPCR was  run as a duplex-assay with the AAP3-Assay and the
TaqMan® Copy Number Reference Assay, Mouse, Tfrc (Applied
Biosystems, Foster City, CA, USA), as a reference assay. This pre-
made reaction mixture consists of primers and a VIC® dye-labeled
TAMRATM probe which detects the single-copy transferrin receptor
gene (Tfrc) in the mouse genome.
Each qPCR test was performed in triplicate in a 20 l reaction
mixture. The reaction mixture was  as in Section 2.2.2, except that
100 ng of DNA sample was used as template. Initial dilution exper-
iments showed that with 100 ng of DNA the background level, or
inhibition, was  negligible.
Fivefold dilution series of BALB/c mouse DNA (range
1050 ng–0.33 ng) were prepared for creating standard curve
and estimating assay performance for the Tfrc-Assay. For esti-
mating repeatability and reproducibility, replicates of a DNA
sample from the footpads of BALB/c mice infected with L. (L.)
102 M.G. Tellevik et al. / Acta Tropica 137 (2014) 99–104
major parasites were used. DNA was quantified using the Absolute
Quantification Assay. Thresholds were set automatically. The
parasite load in tissue samples was given as the ratio between
Leishmania DNA and genomic mouse DNA in the 100 ng DNA
applied to each PCR reaction. Since the amount of DNA cannot be
reliably estimated outside the linear area of the standard curve,
the DNA quantity for samples with Leishmania DNA less than the
LOQ was set to be equal to or less than the LOQ. Parallels with
Cq-value differing by more than 0.3 were omitted.
3. Results
3.1. Specificity of the AAP3-Assay and the Tfrc-Assay
The primers and probe for the AAP3-Assay were designed for
L. (L.) major.  We  also experimentally tested the ability of these
oligonucleotides to detect other different Leishmania species, rep-
resenting nine different species, either isolated from cell pellets or
cultured promastigotes. L. (L.) aethiopica,  L. (V.) amazonensis, L. (V.)
braziliensis, L. (L.) donovani, L. (V.) guyanensis,  L. (L.) major,  L. (L.)
mexicana, L. (V.) naiffi and L. (L.) tropica could all be amplified with
the AAP3-Assay, as seen from Table 1. The PCR resulted in ampli-
cons of the correct size, 74 bp, as visualized by gel electrophoresis
(results not shown). Neither the AAP3-Assay nor the Tfrc-Assay
could amplify T. brucei and T. cruzi, or genomic DNA from humans
or mice (AAP3-Assay only).
The global BLAST search with the 74 bp region (wherein the
primers and the probes bind) gave only hits indicating generation
of positive signals of the assay when targeting DNA from Leish-
mania species. Likewise, investigation of the bacterial genomic
sequences did not reveal strong binding of any combinations of
applied primers in a way that would generate amplification of any
segment to which the probe would bind, and thereby giving rise to
a positive signal.
3.2. Sensitivity of the AAP3-Assay
LOD and LOQ were estimated for L. (V.) braziliensis,  L. (L.) dono-
vani and L. (L.) major using serial dilutions of DNA purified from
in vitro cultivated parasites. With the applied method used for
DNA extraction, 100 fg corresponded to 2 parasites (p). For L. (V.)
braziliensis, L. (L.) donovani and L. (L.) major the LODs, given in fg
with number of parasites with our extraction method in brackets,
were: ≥100 fg (2 p), ≥10 fg (0.2 p) and ≥10 fg (0.2 p), respectively.
The LOQs for L. (V.) braziliensis, L. (L.) donovani and L. (L.) major were
≥1000 fg (20 p), ≥10 fg (0.2 p) and ≥100 fg (2 p), respectively.
3.3. Assay performance
From the DNA dilution series parameters of assay perfor-
mance other than sensitivity was calculated. From repeated runs
the mean slopes of the AAP3-Assay and Tfrc-Assay were −3.205
(range −2.994 to −3.305) and -3.193 (range −3.083 to −3.313),
respectively. Efficiency, as determined from the slope and using
the formula E = 10−1/slope − 1, was 105.1% for the AAP3-Assay
and 105.7% for the Tfrc-Assay. The correlation coefficient, R2,
was 0.999 (range 0.996–0.999) for the AAP3-Assay and 0.997
(range 0.996–0.999) for the Tfrc-Assay, and the Y-intercept was
19.48 (range 18.26–20.85) for the AAP3-Assay and 31.83 (range
31.43–32.11) for the Tfrc-Assay. A DNA sample from the footpads
of BALB/c mice infected with L. (L.) major parasites was  used for
estimating repeatability and reproducibility. The intra-assay coef-
ficient of variation (CV) for the AAP3-Assay, calculated from DNA
quantity of replicates, was for each of three separate runs 0.0908,
0.0901 and 0.0882, respectively. For the Tfrc-Assay the intra-assay
CV was for each of two separate runs 0.0179 and 0.021. Inter-assay
Fig. 1. Amplification plot for the AAP3-Assay and the Tfrc-Assay. Amplification
curves for DNA isolated from footpad of uninfected Control mouse (Control) and
mouse infected with L. (L.) major.
CV, calculated from DNA quantity of separate runs, was 0.052 for
the AAP3-Assay and 0.059 for the Tfrc-Assay. The ratio in 100 ng
DNA between quantity of L. (L.) major DNA, as measured by the
AAP3-Assay, and mouse DNA, as measured by the Tfrc-Assay, was
3.22 × 10−4 and 3.25 × 10−4 for the same sample on two separate
runs.
No amplification of any of the no-template controls was
detected.
3.4. Estimation of L. (L.) major DNA in mice footpads
For analyzing and quantification of parasite load of footpads
from L. (L.) major-infected mice, the AAP3-Assay was run in duplex
with a host specific gene-assay; the Tfrc-Assay, which detects
mouse DNA. Leishmania DNA was successfully amplified from all
the infected mice, but not from the control mice. Fig. 1 shows
amplification plots for the AAP3-Assay and the Tfrc-Assay when
analyzing a sample of Leishmania-infected tissue, together with
plots for the Tfrc-Assay when analyzing a control sample of unin-
fected tissue. As the mice DNA constitute the majority of the DNA
in the infected tissue, all plots from the Tfrc-Assay make up a con-
current curve. Values for the AAP3-Assay triplicates and for the
triplicates of the Tfrc-Assay are given in Table 2. In addition, DNA
isolated from the footpad of one of the other L. (L.) major-infected
mice was analyzed, where we  made two  different dilutions of the
DNA to confirm that the same ratio between Leishmania DNA and
mouse DNA would still be obtained. For 148.5 ng sample the ratio
was 1.99 × 10−4 and using 74.3 ng of the same sample the ratio was
1.93 × 10−4.
4. Discussion
Microscopy has traditionally been the cheapest and easiest
method for detecting and counting, Leishmania parasites. How-
ever, real-time PCR is superior regarding sensitivity, specificity,
capacity and has in addition short time of analysis and minimized
subjectivity of laboratory staff. We have developed a qPCR assay
able to detect as little as 10 fg of DNA, and to quantify down to
the limit of 10 fg (L. (L.) donovani). The AAP3-Assay is effective
in detecting several different species, and possibly the species
range for our assay is broader than we  have tested for. Regarding
specificity, both experimental and bioinformatic analyzes show no
homology of the target sequence to non-Leishmania sequences.
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Table  2
Quantification of L. (L.) major DNA in footpad from experimental infected mouse.
Samplea CqAAP3-Assayb,c Qty LeishDNAd CqTfrc-Assayb Qty mouseDNAe Qty LeishDNA/Qty mouseDNA
L. (L.) major-1 28.08 2.3 × 10−3 25.55 90.03 2.55 × 10−5
L. (L.) major-2 27.96 2.5 × 10−3 25.46 96.18 2.60 × 10−5
L. (L.) major-3 28.03 2.4 × 10−3 25.46 95.99 2.50 × 10−5
Control 1-1 Undet. – 25.46 95.79 –
Control 1-2 Undet. – 25.51 92.54 –
Control 1-3 Undet. – 25.49 93.84 –
a Control 1, uninfected mice; results are shown for all triplicates for each sample.
b Cq, quantification cycle.
c Undet., Undetermined.
d Qty LeishDNA, Quantity Leishmania DNA in ng detected by the AAP3-Assay per 100 ng DNA.
e Qty mouseDNA, Quantity mouse DNA in ng detected by the Tfrc-Assay per 100 ng DNA.
With the applied method used for DNA extraction, 100 fg cor-
responded to 2 parasites. Assuming 80 fg of Leishmania DNA is
equivalent to one parasite, then 100 fg corresponds to 1.2 parasites,
indicating that the sensitivity of the AAP3-Assay actually is better
than experienced, and can be further improved by optimizing DNA
extraction.
Regarding sensitivity in terms of DNA quantity, the LOD of our
assay equals that of some of the publications targeting both rRNA-
and kDNA minicircle genes (Berzunza-Cruz et al., 2009; Nicolas
et al., 2002; Prina et al., 2007; Gomes et al., 2012; Talmi-Frank
et al., 2010; Wortmann et al., 2001), which are genes with high
copy numbers, but there are also publications targeting multicopy
genes showing higher sensitivity (Francino et al., 2006). However,
when using multicopy genes for quantification there might be a
need for a species specific standard curve as number of gene copies
vary between species (Weirather et al., 2011), thus making those
assays little suitable for a universal quantitative Leishmania-assay.
Like the AAP3-Assay, the assay of (Wortmann et al., 2001), targeting
the Leishmania 16S rRNA, was also able to amplify a wide range of
Leishmania strains at the genus level. However, the sensitivity was
only determined for L. (L.) mexicana, the Cq-values both within and
between species had a great range, though they not clearly spec-
ify if the same amount of DNA was used, and parameters for assay
performance, like efficiency, LOQ, reproducibility and repeatability
was not estimated, or at least not given in the text.
The chromosome that hosts the AAP3 gene is supernumerary;
tetrasomic for some species, like L. (L.) major,  L. (L.) infantum and
L. (L.) donovani, and hexasomic for L. (V.)  braziliensis (Rogers et al.,
2011). In L. (L.) major,  L. (L.) infantum, L. (V.) amazonensis and L. (L.)
donovani there are two identical copies of AAP3 (Castilho-Martins
et al., 2011; Shaked-Mishan et al., 2006), whereas in L. (L.) mex-
icana there is no reported equivalent gene duplication. We  have
included 22 Leishmania strains, representing 9 different species.
The Cq-values for these strains using 100 pg DNA as template in
the AAP3-Assay are shown in Table 1. There is very little intra-
species variation in Cq-value, but some inter-species variation,
mainly between L. (V.) braziliensis and L. (V.) guyanensis against the
others species included in our study. This might indicate that ploidy
between strains and species does not largely affect the results of
the assay, but this should be investigated further. Tupperwar et al.
(2008) describes a PCR assay targeting the Leishmania GP63 able
to amplify several different species, but compared to the AAP3-
Assay there is a markedly difference in the Cq-valuable between
species when the same amount of template was  used. Whether
there is a need for a species specific, or even strain specific, standard
curve for the AAP3-assay depends on the specific application and
the required accuracy, and has yet to be more thoroughly evalu-
ated. In contrast to other multicopy genes like the kDNA minicircle
and ITS1, with copy numbers around 10 000 and 200 respectively,
and as seen from Table 1, it is less likely, and for several species
probably species group-specific standard curve will be sufficient.
A way of avoiding a species specific standard curve could be to
use the DNA concentrations for the dilutions of the standard curve
instead of the number of parasites, and then using species related
conversion factors.
In this study we developed a qPCR assay that can be applied on
a broad range of species of the Leishmania genus, from both the
Old- and New World groups, including both L. (Leishmania) spp.
and L. (Viannia) spp., and which in addition can be used to analyze
DNA from both cell cultures and mouse tissue, and most likely DNA
from several other kinds of sample materials. By using a standard
curve one can determine the amount of target DNA in a sample,
and from that also calculate the number of parasites. However,
when isolating DNA from infected tissues the amount of DNA will
be dependent on the size of the tissue sample and the recovery
of DNA at the different steps of the isolation protocol. The use of
host reference gene can circumvent this problem. When applied
to Leishmania infected mouse, the AAP3- and Tfrc-Assays give a
ratio between Leishmania DNA and mouse DNA. This ratio, which
is independent of the amount of total DNA applied for the analy-
sis, is reflecting parasite load in the tissue and hence differences
can be detected. In a study by Tupperwar et al. (2008), they nor-
malized the parasite number to the total DNA isolated from the
mice tissue samples, and finally reported the parasite number per
milligram of original tissue, not using a host reference gene. This
reported result could then be prone to differences in recovery of
DNA during the extraction process. Nicolas et al. (2002) describe
a real-time PCR assay which successfully detects four different
Leishmania species from a wide range of mouse infected tissues.
However, the study does not include a method, like using a host
reference gene, for estimating and normalization of the parasite
burden of the tissue. They also target the high copy number mini-
circle kDNA, which might have drawbacks, as mentioned above.
A limitation of our method is that it not necessarily discriminates
between live and dead parasites. However, the levels of Leishmania
DNA detected will still indicate the parasite load at the time of
sampling.
In summary, we have developed a very sensitive method for
detection of Leishmania that can be applied for several different
species of the parasite. In combination with an assay for quantifica-
tion of host DNA, it is possible to measure the load of Leishmania in
infected tissues. With its high sensitivity the method has potential
as a tool for diagnostic purposes, including detecting asymptomatic
infections. Due to the quantification possibility, the method can be
used to monitor the progress of infection, which will be a valuable
tool in testing new drugs and in vaccine development.
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Amino acid permease 3 (aap3) coding
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Abstract
Background: The leishmaniases comprise a spectrum of clinical manifestations caused by different species of
Leishmania. Identification of species is important for diagnosis, treatment and follow-up management. However,
there is no gold standard for species identification. High resolution melting analysis (HRM) offers a possibility to
differentiate Leishmania species without the need for processing of the PCR-product. The amino acid permease 3
(aap3) gene is an exclusive target for trypanosomatids and is conserved among Leishmania spp., thus it can be a
valuable target for an HRM assay for diagnosis of the leishmaniases.
Results: The HRM dissociation profiles of three amplicons targeting the aap3-coding region allowed the discrimination
of L. (Leishmania) donovani, L. (L.) infantum, L. (L.) major, L. (L.) tropica, L. (L.) mexicana, L. (L.) amazonensis, L. (Viannia)
braziliensis, L. (V.) guyanensis, L. (V.) lainsoni, L. (V.) naiffi and L. (V.) shawi using DNA from promastigote cultures. The
protocol was validated with DNA samples from clinical infection in humans and a cat, naturally infected sand flies, and
experimentally infected mice.
Conclusions: HRM analysis using the aap3 coding sequence as target is a relatively cheap, fast and robust strategy to
detect and discriminate Leishmania species from all the endemic regions worldwide. The target and method proved to
be useful in clinical, field and experimental samples, thus it could be used as a tool in diagnosis as well as ecological
and epidemiological studies.
Keywords: PCR, HRM, Infectious diseases, Leishmania discrimination
Background
The leishmaniases are a group of diseases caused by Leish-
mania spp. Clinical presentations range from self-healing
cutaneous lesions to potentially lethal visceral leishmaniasis
[1]. It is defined by the World Health Organization (WHO)
as a neglected tropical disease, meaning it is underreported,
underestimated, underfunded and underprioritized by the
pharmaceutical industry and often by public health author-
ities alike [2]. Over 350 million people are at risk of being
infected, and it is estimated that 20,000 to 40,000 die each
year of the leishmaniases [3]. In some regions, it is consid-
ered as largely an anthroponotic disease, while in others it
is a zoonosis. The reservoir of the parasite can be domestic,
sylvatic, and in some areas, both. Over 20 different species
of Leishmania can cause the disease in humans [1, 4]. The
species that cause disease in humans are grouped into
two subgenera: Leishmania (Leishmania) and Leishmania
(Viannia), based on biological features of the parasites [5].
Species identification is important for clinical diagnosis,
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prognosis, treatment and follow-up management. For
example, some L. (Viannia) species, such as L. (V.) bra-
ziliensis, are known to cause cutaneous lesions and may
later reappear as mucocutaneous lesions, thus requiring
systemic treatment, while other lesions infected by strains
known to only cause cutaneous manifestations may be
treated with local treatment or observation therapy [6].
The leishmaniases can be diagnosed in various ways,
all with their strengths and limitations. However, there is
no gold standard for diagnosing the diseases. Microscopy
is useful in a high-endemic setting, but lacks sensitivity
and needs a trained microscopist, not easily found in most
non-endemic areas. Diagnostic tests involving serology,
such as the direct agglutination test (DAT) and lateral flow
immunochromatographic tests can also be useful. Espe-
cially lateral flow immunochromatographic tests can give
a rapid diagnosis, are simple to use, easy to interpret and
relatively cheap - all qualities which are very important in
a low-resource setting in many endemic areas. However,
serological tests may vary greatly in their sensitivity and
specificity between endemic regions [7]. Furthermore, ser-
ology is not able to determine the species causing the dis-
ease. Diagnosis involving nucleic acid detection is valuable
due the high sensitivity and specificity, and for the poten-
tial ability to quantify and identify the infecting species.
There is a plethora of possible techniques and an equal
amount of possible targets [8].
Real-time PCR, followed by high-resolution melting
analysis (HRM), generates thermodynamic differences in
the dissociation profile of amplicons resulting in specific
signatures of polymorphisms due to small differences in
nucleotide composition [9]. HRM is rapid, comparatively
little laborious and a relatively cheap method where the
post-PCR treatment is contained in the tubes with small
risk for lab-contamination. HRM has been used for iden-
tification of other infectious agents [10–13]. In earlier
work, we have already shown that HRM can be a valu-
able tool for Leishmania genotyping, using hsp70 as a
target [14]. AAP3 is an amino acid transporter, which
mediates uptake of lysine, histidine, phenylalanine, cit-
rulline and arginine, with the highest affinity for the last
one [15–20]. AAP3 is involved in the polyamine pathway,
essential for parasite replication [17, 21–23]. The coding se-
quence for AAP3 is conserved among Leishmania spp., in-
dicating its value as the chosen target [17]. We already
demonstrated aap3 as an attractive target for detecting
Leishmania, by a real-time PCR method, but this approach
did not discriminate the species [24]. In this paper, we de-
scribe the use of the aap3 coding sequence as target for dif-
ferentiation of Leishmania spp., using HRM analysis. The
aap3-HRM method showed to be a specific and sensitive
tool to differentiate Leishmania spp., using reference strain
cultures and validated using clinical samples, naturally in-
fected sand flies and experimentally infected mice samples.
Methods
Organisms
Promastigotes of Leishmania spp. (see Table 1) were
grown at 25 °C in M199 medium containing Earle’s salts,
supplemented with 10% fetal bovine serum, 40 mM
HEPES (pH 7.4), 100 μM adenine, 5 mg/l hemin, 0.05
mg/ml streptomycin and 4550 U/ml penicillin. Trypano-
soma cruzi (Y-strain), Crithidia fasciculata (TCC-039)
and Endotrypanum schaudinni (MCHO/BR/80/M6159)
were grown at 28 °C in liver-tryptose medium supple-
mented with 10% fetal bovine serum and 0.05 mg/ml
streptomycin and 4550 U/ml penicillin. Trypanosoma
brucei (Lister 427) was grown at 28 °C in SDM-79
medium (LGC Biotecnologia, Cotia, São Paulo, Brazil),
supplemented with 10% fetal bovine serum, 0.05 mg/ml
streptomycin and 4550 U/ml penicillin. Mammalian DNA
from BALB/c mouse and Wistar rat were obtained from
the DNA repository of the Laboratory of Trypanosomati-
dae at Physiology - IB-USP and were used as negative con-
trols (see Additional file 1: Figure S1 and Additional file 2:
Figure S2).
Naturally and experimentally infected samples
To validate the standardized protocols, samples previously
identified by other diagnosis tests for the leishmaniases
were used as a template in aap3-HRM assays [14, 26].
Human paraffin-embedded samples (from patients from
Hospital das Clínicas da Universidade de São Paulo or
Hospital da Irmandade da Santa Casa de Misericórdia
de São Paulo), a sample from an infected cat (from
Instituto de Medicina Tropical de São Paulo - USP),
naturally infected sand flies (from Superintendência de
Controle de Endemias de São Paulo), and samples from
experimentally infected mice (from Instituto de Biociências -
USP) were included.
DNA extraction
The Leishmania strains used as assay-standards, T. cruzi,
T. brucei, C. fasciculata, E. schaudinni and the mamma-
lian DNA was isolated using a modified salting out tech-
nique, as previously described [14]. The DNA from the
additional strains used for specificity studies was isolated
using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
DNA from mouse was isolated from whole blood and
DNA from rat was isolated from liver-tissue, both by using
the DNeasy Blood and Tissue Kit (Qiagen), according to
the manufacturer's instructions. DNA quality and concen-
tration were determined by NanoDrop ND-1000 Spectro-
photometer (Thermo Scientific, USA). All DNA was
stored at -20 °C until further use.
For the paraffin-embedded tissues, a first step of wash-
ing was performed with xylol heated to 95 °C to remove
paraffin, followed by repetitive washes of absolute ethanol.
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Then DNA was purified by an organic extraction with
phenol-chloroform according Uliana et al. [27]. For sand
flies, cultured Leishmania and mice samples, DNA was
purified by silica columns, using DNeasy Blood & Tissue
Kit (Qiagen).
Primer design
The primers (listed in the Table 2) were designed based on
the following sequences: L. (L.) amazonensis (HQ912026.1
and HQ912027.1), L. (V.) braziliensis (XM_001567050.2),
L. (L.) major (XM_001685021.1), L. (L.) donovani
Table 1 Leishmania reference strains and additional strains used in this study with information about international code number,
clinical form and host according to the World Health Organization classification [25]
Strain International code number Clinical form Isolated from WHO reference strain
Assay standard strains
L. (L.) donovani MHOM/IN/80/DD8 Visceral Homo sapiens Yes
L. (L.) infantum MCER/BR/1981/M6445 Visceral Cerdocyon thous No
L. (L.) tropica MHOM/SU/60/OD Cutaneous Homo sapiens No
L. (L.) major MHOM/IL/81/Friedlin Cutaneous Homo sapiens No
L. (L.) amazonensis MHOM/BR/1973/M2269 Cutaneous Homo sapiens Yes
L. (L.) mexicana MNYC/BZ/62/M379 Cutaneous Nyctomys sumichrasti Yes
L. (V.) lainsoni MHOM/BR/81/M6426 Cutaneous Homo sapiens Yes
L. (V.) braziliensis MHOM/BR/1975/M2903 Cutaneous Homo sapiens Yes
L. (V.) guyanensis MHOM/BR/1975/M4147 Cutaneous Homo sapiens Yes
L. (V.) naiffi MDAS/BR/1979/M5533 na Dasypus novemcinctus Yes
L. (V.) shawi MCEB/BR/84/M8408 Cutaneous Cebus apella Yes
Additional strains used for specificity studies
L. (L.) donovani MHOM/CY/2006/CH33 Visceral Homo sapiens No
L. (L.) tropica MHOM/SU/74/K27 Cutaneous Homo sapiens Yes
L. (L.) tropica MHOM/MA/2000/INHW10 Cutaneous Homo sapiens No
L. (L.) major MHOM/AF/2006/LEM5344 Cutaneous Homo sapiens No
L. (L.) major MHOM/MA/2004/LEM4905 Cutaneous Homo sapiens No
L. (L.) major MHOM/TN/2006/LPN296 Cutaneous Homo sapiens No
L. (L.) major MRHO/SU/59/LV39 na Rhombomys opimus No
L. (L.) mexicana MHOM/BZ/82/BEL21 Cutaneous Homo sapiens Yes
L. (L.) mexicana MHOM/MX/93/CRE47 Cutaneous Homo sapiens No
L. (L.) mexicana MHOM/MX/96/NAN01 Cutaneous Homo sapiens No
L. (V.) braziliensis MHOM/BR/75/M2904 Cutaneous Homo sapiens Yes
L. (V.) braziliensis MHOM/BR/87/LTB12MAR87 Mucocutaneous Homo sapiens No
L. (V.) guyanensis MHOM/GF/94/22319 Cutaneous Homo sapiens No
L. (V.) naiffi MHOM/GF/97/CRE88 Cutaneous Homo sapiens No
Abbreviation: na not applicable
Table 2 Primer sequences used in this study based on the amino acid permease 3 (aap3) coding sequence, for amplicon 1 (Amp1),
amplicon 2 (Amp2) and amplicon 3 (Amp3)
Name Sequence (5'-3') Length (bp) Orientation Amplicon size (bp)
AAP3-Amp1-F ATCCGCTACGTCTCCGCCATCGG 23 Forward 123
AAP3-Amp1-R CGTGGTGAAGTACTTCATGTCGC 23 Reverse
AAP3-Amp2-F GCCGTCGATAAACACCCGAGC 21 Forward 131
AAP3-Amp2-R AAGCGGAAGATGATGTTGCGCCC 23 Reverse
AAP3-Amp3-F GGCGGTCGCCTACATCAGCG 20 Forward 140
AAP3-Amp3-R CGGGCACCATGAACACGAGCCATA 24 Reverse
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(AY247004.1), L. (L.) infantum (XM_001467313.2) from
GenBank, and L. (L.) aethiopica (LAEL147_000015800), L.
(L.) mexicana (L.mxM.30.0870), L. (L.) tropica (LTRL590_
310015200) and L. (V.) panamensis (LPAL13_000030300)
from the TriTryp Database [28]. To predict melting temper-
atures (Tm), Oligo Calculator version 3.27 was used [29].
The nucleotide sequences of the amplicons and primer lo-
calizations are detailed in Additional file 3. A global BLAST
search was performed for the three amplicon regions using
the available amplicon sequences from the strains listed
above.
PCR assays
Conventional PCR with the primers (Table 2) was per-
formed for testing amplicon specificity. PCR reactions
were performed using TopTaq Master Mix (Qiagen, Hilden,
Germany) in a final volume of 25 μl with 200 nM of each
primer and 25 ng of genomic DNA as a template. The cyc-
ling conditions were as follows: initial denaturation at 94 °C
for 3 min, followed by 25 cycles of denaturation at 94 °C for
1 min, annealing at 60 °C for 1 min and extension at 72 °C
for 30 s and a final extension at 72 °C for 10 min.
Real-time PCR was performed using MeltDoctor HRM
Master Mix (Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s instructions. Final reaction
volume was 20 μl, including 200 nM of each primer and
25 ng of genomic DNA as a template. Real time amplifica-
tion conditions were as follows: an initial denaturation step
at 95 °C for 5 min, followed by 40 cycles of denaturation at
94 °C for 30 s and annealing/extension at 60 °C for 1 min,
with the acquisition of fluorescent signals at the end of
each extension step, followed by the dissociation curve for
HRM analysis. All reactions were performed in a Ther-
mocycler PikoReal96 (Thermo Fisher Scientific, Walthan,
MA, USA).
High resolution melting analysis
For HRM analysis, fluorescent signals were detected at
0.2 °C intervals, with hold-time for 10 s, between 60–95 °C.
Data analysis was performed using PikoReal 2.1 Software
(Thermo Fisher Scientific, Walthan, MA, USA).
Sensitivity assays
For sensitivity assays we tested the performance of the
three amplicons with standard strains which produced an
overlapped melting profile (see Table 1 for information
about the strains).
For amplicon 1, we tested L. (L.) donovani, L. (L.) mexi-
cana, L. (V.) braziliensis and L. (V.) guyanensis. For ampli-
con 2, we tested L. (L.) donovani, L. (L.) mexicana, L. (L.)
infantum and L. (L.) tropica. For amplicon 3, we tested L.
(L.) donovani, L. (L.) mexicana, L. (V.) braziliensis and L.
(V.) guyanensis. For all amplicons, a range of parasite
DNA from 25 ng to 100 fg was tested, with or without
25 ng/μl of human DNA. The DNA from standard
strains was purified from in vitro cultivated parasites,
as described above. Efficiency calculations were made
for each amplicon from template ranging from 25 ng to
50 pg (see Additional file 4: Figure S3).
Statistics
All samples were tested in duplicate in at least three in-
dependent experiments. One-way ANOVA was used to
calculate statistical difference between the Tm’s of paired
species for each amplicon. The results are presented as
mean differences with 95% confidence intervals, and stat-
istical significance set to P < 0.05. The results were ana-
lyzed and graphs were produced using GraphPad Prism
version 7 (Additional file 5).
Results
Specificity
Three amplicons were designed based on available se-
quences from GenBank or TriTryp database [28], con-
sidering that aap3 is present in two copies situated in
tandem around 4 kb apart in most of Leishmania spe-
cies [16, 47]. As expected, the BLAST search did not re-
veal any other hits than for Leishmania spp. As shown
in Additional file 1: Figure S1, designed primers generated
amplicons of the same size for all the species, presenting
differences in nucleotide composition. To predict and to
delimit potentially informative polymorphic regions, the-
oretical melting temperatures were calculated in silico
using the OligoCalc tool [29] (data not shown), to guide
primer design. In addition, the two copies of the gene
were aligned concomitantly for the choice of primers that
amplify both copies (data not shown). Although some
single nucleotide polymorphism (SNP’s) were detected
between the two copies of the gene, it did not alter the
Tm values. The alignments also allowed the selection
of conserved regions for the design of oligonucleotides
common to all species, which were used to generate
products containing differences in nucleotide composition
that were able to distinguish species or groups of species.
Furthermore, we analyzed the amplification profile by con-
ventional PCR using the same primers (Additional file 1:
Figure S1). We observed specific products of the same size
for all species analyzed for each set of primers: 123, 131
and 140 bp for amplicon 1, amplicon 2 and amplicon 3,
respectively. No formation of dimers of primers were
detected. Control samples were used and no amplifica-
tion was observed for T. brucei, T. cruzi, E. schaudinni,
rat, mouse and human DNA (Additional file 1 and
Additional file 2). The analysis of amplicon 3 showed an
amplification of C. fasciculata, a non-pathogenic and
closely related organism to Leishmania spp., but the Cq
and Tm values were able to distinguish C. fasciculata from
all Leishmania spp. tested (Additional file 1: Figure S1 and
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Additional file 2: Figure S2 ). Individual Tm values and
normalized melting profiles of 3 amplicons for reference
strains are presented in Fig. 1, indicating that these differ-
ential profiles distinguished among Leishmania spp. To re-
liably distinguish different species, we only considered
differences in Tm values exceeding ± 0.25 °C, an interval
statistically determined as discriminatory (Additional file 5:
Figure S3).
According to Tm and melting curves, amplicon 1 was
able to distinguish the species into 3 clusters for sub-
genus L. (Leishmania): the visceral L. (L.) donovani and
L. (L.) infantum, cutaneous strains from Eurasia and Af-
rica [L. (L.) major and L. (L.) tropica], and cutaneous
and mucocutaneous strains from the Americas L. (L.)
amazonensis, L. (L.) mexicana, and strains of subgenus
L. (Viannia). Furthermore, it was also able to distinguish
Fig. 1 Melting temperatures and normalized melting profiles obtained with the HRM assays. a Melting temperatures (Tm) for all amplicons and
standard species. For all amplicons 25 ng of genomic DNA was used as template. The plots show the mean, minimum and maximum of the Tm-
values. Each species was tested in duplicate in three independent experiments. b Normalized HRM plots for all amplicons: (i), (ii) and (iii) represent
the normalized melting profile for amplicon 1, amplicon 2 and amplicon 3, respectively. Each sample was tested in duplicate in three independent
experiments. For (i), the bundles circled in the blue line, respectively from the left to the right, represent the profiles for L. (L.) tropica/L. (L.) major, L. (L.)
donovani/L. (L.) infantum, L. (L.) amazonensis/L. (L.) mexicana, L. (V.) braziliensis, L. (V.) naiffi, L. (V.) guyanensis/L. (V.) shawi and L. (V.) lainsoni. For (ii), the
bundles circled in the blue line, respectively from the left to the right, represent the profiles for L. (L.) amazonensis, L. (L.) mexicana, L. (L.) infantum, L. (L.)
donovani, L. (L.) major and L. (L.) tropica. For (iii), bundles circled in the blue line, respectively from the left to the right, represent the profiles for L. (L.)
infantum/L. (L.) major, L. (L.) tropica/L. (V.) lainsoni/L. (V.) naiffi, L. (L.) donovani/L. (V.) braziliensis/L. (V.) guyanensis/L. (V.) shawi, L. (L.) amazonensis, L. (L.)
mexicana. Abbreviation: RFU: relative fluorescence units
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some species of the subgenus L. (Viannia) into 3 clus-
ters: L. (V.) lainsoni, L. (V.) braziliensis from the other
species in that subgenus (Fig. 1).
Amplicon 2 was especially designed for strains of the
subgenus L. (Leishmania). No amplification for subgenus
L. (Viannia) was observed (Additional file 1: Figure S1).
It was able to further distinguish the visceral strains into
two different clusters: L. (L.) donovani and L. (L.) infan-
tum. For the cutaneous species, it was able to distinguish
the Eurasian and African cutaneous strains L. (L.) major
and L. (L.) tropica. However, no difference in melting
temperature was detected for the American cutaneous
strains L. (L.) amazonensis and L. (L.) mexicana (Fig. 1).
Therefore, amplicon 3 was designed for this purpose.
Amplicon 3 was, as predicted, able to further distinguish
L. (L.) amazonensis from L. (L.) mexicana. Furthermore, it
was able to distinguish L. (L.) donovani from L. (L.) infan-
tum, thereby distinguishing the two species commonly
causing VL. It was also able to distinguish the more com-
mon causes of CL in Eurasia and Africa: L. (L.) major and
L. (L.) tropica.
Differences in amplification efficiencies could be ob-
served when the amplification curves from real-time
PCR were analyzed. Cq (quantification cycle) data were
used as a relative parameter of quantification for the 3
targets when normalized amounts of samples were com-
pared (see Additional file 2: Figure S2). Using 25 ng as
template, for all Leishmania species, the amplification
reactions produced curves with similar Cq values for
amplicon 1 and 3, indicating a good specificity for all
species. For amplicon 2, no amplification of DNA from
subgenus L. (Viannia) was observed. In addition, high
Cq-values for L. (L.) amazonensis, L. (L.) major and L.
(L.) mexicana indicate a lower efficiency compared with
the other L. (Leishmania) species, which also could be
used as a parameter of discrimination. For amplicon 1,
there was an unspecific amplification of human DNA.
However, both the Cq and Tm values were distinct.
For all amplicons, additional strains were tested for
specificity for all species, except L. (L.) infantum, L. (L.)
amazonensis, L. (V.) lainsoni and L. (V.) shawi, as we did
not have additional strains for these species available.
For amplicon 1, we found that most strains, except L.
(L.) major and L. (V.) naiffi showed a consistent profile
for their melting temperatures. For amplicon 2 a rela-
tively large SD was found for L. (L.) donovani (Table 3).
Sensitivity
To evaluate the role of DNA-concentration, we tested
the performance of the three amplicons in strains that
presented close melting temperatures, based on the spe-
cificity assays. The limit of detection (LOD) was esti-
mated using ten-times serial dilutions from 25 ng to 100
fg of DNA from standard strains purified from in vitro
cultured parasites. For amplicon 1 the LOD was 100 fg
for all species tested except L. (L.) mexicana, which had
a LOD of 250 fg. For amplicon 2 the LOD was 100 fg
for all species tested except for L. (L.) mexicana, which
had a LOD of 50 pg. For amplicon 3, the LOD was lower
for all species, with 500 fg for L. (L.) donovani, L. (L.)
mexicana and L. (L.) guyanensis, while for L. (V.) brazi-
liensis the LOD was 50 pg. The LOD was the same for
all amplicons and all species in mixtures of Leishmania
and human DNA (data not shown). Considering that the
Leishmania genome sizes range between 29 Mb and 33
Mb, varying from 34 to 36 chromosomes [30], the esti-
mated single-cell DNA is approximately 75 fg. Thus, we
can assume that 100 fg is equivalent to just above one
parasite in most of the Leishmania species.
We further tested if the initial amount of DNA would
cause a variation in the melting temperature by serially
diluting DNA from 25 ng to 100 fg with or without 25
ng/μl of human DNA. For all three amplicons, the re-
sults were the same with or without human DNA. There
was a slight variation in melting temperature for all the
species, only exceeding 0.2 °C for L. (V.) guyanensis in
amplicon 1 with human DNA (Table 4). Furthermore,
for amplicon 1 the difference in melting temperature be-
tween L. (L.) mexicana and L. (V.) braziliensis could po-
tentially cause a confusion between these two species if
melting temperatures were considered for this amplicon,
the same can be noticed for L. (L.) donovani, L. (L.) bra-
ziliensis and L. (L.) guyanensis for amplicon 3 (Fig. 2).
Efficiency
The reaction efficiency for each amplicon was performed
using 25 ng, 5 ng and 50 pg of DNA from each reference
Leishmania species. Efficiency curves, slopes and R2
Table 3 Average melting temperatures and standard deviations
(SD) for standard strains and additional strains (see Table 1 for
further information on all strains tested)
Species Amplicon 1 Amplicon 2 Amplicon 3
Average SD Average SD Average SD
L. (L.) donovani 82.47 0.16 85.23 0.30 86.04 0.08
L. (L.) infantum 82.51 na 85.02 na 85.67 na
L. (L.) tropica 82.22 0.02 86.47 0.08 85.91 0.07
L. (L.) major 82.29 0.24 85.90 0.11 85.57 0.04
L. (L.) amazonensis 83.00 na 84.43 na 86.45 na
L. (L.) mexicana 83.12 0.00 84.46 0.05 86.88 0.09
L. (V.) lainsoni 84.39 na na na 85.88 na
L. (V.) braziliensis 83.44 0.18 na na 85.97 0.04
L. (V.) guyanensis 83.83 0.15 na na 86.14 0.11
L. (V.) naiffi 83.89 0.26 na na 86.00 0.21
L. (V.) shawi 83.92 na na na 86.20 na
Abbreviation: na not applicable, where only one strain was tested
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values were calculated (see Additional file 4: Figure S3).
The template points produced Cq values between 20 and
30, where the PCR reactions produced copies of template
at exponential ratios and with 95–105% of efficiency.
The efficiency patterns were similar for all species tes-
tes for each amplicon, except for L. (L.) mexicana in
amplicon 2. The lower efficiency for L. (L.) mexicana
for amplicon 2 can be explained by the presence of mis-
matches comparing in primers (see Additional file 3),
as can also be observed in the Cq values showed in
Additional file 2: Figure S2.
Validation using naturally and experimentally infected
samples
To validate the aap3-HRM protocol with other samples
than reference strain cultures, we applied this protocol in
seven biological samples from naturally infected humans,
naturally infected cat, naturally infected sand flies, and ex-
perimentally infected BALB/c mice (Table 5). The results
of amplicon 1 showed a correlation with those obtained
with other diagnostic targets; small subunit ribosomal
DNA (SSU rDNA) [26], glucose-6-phosphate dehydrogen-
ase (g6pd) PCR [31] and heat-shock protein 70 (hsp70)
HRM [14]. Although amplicons 2 and 3 were not able to
amplify all samples, the positive samples correlated with
results obtained with other targets.
Discussion
Diagnosing Leishmania infection at the species level is
important, as it may guide treatment options and follow-
up protocols. Accurate diagnosis is also important in an
ecological and epidemiological sense. Unfortunately, in
most endemic regions, the leishmaniases are underre-
ported, and the true burden of the disease remains un-
known. Techniques that target genomic or mitochondrial
DNA by PCR or related techniques are today the most
common for detection and identification of Leishmania
spp. However, there is no gold standard in methods and
targets [8]. Common targets such as kinetoplast DNA
(kDNA) and SSU rDNA gene have been used for parasite
detection. On the other hand, the g6pd coding region, in-
ternal transcribed spacer 1 (ITS1) rRNA, and hsp70 cod-
ing region have been more commonly used to identify the
parasite at the species level [14, 32–38]. Conventional
PCR and real-time PCR often followed by sequencing is
increasingly being used for detection and identification of
Leishmania spp. [6, 39]. Both methods are relatively la-
borious and time-consuming and they require PCR
product manipulation, increasing the risk of laboratory
contamination. Furthermore, the interpretation of the
results requires also considerable skill and experience.
HRM is a relatively new real-time PCR coupled tech-
nique, with the first papers appearing in 2003 [40, 41]. The
technique identifies nucleotide composition polymorphisms
Table 4 Effect of initial amount of DNA on melting
temperature. Mean and standard deviation (SD) for serial
dilutions of DNA from standard strains. DNA concentration
ranged from 25 ng to 100 fg. Human DNA concentration was
kept constant at 25 ng/μl
Strain Without human DNA With human DNA
Mean Tm ± SD (°C) Mean Tm ± SD (°C)
Amplicon 1
L. (L.) donovani 82.52 ± 0.10 82.64 ± 0.18
L. (L.) mexicana 83.16 ± 0.10 83.23 ± 0.13
L. (V.) braziliensis 83.31 ± 0.09 83.43 ± 0.11
L. (V.) guyanensis 83.83 ± 0.08 83.96 ± 0.34
Amplicon 2
L. (L.) donovani 85.44 ± 0.14 85.44 ± 0.14
L. (L.) mexicana 84.40 ± 0.08 84.56 ± 0.07
L. (L.) infantum 84.92 ± 0.11 85.17 ± 0.14
L. (L.) tropica 86.33 ± 0.13 86.73 ± 0.18
Amplicon 3
L. (L.) donovani 86.17 ± 0.12 86.15 ± 0.12
L. (L.) mexicana 86.77 ± 0.16 86.91 ± 0.16
L. (V.) braziliensis 86.00 ± 0.14 86.17 ± 0.15
L. (V.) guyanensis 85.97 ± 0.13 86.36 ± 0.13
Fig. 2 Effect of DNA-concentration on melting temperature (Tm °C).
Dispersion graph of Tm values for amplicons 1, 2 and 3 from a
range of 25 ng to 100 fg of DNA template. The plot shows mean,
minimum and maximum Tm-values
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in real-time PCR products. The HRM methodology pre-
sents several attractive features: the whole process is per-
formed in a closed-tube system (avoiding contamination in
the laboratory) and it is relatively fast and cheap. The ana-
lysis may also be automated. The melting temperature gen-
erated depends on a range of factors, where GC-content,
sequence, and length of the sequence are central. The melt-
ing curves can be objectively differentiated from each other
by differences in melting temperature and shape [9].
For Leishmania, there are few studies utilizing HRM
for detection and species identification. One of the earli-
est reports on the usefulness of HRM in differentiation
of Leishmania species is by Nicolas et al. [42] who uti-
lized polymorphisms in the coding sequence for minicir-
cle kDNA to differentiate Eurasian and African species,
L. (L.) major, L. (L.) donovani and L. (L.) tropica, and L.
(L.) infantum. Later, Talmi-Frank et al. [43] utilized the
ITS1 rRNA region to identify, distinguish and quantify
Eurasian and African species, L. (L.) infantum/L. (L.)
donovani, L. (L.) aethiopica, L. (L.) tropica and L. (L.)
major. Both Nicolas et al. [42] and Talmi-Frank et al.
[43] only targeted Eurasian and African species, making
the approaches valuable in these endemic areas, al-
though of limited value in other endemic areas and in a
non-endemic settings where species from all endemic re-
gions could be expected. Pita-Pereira et al. [33] also uti-
lized the minicircle kDNA to discriminate among strains
from the subgenus L. (Viannia) and L. (L.) infantum and
L. (L.) amazonensis, making it an attractive methodology
in an American setting to differentiate strains commonly
causing cutaneous, mucocutaneous and visceral manifes-
tations. Ceccarelli et al. [44] also demonstrated an ability
to differentiate species of the subgenus L. (Leishmania)
from L. (Viannia). HRM has also been used for detec-
tion of Leishmania in sand flies, where Aghaei et al. [45]
used ITS1 to identify L. (L.) tropica in sand flies. Kuang
et al. [46] utilized the lack gene to differentiate five Eur-
asian and African species from one American species, L.
(V.) braziliensis. Although they showed its usefulness in
clinical samples, the relatively few Leishmania species
tested made it difficult to conclude if this target could
be useful in other endemic areas. With increasing travel
to several endemic regions, the correct diagnosis and
species identification for the leishmaniases is of para-
mount interest. Hernandez et al. [36] utilized the ITS1
and hsp70 to differentiate L. (L.) mexicana, L. (L.) infan-
tum, L. (L.) amazonensis, L. (V.) panamensis, L. (V.)
guyanensis and L. (V.) braziliensis. Although they found
some ambiguities in species identification between the
targets, they showed that ITS1 and hsp70 had potential
as diagnostic targets utilizing HRM. Zampieri et al. [14]
showed, in a recent paper, that HRM targeting several
polymorphic sites on the hsp70 coding region could suc-
cessfully be used to differentiate several Eurasian, Afri-
can and American species. This makes it the most
attractive target reported so far, especially useful in a
non-endemic setting where the patient could have trav-
elled to several endemic areas.
In this work, we describe a method for rapid detection
and discrimination of most Leishmania species. We used
the aap3 coding sequence as target. Leishmania aap3
coding sequences available in the GenBank and TriTryp
databases were aligned to search for relatively conserved
regions but present polymorphisms that enable the iden-
tification of different species. For this, the available cod-
ing sequences of some species from the subgenus L.
(Leishmania) and L. (Viannia) were analyzed in silico.
The coding sequence for aap3 is present in two copies
and organized in tandem in most of the Leishmania spp.
genomes. For L. (L.) donovani and L. (L.) amazonensis a
98% identity has been described between the copies of
coding regions and a 93% identity between these two
Table 5 Identification of Leishmania in naturally and experimentally infected samples by HRM analysis targeting the aap3 gene
Sample
source
HRM identification Previous diagnosis
Amplicon 1 Amplicon 2 Amplicon 3 Diagnostic method Species identification
Humana L. (L.) amazonensis negative negative SSU rDNA sequencing L. (L.) amazonensis
Humanb L. (L.) infantum L. (L.) infantum L. (L.) infantum SSU rDNA sequencing L. (L.) infantum
Catc L. (L.) infantum L. (L.) infantum L. (L.) infantum hsp70 HRM L. (L.) infantum
Moused L. (L.) amazonensis L. (L.) amazonensis L. (L.) amazonensis SSU rDNA sequencing L. (L) amazonensis
Moused L. (V.) braziliensis negative L. (V.) braziliensis g6pd PCR L. (V.) braziliensis
Sand fliese L. (L.) infantum L. (L.) infantum L. (L.) infantum SSU rDNA sequencing L. (L.) infantum
Sand fliesf Subgenus Viannia negative Subgenus Viannia g6pd PCR L. (V.) braziliensis
Note: The aap3 amplicons 1, 2 and 3 of DNA from each sample was submitted to HRM analysis. The result was compared with previous identification performed
by SSU rDNA-sequencing [26], hsp70 HRM [14] or g6pd PCR [31]
aHuman paraffin-embedded tissue from Hospital das Clínicas de São Paulo
bHuman paraffin-embedded tissue from Irmandade da Santa Casa de Misericórdia de São Paulo
cIsolated parasites from cat
dExperimentally infected BALB/c mice
eNaturally infected Lutzomyia (Lutzomyia) longipalpis
fNaturally infected Lu. (Nyssomyia) whitmani
Müller et al. Parasites & Vectors  (2018) 11:421 Page 8 of 12
species [16, 47]. In addition, aap3 appeared conserved
among other Leishmania species [17]. Although some
species present only one aap3 gene copy, for example L.
(V.) braziliensis, this could be due the misannotation in
the genome database. Considering these observations,
the polymorphisms found between the two copies of the
coding region did not affect the Tm analysis.
Amplicon 1 was able to discriminate the two strains
causing visceral leishmaniasis from strains causing Ameri-
can cutaneous leishmaniasis. Furthermore, it was able to
differentiate the American cutaneous strains and several of
the strains of the subgenus L. (Viannia). The inability to
differentiate the two visceral strains L. (L.) donovani from
L. (L.) infantum was compensated with these strains having
distinct Tm’s in amplicon 2 and amplicon 3. The same
situation is true for the Eurasian cutaneous species: L.
(L.) major and L. (L.) tropica were indistinguishable in
amplicon 1, but had distinct Tm’s in amplicons 2 and 3.
Leishmania (L.) amazonensis and L. (L.) mexicana are
phylogenetically closely related species [48], and the
difficulty in differentiating these species for diagnostic
purposes has been described elsewhere [14]. Both amplicon
1 and 2 showed similar profiles for these two species, while
amplicon 3 was able to distinguish them. Amplicon 2 was
specifically designed for the subgenus L. (Leishmania), and
there was no amplification of L. (Viannia) spp. High Cq
values, observed for L. (L.) amazonensis, L. (L.) mexicana
and L. (L.) major for amplicon 2, could be explained by
primer-mismatches. Some caution should be taken
when analyzing the result in a diagnostic setting, espe-
cially if negative. However, taken together the results
from all amplicons can be considered to strengthen the
diagnosis.
Diagnosing leishmaniasis relies on patient and travel his-
tory, clinical information (symptoms and clinical findings),
and results from laboratory tests. Thus, for example, the
inability of amplicon 1 to reliably distinguish L. (L.) dono-
vani from L. (L.) infantum, in a patient with suspected vis-
ceral leishmaniasis is of little importance in a clinical
setting, as the patient would receive the same treatment
and follow-up regime regardless. But in an epidemiological
setting, it is of importance to distinguish the species from
each other to generate reliable data.
In general, multi-copy genes can be expected to yield a
higher sensitivity in molecular diagnostics. The assays
developed by Talmi-Frank et al. [43], Hernandez et al.
[36] and Zampieri et al. [14], all report a limit of detec-
tion (LOD) of less than one parasite. Despite that aap3
only comes in two copies we report a relatively good
sensitivity with a LOD of 100 fg for amplicon 1 (just
above 1 parasite) to 500 fg for amplicon 3 (approximately
5 parasites). This could probably be improved with a
pre-amplification step.
Some HRM assays have found little evidence that
DNA concentration of the initial template influences the
Tm [36, 46]. However, the initial amount of DNA for
Fig. 3 Proposed strategy for Leishmania species identification. Diagram of a proposed strategy using aap3-HRM for species identification. For VL
patients from the Americas, amplicon 1 would suffice, while for VL patients from Eurasia and Africa we suggest the use of either amplicon 2 alone or
amplicon 1 and 2. For patients with CL and MCL form the Americas, we suggest the use of both amplicon 1 and 3
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this assay influenced the Tm for some of the species.
This is in concordance with the findings of Zampieri et
al. [14], who also found that initial DNA applied to the
assay did affect the Tm for several strains. For the ampli-
cons investigated in our study, this could lead to a mis-
identification for L. (L.) mexicana and L. (L.) braziliensis
for amplicon 1. However, it should be noted that we
propose the use of the three amplicons in the identifica-
tion to strengthen the diagnostic validity and avoid spe-
cies misidentification. A strategy for Leishmania species
identification in patients with suspected leishmaniases is
proposed in Fig. 3.
The validation of the target and the technique with
clinical and experimentally infected samples from human,
cat, mice and sand flies indicated a good correlation with
other diagnostic targets and techniques. Not all amplicons
were able to yield a result for all the samples, as could be
expected due to differences in specificity and sensitivity of
the primers, where amplicon 2 was not produced for any
species belonging to the subgenus L. (Viannia). Despite
the limited number of samples tested, the data indicate
the potential of the aap3-HRM method to identify Leish-
mania species.
Conclusions
Overall, the aap3 coding sequence can be a promising
target since it is specific and conserved for Leishmania
spp. The design of the aap3-HRM protocol described is
a relatively rapid, simple, sensitive and specific method
to identify and distinguish several Leishmania spp. There
is no need for sequencing or gel fractionation to analyze a
PCR-product, minimizing the laboratory contamination as
all the reactions are performed within a closed tube. The
method can be automated, dispensing a trained technician
to analyze the results. It also has the potential to quantify
parasites present in samples, as it is a real-time PCR
technique, able to detect a small number of parasites.
In conclusion, the protocol described may offer a relatively
low-cost and reliable method for detection and identifica-
tion of Leishmania in biological and clinical samples.
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Additional file 1: Figure S1. Agarose gel electrophoresis of PCR products.
Reactions were performed using TopTaq Master Mix (Qiagen, Hilden,
Germany) in a final volume of 25 μl with 200 nM of each primer and 25
ng of genomic DNA as a template. The PCR product was applied to a
3% agarose gel and stained with ethidium bromide. Conventional PCR
products for standard strains and controls: A, amplicon 1 (expected 123
bp); B, amplicon 2 (expected 131 bp); C, amplicon 3 (expected 140 bp).
(DOCX 8881 kb)
Additional file 2: Figure S2. Specificity using Cq values as parameter.
Representative graph of Cq values obtained with HRM assays. The same
amount of genomic DNA from all species was used as template to
evaluate amplification efficiency. The samples used as negative controls
are marked in red. Products generated in late Cq's (>30) were evaluated
in the PikoReal software and revealed that Tm´s and melting profiles
were different than for Leishmania. The fluorescence generated for these
samples was due to unspecific amplification or noise. (DOCX 152 kb)
Additional file 3: Alignment of nucleotide sequences of aap3 coding
regions and primer localization. The underlined sequences indicate the
position of the primers used and the grey boxes represent the variable
regions found among the Leishmania strains based on in silico analysis.
The numbers at the top of each amplicon are based on the position of
the nucleotides in relation to the whole coding sequence in L. (L.)
amazonensis. (DOCX 21 kb)
Additional file 4: Figure S3. Efficiency curves for all amplicons. Efficiency
curves, slopes and R2 were calculated from four species for each amplicon
using 25 ng, 5 ng and 5 pg of DNA from each Leishmania species. For
amplicon 1 and 3 two species of L. (Leishmania) and two of subgenus L.
(Viannia) were selected. Amplicon 2 only amplified L. (Leishmania), and
strains from this subgenus were therefore selected. (DOCX 948 kb)
Additional file 5: Statistical analysis of melting temperatures (Tm’s) for
all amplicons. (XLSX 16 kb)
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